The Expression of Stem Cell Inhibitor/Macrophage Inflammatory Protein-1alpha and Macrophage Inflammatory Protein-1beta mRNA in Murine Macrophages by Reid, Alan James
The Expression of Stem Cell Inhibitor / Macrophage Inflammatory 
Protein-la and Macrophage Inflammatory Protein-lp mRNA in Murine
Macrophages.
by
Alan James Reid
Submission for the Degree of Ph. D. to the Faculty of Medicine, 
University of Glasgow.
October 1992
ProQuest Number: 11007675
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 11007675
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346

Abstract
The proliferation of haemopoietic stem cells in the bone marrow is believed to be 
controlled by competing interactions between positive and negative regulators.
The identification and characterisation of specific negative regulators has been the 
subject of much investigation and one of these, an activity termed the Manchester 
Inhibitor, was shown to be effective in inhibiting the proliferation of CFU-S cells.
The presence of this activity in murine bone marrow was also demonstrated to 
correlate inversely with CFU-S proliferative status.
Purification of the active component of the Manchester Inhibitor showed it to be 
functionally and antigenically indistinct from Stem Cell Inhibitor /  Macrophage 
Inflammatory Protein-la (SCI/MIP-la), a member of the MIP-1 family of cytokines. 
Another, closely related, member of this family, Macrophage Inflammatory Protein- 
1(3 (MIP-1 (3), is ineffective as an inhibitor of haemopoietic stem cell proliferation but 
both SCI/MIP-la and MIP-1 p have been shown to be effective in a number of 
inflammatory assays and MIP-1 P may be a specific antagonist of the action of 
SCI/MIP-la.
Understanding the signals and mechanisms controlling the expression of the genes for 
both SCI/MIP-la and MIP-1 p is of fundamental importance for gaining a clear 
picture of the role played by these proteins in the physiology of stem cell proliferation 
regulation and in the inflammatory response.
Previous studies with the Manchester Inhibitor had shown that this activity was a 
product of bone marrow macrophages and that the ability to detect the activity 
correlated with stem cell quiescence; however, only limited studies had been carried 
out on the factors regulating the production of this activity.
In this project, an in vitro culture system was set up to study the regulation of the 
expression of the genes for SCI/MIP-la and MIP-1 p. Macrophages cultured in vitro
from normal murine bone marrow (bone marrow-derived macrophages, BMDM) 
were employed as a surrogate for the SCI/MIP-la and MIP-1 p producer cells in the 
bone marrow. This cultured population has characteristic proliferative properties and 
was demonstrated to express mRNA for SCI/MIP-la and MIP-1 p and secrete 
SCI/MIP-la protein. Previous, limited, studies had observed the expression of 
SCI/MIP-la and MIP-1 p mRNA in macrophage-like or monocyte-like cell lines. 
This study represents the first study of the expression of these genes in 
untransformed, primary macrophages.
The accumulation of SCI/MIP-la and MIP-1 p mRNA was observed to be greatly 
increased by treatment of BMDM with bacterial endotoxin and this was investigated 
in more detail. Both SCI/MIP-la and MIP-1 P mRNAs were observed to be induced 
in a rapid and transient fashion, which was dependent on the early stimulation of 
transcription, in a manner suggestive of this being a part of the early phase of the 
response of BMDM to stimulation by endotoxin. The accumulation of both mRNAs 
was also demonstrated to be independent of de novo protein synthesis, which places 
the expression of SCI/MIP-la and MIP-1 P within the "immediate early" group of 
genes. Furthermore, the glucocorticoid hormone hydrocortisone was seen to be able 
to downregulate the accumulation of both mRNAs and oppose the induction of 
accumulation by endotoxin. These characteristics of expression are typical of those 
observed for cytokine genes.
The accumulation of mRNA for SCI/MIP-la and MIP-1 p was induced by treatment 
of BMDM with conditioned medium from the cell line L929, a potent source of the 
monocyte/macrophage lineage-specific growth factor CSF-1. This induction was 
again observed to be rapid and transient. Attempts to demonstrate increased 
accumulation of either of the MIP-1 mRNAs using recombinant human CSF-1 were 
unsuccessful, possibly due to the poor activity of the preparations used. The 
macrophage priming/ activating factor IFNy, however, was able to induce the
accumulation of both of the MIP-1 mRNAs, again in a transient manner, 
demonstrating that accumulation of both of these mRNAs could be induced by a 
cytokine as well as endotoxin.
Studies in serum-free medium demonstrated the accumulation of both SCI/MIP-la 
and MIP-1 P mRNA on refeeding in the absence of donor horse serum. Both 
SCI/MIP-la and MIP-1 P mRNA was again observed to accumulate with a rapid and 
transient pattern. Donor horse serum was seen to downregulate, and fetal calf serum 
to upregulate, levels of both mRNAs.
The expression of many genes with the characteristics of expression observed for 
SCI/MIP-la and MIP-1 p in this study has been postulated to be linked to the 
induction of cellular proliferation. The proliferative characteristics of the BMDM 
population employed in this study allowed this question to be addressed. While 
several culture conditions were identified where induction of accumulation of 
SCI/MIP-la and MIP-1 p mRNA precedes the induction of proliferation of BMDM, 
the level of expression of these mRNAs can also be increased in the absence of 
proliferation. This suggests that, while there may be some overlap in the signals 
mediating the proliferation of BMDM and the expression of SCI/MIP-la and MIP-1 p 
genes, these signals are not identical and the two processes can be regulated 
independently.
In order to investigate the role played by the expression of the SCI/MIP-la gene in 
haemopoiesis in vivo, studies were carried out on the accumulation of SCI/MIP-la 
mRNA in total murine bone marrow. A low level of SCI/MIP-la mRNA was 
detected in normal, unfractionated murine bone marrow in agreement with ability of 
other investigators to detect Manchester Inhibitor activity by washing normal bone 
marrow and consistent with expression of the SCI/MIP-la gene playing a role in 
marrow haemopoiesis.
On treatment of mice with 5-fluorouracil, a drug with well documented effects on the 
proliferation of haemopoietic stem cells, levels of SCI/MIP-la mRNA were observed 
to change with patterns not inconsistent with changes in SCI/MIP-la gene expression 
playing a role in the control of myeloid stem cell proliferation.
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Chapter 1 
Introduction.
1.1 Composition and Regulation of the Haemopoietic System.
In the adult mammal, blood cells are continually being manufactured in the bone 
marrow and destroyed in the periphery. This is achieved through processes of 
differentiation and cell division involving vast numbers of cells. Humans, for 
example, produce in the order of 10^ platelets, erythrocytes and neutrophils per hour 
(Golde 1991). The fact that, in the normal situation, the numbers of blood and 
developing haemopoietic cells are maintained within fairly narrow ranges and
the relative rarity of neoplastic transformation in these cells indicates that 
haemopoiesis is an extremely effectively controlled process.
The starting point for all blood cell production is the pluripotential haemopoietic stem 
cell. All of the mature haemopoietic cells are derived from this cell by a series of 
differentiation and amplifying divisions.
Conventionally, the haemopoietic system is thought of as consisting of three 
interlinked compartments: the stem cell, progenitor (transient amplifying) cell and 
maturing end cell compartments. These compartments are believed to comprise 0.1- 
0.4%, less than 10% and greater than 90% of the total marrow population 
respectively (Lord and Testa 1988). It should be stressed, however, that these 
categories are not absolute and there may be considerable overlap between the 
compartments.
1.1.1 Maturing End Cells.
The haemopoietic system gives rise to at least eight mature cell types. These cell- 
types have widely divergent functions in the blood and tissues such as carrying
1
oxygen and playing roles in host-defence and the response to injury. The production 
of the various cell lineages from stem cells via progenitor cell stages is illustrated in 
figure 1.1.
1.1.2 Progenitor (Transit Amplifying) Compartment.
It is generally believed that stem cells give rise to precursor cells which in turn give 
rise to unipotent progenitor cells through a series of ill-defined differentiation steps. 
The development of in vitro clonogenic assays for bone marrow lead to the 
identification and description of the lineage-committed progenitor cells. These cells 
differ from stem cells in that they are committed to one, or a few, lineages and have a 
much reduced proliferative capacity. A greater percentage of this compartment is 
proliferating at any one time than the stem cell compartment which reflects the fact 
that these cells are irreversibly committed to becoming post-mitotic end cells 
(Metcalf 1984).
The identification of the various progenitor cells is inextricably linked to the 
discovery and purification of the colony-stimulating factors (CSFs), glycoprotein 
hormones which are absolutely required for the survival, proliferation and 
differentiation of the progenitor cells, at least in vitro (for reviews see Metcalf 1989, 
Morstyn and Burgess 1988, Zipori 1991).
The type of progenitor under investigation is defined by the morphology of the 
resultant colonies which in turn are dependent on the CSF used. Thus, granulocyte- 
colony stimulating factor (G-CSF) will give rise to colonies derived from bone 
marrow consisting predominantly of granulocytic cells. The cell from which the 
colony derives, for which colony formation constitutes a retrospective assay, is 
termed granulocyte-colony forming cell (G-CFC). Colony assays for all of the 
identified blood cell lineages have now been developed (Metcalf 1984).
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Monocytes Eosinophils
Macrophages Mast cells
Figure 1.1 A model of the hierarchical organisation of the murine 
haemopoietic system.
The stem cells and progenitor cells reside predominantly in the 
marrow, whereas the morphologically recognisable cells (except 
megakaryocytes) are found in the peripheral blood. Macrophages and 
mast cells are found in tissues.
PHSC pluripotential haemopoietic stem cell
SI lymphoid-restricted stem cell
Sm myeloid-restricted stem cell
BFU burst forming unit
CFU colony forming unit
Meg megakaryocyte
RBC red blood cell
That cell types approximating to the defined colony-forming cells exist in vivo, rather 
than the progeny of the in vitro colonies being derived purely by induction by the 
growth factor from an undifferentiated pool, was first demonstrated by the separation 
studies of Worton et al (1969). These studies have recently been extended in a series 
of publications by Weissman and colleagues (reviewed in Heimfeld et al 1992). 
Muller-Seiburg et al (1986) have demonstrated that most of the progenitor activity of 
the marrow is contained within a population which stains for the Thy-1 antigen with 
an intensity which is 10-fold lower than that on mature mouse T cells. This 
population can be further divided on the basis of lineage markers for all of the 
haemopoietic lineages. The lineage restricted capacity of these cells is demonstrated 
by in vivo reconstitution experiments (Muller-Seiburg et al 1986, Heimfeld et al 
1990, 1991, Smith et al 1991). It should be noted, however, that some of these sorted 
subpopulations demonstrated a greater degree of developmental restriction in vitro 
than in vivo (Smith et al 1991), which suggests that there may be artificial limitations 
placed on the growth of haemopoietic progenitors in in vitro semi-solid media assays. 
This demonstrates a potential pitfall of all in vitro haemopoietic assays which should 
be borne in mind when interpreting data.
1.1.3 Stem Cell Compartment.
The distinguishing feature of haemopoietic stem cells is their ability to sustain a 
functional haemopoietic system in vivo over an extended period of time (Harrison et 
al 1988, Jordan and Lemischka 1990, Capel et al 1989). To achieve this the stem cells 
must be able to maintain a balance between two apparently antagonistic functions.
1) Firstly, the pluripotential stem cells must be able to undergo a process of 
differentiation which must be unique amongst the stem cells of the adult self- 
renewing tissues in that it ultimately gives rise to a large number of distinct cellular 
lineages of both the lymphoid and myeloid branches of the haemopoietic system.
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Figure 1.1 shows the hierarchical organisation of the haemopoietic system, 
illustrating that the pluripotential haemopoietic stem cell (PHSC) precedes the major 
myeloid-lymphoid branch point and is therefore capable of repopulating both the 
lymphoid and myeloid branches of the haemopoietic system.
The existence of the PHSC has now been well established by several functional 
studies (Abramson 1977, Harrison 1980, Lemischka et al 1986, Lemer and Harrison 
1990, Jordan and Lemischka 1990, Szilvassy et al 1990).
2) Secondly, a quota of potentially active stem cells sufficient to enable the constant 
repopulation of all of the haemopoietic lineages must be maintained. This could be 
achieved in two basic ways.
A) Self-renewal, by which stem cells divide to replicate themselves, has been widely 
postulated to account for the maintenance of the stem cell compartment of the 
marrow (Siminovitch et al 1964, Sprangude et al 1988, Keller 1992, Harrison 1992) 
but has never been formally proven to exist. However, self-renewal of haemopoietic 
stem cells can be inferred from the ability of individual retrovirally marked stem cell 
clones to give rise to mature end cells over an extended period (Lemischka et al 1986, 
Jordan and Lemischka 1990).
B) Alternatively, it is possible to envisage that haemopoiesis might be maintained by 
the successive activation of a reserve of primitive cells which are sufficient in number 
to maintain haemopoiesis for several life-spans, in a way directly analogous to the 
female reproductive system (Kay 1965). Mintz et al (1984) have reported sequential 
activation of uniquely retrovirally marked stem cell clones which would support such 
a model; however, these data may be representative of repopulating marrow rather 
than steady-state haemopoiesis.
Regardless of which mechanism is responsible for the maintenance of a functional 
stem cell compartment, it is generally accepted that proliferation in the stem cell 
compartment is minimal relative to the rest of the haemopoietic system, as assessed
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by the ability of cells of the stem cell compartment to resist the lethal effects of cycle- 
specific agents both in vivo (Lemer and Hamson 1990) and in vitro (Shibagaki et al 
1986). This could be achieved in two ways. First, as is conventionally considered to 
be the case, only a small fraction of the stem cell compartment could be proliferating 
with the majority existing in a quiescent state, making no contribution to 
haemopoiesis. The demonstration by several investigators of pluripotential 
haemopoietic reconstitution by a small number of individually retrovirally marked 
stem cell clones (Keller et al 1985, Capel et al 1989, Jordan and Lemischka 1990) 
and the ability of the majority of assayed primitive myeloid progenitor cells from 
unstressed mice and humans to resist the lethal effects of cycle specific drugs in vitro 
(Shibagaki et al 1986, Cashman et al 1990) would support this idea.
On the other hand, Harrison et al (1988) have presented evidence, using mathematical 
analysis of a long-term repopulation assay (Harrison 1980) that large numbers of 
PHSCs are continually, albeit extremely slowly, proliferating; the low proliferation 
would presumably account for the resistance of most of the PHSCs to the action 
cycle-specific cytotoxic drugs. It is a corollary of this that multiple stem cell clones 
would be contributing to haemopoiesis in an individual.
It is probable that changes in the proliferative rate of haemopoietic stem cells makes 
little or no contribution to haemopoiesis in the unstressed animal, with most of the 
day to day regulation of blood-cell formation taking place at the progenitor cell level. 
However, due to the primary importance of the stem cell in blood cell development 
much attention has been focussed on understanding the basis for the control of stem 
cell proliferation.
It is clear from the studies of Lemer and Harrison (1990) and Harrison and Lemer 
(1991) that the proliferative rate of PHSCs can be ieversibly increased during 
recovery from marrow ablation; however, investigation of biochemical, or otherwise, 
signals controlling the proliferation of stem cells is impossible using long-term
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reconstitution assays. Therefore, studies aimed at understanding the control of stem 
cell proliferation and development have utilised assays which detect primitive, multi­
lineage haemopoietic progenitors with a large proliferative capacity, the relationship 
of which to the PHSC is not always certain.
1.1.4 Actions of the Colony Stimulating Factors and Cvtokines.
Committed haemopoietic progenitor cells, which have been immobilised in vitro in 
semi-solid growth medium can be stimulated to divide and multiply by specific 
growth factors, in which case they will form colonies consisting mainly of 
morphologically recognisable mature haemopoietic cells (Metcalf 1984). Growth 
factors (termed colony-stimulating factors, CSFs) able to promote the growth of 
colonies from bone marrow containing all of the major blood cell lineages have been 
identified using this technique.
The activities of the CSFs include promotion of cell survival, induction of 
proliferation coupled with differentiation and potentiation of the functions of mature 
haemopoietic cells (for reviews see Morstyn and Burgess 1988 and Metcalf 1989). 
Some of the CSFs are relatively restricted in their target cell populations, for example 
colony stimulating factor 1 (CSF-1) also known as macrophage-CSF (M-CSF), 
granululocyte-CSF (G-CSF) and erythropoietin (epo) are restricted to the production 
of colonies consisting of mature macrophages, granulocytes and erythroid cells, 
respectively (Metcalf 1989). Similarly, IL-5 is a specific CSF for the production of 
eosinophils (Sanderson et al 1985) and 1L-2 specifically promotes the development of 
cells of the T and B lymphoid lineages (Smith 1988).
On the other hand, other CSFs appear to have a wider range of activities as judged by 
their ability to promote the formation of colonies containing cells from two or more 
lineages. For example, granulocyte-macrophage CSF (GM-CSF) and EL-3 (or multi- 
CSF) have a much broader target cell population, including cells of the myeloid and
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megakaryocytic lineages, early erythroid cells and primitive myeloid progenitors 
(Morstyn and Burgess 1988). In some cases these growth factors are also able to 
exhibit strong synergy when acting together on a responding cell. These synergistic 
actions are likely to be important in vivo as most cells that produce cytokines secrete 
a mixture of these (Morstyn and Burgess 1988) and because most haemopoietic cells 
have receptors for more than one cytokine (Nicola 1989).
Receptors for several of the CSFs have now been described. The CSF-1 receptor is a 
member of the tyrosine kinase family of receptors. Receptors for the other CSFs 
described to date appear to be structurally related to each other and may mediate their 
effects through additional membrane proteins which bind the growth factor-receptor 
complex and also increase the apparent binding affinity of the growth factor (for 
review see Nicola and Metcalf 1991).
1.1.5 Stem cell assays.
Colony Forming Unit-Spleen fCFU-S).
Much of the work aimed at understanding the physiological control of stem cell 
behaviour has utilised the Colony Forming Unit-Spleen (CFU-S) assay of Till and 
McCulloch (1961). This is a clonal assay (Becker et al 1963) which measures the 
ability of a class of primitive bone marrow progenitor cells to seed in the spleen of a 
lethally irradiated mouse and form macroscopic colonies. The colonies appear on the 
spleen from around day seven after transplantation onwards and can contain erythroid 
cells, granulocytes and platelets as well as cells with the ability to give rise to 
colonies in secondary recipients (Becker 1963). The spleen colony founding cell 
(CFU-S) therefore has the ability to give rise to myeloid lineages and also to display 
self-renewal; this lead to the assumption that the CFU-S represented the pluripotent 
haemopoietic stem cell (Siminovitch et al 1963, Sprangude et al 1988).
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Subsequent studies revealed considerable heterogeneity in the CFU-S population with 
regard to self-renewal ability, (Siminovitch et al 1963) multipotentiality (Curry and 
Trentin 1967) and proliferative status (Baines and Visser 1983, Shibagaki et al 1986). 
CFU-S displaying more and less primitive characteristics can be partially 
distinguished according to their time of appearance on the spleen of the recipient 
animal. Colonies appearing at day 12 after transplantation are generally more 
primitive than those appearing on day 8, although this distinction is not absolute as 
many day 8 colonies remain on the spleen through to day 12 (Wolf and Priestley 
1986). The day 12 CFU-S are believed to be derived from a more primitive cell (pre- 
CFU-S) which resides in the marrow immediately after transplantation (Hodgson and 
Bradley 1979).
It is now also apparent that the cell responsible for the long-term engraftment of 
transplanted marrow (which is functionally analogous to the PHSC) is not contained 
within the CFU-S compartment. Jones et al (1990) and Sprangude and Johnson 
(1990) have demonstrated that the two activities can be physically separated. Given 
that no study has demonstrated repopulation of the lymphoid compartment by CFU-S 
(Abramson et al 1977) it is more likely that CFU-S represents a myeloid stem cell (or 
primitive myeloid progenitor if adhering to a strict definition of the stem cell) rather 
than the PHSC.
In Vitro Stem Cell Assays.
Attempts have also been made to assay for cells with the properties of stem cells by 
in vitro colony assay in semi-solid agar. For a haemopoietic progenitor cell assayed in 
vitro to be designated as having stem cell-like properties it must display at least some 
of the following properties: 1) Low frequency in unfractionated bone marrow 2)
Large colony size, denoting a large proliferative potential. 3) The ability to give rise 
to multiple lineages. 4) Low proliferative activity. 5) Delayed onset of growth. 6) The
8
capacity of the primary colonies to give rise to secondary progeny. These properties 
are displayed to varying extents by the cells detected in the assays described below 
which illustrates the heterogeneous nature of the stem cell compartment.
High Proliferative Potential Colony Forming Cells (HPP-CFC V 
HPP-CFC are amongst the most primitive haemopoietic cells identified in vitro. They 
have a fairly low frequency (approximately 250 per 10^ normal bone marrow cells) 
and are extremely quiescent in normal marrow (Hodgson and Bradley 1984). In 
addition to this, they are multipotential and are able to give rise to transplantable and 
in vitro progenitors of various lineages (McNiece et al 1987).
The growth of HPP-CFC colonies is absolutely dependent on the presence of multiple 
cytokines acting in synergy, and the particular combinations used, in addition to 
differential sensitivity to the cytotoxic effects of 5-fluorouracil (5-FU), have allowed 
HPP-CFC to be divided into a least two groups according to their degree 
j of primitiveness.
The 40% of HPP-CFC which survive 5-FU treatment can only be detected by the 
combined action of IL -la  plus IL-3 plus CSF-1 (Bartlemez 1989). HPP-CFC with 
more restricted requirements for growth, displaying properties of less primitive cells 
reappear sequentially in the marrow in the regeneration period following 5-FU 
treatment (reviewed in Bertoncello 1992).
The resistance to 5-FU of HPP-CFC responsive to IL -la  plus IL-3 plus CSF-1 
indicates that these cells are probably more primitive than CFU-S whose numbers are 
ablated by about 98% within 24 hours by this treatment (Hodgson and Bradley 1979, 
Van Zant 1984, Lorimore et al 1990). In addition to this there is some evidence 
correlating 5-FU-resistant HPP-CFC and bone marrow populations capable of 
conferring long-term haemopoietic reconstitution in vivo, though this data is not 
conclusive (reviewed in Bertoncello 1992). Taken together, the data indicate that
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HPP-CFC are probably the in vitro representatives of a fairly primitive component of 
the myeloid stem cell compartment
Blast-Colonv Forming Cells (Blast-CFC).
Nakahata and Ogawa (1982) have described a class of haemopoietic progenitor found 
in colonies of 40-1000 cells sixteen days after incubation of bone marrow in semi­
solid medium in the presence of pokeweed mitogen spleen conditioned medium 
(PWMSCM), which is known to be a source of at least M-CSF, IL-3 and GM-CSF 
(Broxmeyer 1990). These cells display no signs of terminal differentiation (hence the 
designation blast-CFC). On replating, the colonies produced secondary multi-lineage 
colonies with some displaying 100% replating efficiency. Leary et al (1989) observed 
that blast-CFC may remain quiescent as single cells for more than two weeks of 
culture in the absence of exogenously added growth factors. The use of neutralising 
antibodies to IL-la, EL-3, IL-6 and G-CSF indicated that dormancy of blast-CFC is 
maintained independently of these factors. The frequency of blast-CFC (4 per 10^ 
normal marrow cells) and the properties described above suggest that these cells may 
be equivalent to a pre-CFU-S cell. This question may be resolved by in vivo 
repopulation studies.
Colony Forming Unit-Assav (CFU-A).
When normal unffactionated bone marrow is incubated in semi-solid medium at a 
low density (2.5.10^/ml) in the presence of medium conditioned by the cell lines 
L929 and AF1-19T (Franz et al 1985) a number of colony-types are found to be 
present after 11 days, including colonies of diameters of greater than 2mm, derived 
from a cell now designated CFU-A (Pragnell et al 1988, Eckmann et al 1989). On 
morphological examination, the CFU-A-derived colonies can contain cells from
several haemopoietic lineages, including macrophages, granulocytes and 
megakaryocytes (Eckmann et al 1989).
Several properties of the CFU-A cell, including its low proliferative status, incidence 
in bone marrow (150-200 per 10^), buoyant density, recovery after 5-FU treatment in 
vivo, radial distribution in the femur and response to ionising radiation indicate 
overlap between CFU-A and CFU-S but not GM-CFC populations (Eckmann et al 
1989, Lorimore et al 1990). In addition to this Pragnell et al (1988) report recovery of 
CFU-S cells from CFU-A-derived colonies.
The two conditioned media used in this assay are known to contain GM-CSF and M- 
CSF, however it is unlikely that stimulation of CFU-A growth can be achieved by 
these factors alone as the colonies stimulated by iGM-CSF and rM-CSF, although 
macroscopic (Pragnell et al 1988, McNiece et al 1988) do not display the same 
capacity for multipotentiality (I.Pragnell personal communication.); it is likely, 
therefore, .that additional factors, probably contained in AF1-19T conditioned 
medium are contributing to the development of colonies from CFU-A. The AF1-19T 
line does not express mRNA for IL-3 (Pragnell et al 1988); however, Kriegler et al
(1990) have reported evidence that these cells produce IL -la  and an IL-6-like 
activity, so it is possible that these factors may be contributing to the assay. Pragnell 
et al (1988), on the other hand, found that a neutralising antibody against IL -la  had 
no effect on CFU-A colony formation. Pragnell et al (personal communication) have 
recently demonstrated that addition of stem cell factor (SCF) in the CFU-A assay 
along with GM-CSF and M-CSF allows the detection of colonies with very similar 
appearance to those detected using conditioned media, so it is possible that SCF is an 
important regulator of CFU-A proliferation.
1.1.6 Positive Regulation of Haemopoietic Stem Cell Proliferation.
It is now a generally accepted hypothesis that the proliferation of haemopoietic cells 
is determined by a balance between positive and negative regulators produced by the 
stroma.
The importance of the stromal microenvironment in both the maintenance and 
regulation of stem cell proliferation is illustrated by the (Steel) SI and W (white 
spotting) anaemic mice. These two mutants have similar phenotypic abnormalities, 
including deficiency of the activity of very primitive haemopoietic stem cells (Russell
1979). Transplantation and studies with long-term bone marrow cultures showed that 
the W defect is intrinsic to the stem cells themselves while the SI deficiency is a 
function of the haemopoietic microenvironment (Russell et al 1979, Dexter and 
Moore 1977).
The gene products of the W and SI loci have now been identified. The W locus 
product codes for the c-kit proto-oncogene, a tyrosine kinase receptor (Chabot et al 
1988, Geissler et al 1988) which is structurally related to the receptors for CSF-1 and 
platelet-derived growth factor (PDGF) (Qui et al 1988).
The SI locus encodes the ligand for the c-kit receptor. Several groups have isolated 
cDNAs for this growth factor (Williams et al 1990, Copeland et al 1990, Flanagan 
and Leder 1990, Zsebo et al 1990a, 1990b, Martin et al 1990, Huang et al 1990, 
Anderson et al 1990) called variously, mast cell growth factor (MGF), stem cell 
factor (SCF) or kit ligand (KL) which predicts a protein product with a signal peptide 
and intracellular, transmembrane and extracellular domains. Both the soluble and 
transmembrane forms of SCF are biologically active (Anderson et al 1990).
The biological effects of deficiency in SCF activity are a powerful demonstration of a 
role for this molecule in stem cell biology. Other factors which have been proposed to 
have a positive effect on stem cells have been identified by virtue of their effects in
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the in vitro assays for primitive progenitors discussed above. This means that their 
effects on stem cells in vivo can only be inferred rather demonstrated.
One general feature which appears to be emerging from the in vitro studies is that 
colonies derived from very primitive stem cells are only observed upon stimulation 
with multiple cytokines as illustrated by the dependence of both CFU-A and the more 
primitive HPP-CFC on at least three different growth factors (Pragnell et al 1988, 
Bradley and Hodgson 1979, Bertoncello et al 1992) for colony formation.
Two types of activity appear to be necessary for the maximal colony formation by 
very primitive progenitors and these can be illustrated by considering the growth 
factor combinations necessary for HPP-CFC colony development.
SCF and IL-1 on their own have a minimal effect, if any, on the proliferation of 
purified or enriched primitive cells (De Vries et al 1991, Bartlemez and Stanley 
1985). However, either of these factors, in conjunction with a later acting lineage- 
restricted cytokine (such as CSF-1 or G-CSF) can stimulate the proliferation of HPP- 
CFC colonies (Zsebo et al 1990a, McNiece et al 1989, Moore and Warren 1987), 
seemingly expanding the range of progenitor cells able to respond to the CSF in the 
primitive direction. Therefore, it can be seen that molecules conferring ability to 
respond to colony stimulating factors in addition to the CSFs themselves are essential 
for the proliferation of the most primitive cells of the haemopoietic system.
Bartlemez and Stanley (1985) have demonstrated the ability of EL-1 to increase the 
number of receptors for CSF-1 in cultures of bone marrow enriched for primitive 
cells. This is one possible mechanism by which SCF and EL-1 exert their effects on 
stem cell proliferation.
IL-3 and GM-CSF, as single agents, have been shown to promote the growth of a 
subpopulation of blast-CFC after a lag of several days (Koike et al 1988). This may 
be taken as evidence that single growth factors are able to induce the proliferation of 
stem cells; however, the primitive status of blast-CFC is a matter of controversy and
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further studies await the resolution of this point. What is clear, however, is that a 
number of growth factors, which are ineffective on their own, including IL-1, IL-6, 
G-CSF (Ikebuchi et al 1987) IL-4 (Kishi et al 1989), IL-11 (Musashi et al 1990), LIF 
(Leary et al 1990) and SCF (Williams et al 1991) have been demonstrated to hasten 
the entry of quiescent blast-CFC cells into active cell cycle.
These data therefore, reinforce the idea that the proliferation of primitive 
haemopoietic progenitors with stem-like properties are regulated by combinations of 
growth factors.
1.1.7 The Role of Bone Marrow Stroma in Haemopoiesis.
In the marrow, the haemopoietic cells are associated with stromal tissue, a network of 
cells and extracellular matrix which not only physically supports the haemopoietic 
cells but is also believed to influence their differentiation through the creation of an 
inductive microenvironment. The bone marrow stroma contains several types of 
adherent cells including fibroblasts, reticular adventitial cells and macrophages (for 
reviews see Owen 1988, Dexter et al 1990, Greenberger 1991, Quesenberry 1992). 
Much of what is known about the interactions between stromal and haemopoietic 
cells is derived from studies involving the long-term bone mairow culture (LTBMC) 
system. If normal murine bone marrow is cultured in vitro under appropriate 
conditions, an adherent layer is formed on the surface of the culture dish which can 
subsequently support active haemopoiesis, in the absence of exogenously added 
cytokines, including the maintenance of CFU-S and the proliferation and 
development of progenitor cells able to produce erythrocytes, neutrophils, 
macrophages, eosinophils, megakaryocytes, mast cells for prolonged periods (Dexter 
et al 1977, Schofield and Dexter 1985).
The presence of the stromal layer is absolutely required for the maintenance of 
haemopoiesis over extended periods, from which it is inferred that the growth-
14
promoting, differentiation-inducing and regulatory activities necessary for 
haemopoiesis are produced by these cells. However, the mechanism(s) by which this 
is effected, especially the nature of the role played by cytokines, if any, is still a 
matter of some controversy.
The results of attempts to demonstrate the production of cytokines by the stromal 
cells of LTBMC have been highly variable.
Several groups investigating the expression of either bioactivity or mRNA expression 
of the CSFs by bone marrow stromal cells have only detected constitutive production 
of CSF-1 (M-CSF) (Fibbe et al 1988, Sieff et al 1988, Piersma et al 1984, Schaafsma 
et al 1989).
The expression of protein and/or mRNA for several cytokines, such as EL-6, GM- 
CSF, G-CSF and IL-7 by LTBMC stroma (Gualtieri et al 1984, Quesenberry et al 
1990) and of mRNA for the positive regulators IL-7, IL-6, G-CSF and the negative 
regulators TGFp and TNFa in specific cloned stromal cell lines (Gimble et al 1989) 
is clearly demonstrable; however these factors are only readily detectable after 
stimulation.
Dexter et al (1990) and Zipori (199 f )have argued that the available information does 
not support a role for the myeloid colony-stimulating factors in the stroma-dependent 
development of haemopoietic cells in LTBMC. However, it is possible that stromal 
cells which have not been exposed to strong inducing signals are capable of 
producing levels of cytokine mRNA and protein below the level of detection by 
conventional techniques.
Kittler et al (1992) have recently reported the detection of mRNA for IL-3 in LTBMC 
stroma by the highly sensitive polymerase chain reaction (PCR) technique. The 
ability of LTBMC stroma (depleted of haemopoietic cells by irradiation) to support 
the growth of factor-dependent haemopoietic cell lines and the abolition of this 
support by antibodies specifically directed against IL-3 or GM-CSF demonstrates that
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these CSFs can be produced by LTBMC stroma and is strongly indicative of a role 
for these factors in the maintenance of haemopoiesis in this system.
Interestingly, Gualtieri et al (1984) demonstrated, using an in situ detection method 
which allows detection of very low levels of colony stimulating activity, an inverse 
correlation between colony-stimulating activity for granulocyte/macrophage colonies 
and haemopoietic activity in LTBMC. One interpretation of this data is that CSFs are 
being utilised or degraded by haemopoietic cells, which would account for the 
inability of many investigators to detect cytokine activity in haemopoietically active 
LTBMC.
An additional issue in this argument is whether the CSFs, even if they are produced 
by haemopoietic stroma are actually relevant to stroma-dependent haemopoiesis.
The role of SCF in the stromal control of stem cell proliferation has been discussed 
above (section 1.1.6).
Yoshida et al (1990) have demonstrated that the approximately 50% reduction in the 
numbers of macrophages and severe reduction in the number of osteoclasts in the 
op/op strain of mice is due to a failure to produce CSF-1. The fact that the op/op 
mutation can not be corrected by transfer of normal haemopoietic cells (Yoshida et al 
1990) suggests that this is a stromal defect. It seems, therefore, that CSF-1 has a 
definite role to play in the maintenance of haemopoiesis.
The fact that some CSFs associated with stroma are found only in barely detectable 
amounts may mean that haemopoietic cells are only ever exposed to suboptimal 
concentrations of these factors; again throwing some doubt on the predominance of 
the CSFs as the determining factor in the differentiation and development of these 
cells. However, the context in which the CSF is presented to the growth factor may 
greatly influence the effective concentration of the CSF at the cell surface.
Gordon et al (1987) and Roberts et al (1988) have demonstrated that molecules of the 
extracellular matrix (in particular glycosaminoglycans) are capable of binding GM-
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CSF and EL-3 in a biologically active form. Given that direct contact (Dexter et al 
1977) or at least extremely close association (Verfaille 1992) between haemopoietic 
cells and stroma is necessary for active haemopoiesis in LTBMC, the concentration 
of even a small number of growth factor molecules to a discrete site on the stroma in 
this way might constitute an effective method way of directing haemopoietic 
development with a relatively small number of CSF molecules and of confining CSF- 
directed haemopoiesis to particular discrete sites on the stroma.
Interestingly, Rathjen (1990) have shown LIF can be secreted in two forms by 
embryonic fibroblasts, one which is soluble and another which is immobilised by 
being bound by molecules of the extracellular matrix by virtue of having a portion of 
the N-terminal end of the molecule encoded by an alternative first exon. It will be 
interesting to see whether this is a general feature of the expression of cytokines by 
stromal cells.
Basic fibroblast growth factor (bFGF), which has potent mitogenic activity in several 
cell types has been shown to bind extracellular matrix molecules, in particular the 
glycosaminoglycan heparin. Yayon et al (1991) have demonstrated that binding of 
bFGF to heparin is a prerequisite for binding to its specific high-affinity receptor.
This represents yet another way of ensuring that the activities of growth factors is 
context-dependent and it is possible that such a mechanism could also be involved in 
controlling the action of cytokines in marrow haemopoiesis.
Another way in which cytokine activity can be localised to the surface is to have the 
cytokine expressed as an integral membrane protein rather than as a soluble molecule. 
Anderson et al (1990) have demonstrated that SCF exists in both soluble and 
membrane-bound forms in fibroblasts. Furthermore, Flanagan et al (1991) have 
demonstrated the defective haemopoiesis seen in the Dickie strain of steel (Sl^) to be 
associated with the failure to express the membrane-bound form of SCF, indicating 
the potential importance of membrane-bound forms of cytokines.
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It is also important to note that the maximal activity of many colony stimulating 
factors can be achieved by as little as 10% receptor occupancy (Nicola 1989) which is 
also consistent with extremely low levels of cytokines being biologically relevant.
1.1.8 Two Types of Haemopoiesis.
While the role of the CSFs and cytokines in normal steady-state haemopoiesis is still 
a matter of debate, the importance of these molecules in many processes involved in 
immune defence and tissue remodelling is now well established.
Cytokines are produced on activation of monocytes and macrophages, T and B 
lymphocytes and mast cells (Arai et al 1990, Gordon et al 1990). Many of these are 
induced as part of the early programme of these cells in response to stimulation by 
non-specific inflammatory signals (monocytes/macrophages) or as part of an antigen- 
specific activation programme (T and B cells and mast cells). The mechanisms 
underlying the expression of cytokine genes are discussed in section 1.4.
In addition to their effects on haemopoietic progenitor cells, cytokines are able to 
alter the behaviour of mature, functional haemopoietic cells. For example, GM-CSF 
has effects on both mature neutrophils and macrophages which include the 
maintenance of survival and induction of proliferation in vitro (as with haemopoietic 
progenitors) (Vairo and Hamilton 1991). In addition to this GM-CSF has also been 
demonstrated to enhance the capacity of neutrophils (Weisbart et al 1985, Vadas et al 
1985) and macrophages (Hamilton et al 1988) to undergo oxidative burst. Adherence 
and chemotaxis of neutrophils and macrophages can be enhanced by the action of 
several cytokines. For example, it is now well established that IL-8 is a 
chemoattractant for neutrophils (for review see Schall 1991) and MCP-1 (monocyte 
chemotactic protein-1) appears to be a specific chemoattractant for monocytes (for 
review see Rollins 1991). Both of these cytokines can be produced by a variety of 
cells such as stimulated endothelial cells and activated monocytes.
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These latter effects are strongly indicative of a role for cytokines in the recruitment of 
leukocytes to sites of infection in injury. It is possible that the numbers of immune 
effector cells recruited to these sites could be augmented by the clonal expansion of 
blood-borne haemopoietic progenitors. Given that marrow haemopoiesis is 
exclusively associated with stromal cells, it is possible that the activities of cytokines 
uncovered by semi-solid clonal agar assays are more analogous to the action of 
soluble cytokines in the blood-stream. Indeed, Arai et al (1990) and Zipori (1990) 
have argued that the main role for the CSFs is as directors of "emergency" 
haemopoiesis associated with immune defence. Obviously, such a process would 
have to be well-regulated with mechanisms responsible for limiting the extent of the 
response both spatially and temporally.
1.2 Negative Regulation of Stem Cell Proliferation.
It has long been postulated that the size of a cellular population in a developing tissue 
could be controlled by regulating the production of mature cells from their 
progenitors. Specifically, it has been postulated that the production of cells in a 
biological system needs to be limited by a feedback message(s) which is proportional 
to the size of the resultant population (Lord 1988).
There are basically two ways in which such a negative feedback loop could be 
organised. Firstly, a negative regulator of producer cell activity could be produced by 
the resulting cells as illustrated in figure 1.2. In this way the level of negative 
regulator produced is proportional to the size of the mature population; hence, this is 
a self-regulating system, as fluctuations in mature cell numbers | are directly 
compensated for by changes in the activity of the progenitor populations.
An example of such a system might be the regulation of megakaryopoiesis in the 
bone marrow by platelet factor 4 (PF4). PF4 is a multifunctional protein specifically
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Inhibitor
Growth and Differentiation
Source Product
Figure 1.2
Figure 1.2 A model for the organisation of a simple feedback 
loop.
The source cells give rise, through a series of growth and 
differentiation events, to the product cells, which produce an 
inhibitor which feeds back to prevent the proliferation of the 
producer cell.
synthesised in megakaryocytes and stored and released by platelets which appears to 
play a role in the response to wounding. However, several investigators have 
demonstrated dose-dependent suppression of megakaryocyte progenitor maturation 
by platelet factor 4 in vivo and in vitro (Han et al 1991b). It is possible, therefore, that 
the production of megakaryocytes (and hence platelets) could be self-regulating via a 
system of simple negative feedback (for review see McDonald 1989).
Alternatively, it is possible to construct a model for negative feedback, whereby, the 
negative regulator is produced by an intermediary cell, the numbers of which do not 
fluctuate. The production of the negative regulator by the intermediary cell is 
dependent on signals received from the product cells. This system is more flexible 
than a simple negative feedback loop as it allows for the possibility of the integration 
of several types of signals, including stimulatory ones. It is likely in such situations 
that the production of the negative regulator would be controlled by signals from a 
number of sources.
It has been widely postulated that the proliferation of haemopoietic stem cells might 
be controlled, at least in part, by the modulation of production of negative feedback 
regulators.
Pluripotential haemopoietic stem cells (PHSC), as defined by the studies of Harrison 
and his co-workers appear to greatly increase their proliferative rate during the 
regeneration of marrow after administration of the cycle-specific drug 5-fluorouracil 
and return to quiescence within about five days (Harrison and Lemer 1991). It has 
been repeatedly demonstrated that the proliferation of CFU-S during marrow 
regeneration is induced and curtailed in a predictable time-frame (Siminovich et al 
1963, Shibagaki et al 1986). These observations indicate that the control of 
proliferation of the haemopoietic stem cell compartment is under both positive and 
negative controls.
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As indicated above, the level of a negative regulator should relate directly to the state 
of the haemopoietic tissue, but might also be regulated by other factors such as the 
relative level of positive regulators of stem cell proliferation. Understanding the 
signals and mechanisms which regulate the production of negative (and positive) 
regulators is essential for a full appreciation of the molecular basis of haemopoietic 
stem cell proliferation.
The stimulation of haemopoietic stem cell proliferation and differentiation was dealt 
with in section 1.1. This section will primarily deal with negative regulation.
Two seminal observations, in the 1970s, on the proliferation of murine CFU-S gave 
rise to the idea that the proliferation of these cells might be subject to control by 
specific, locally produced regulators. Gidali and Lajtha (1972) demonstrated that the 
rapid proliferation of marrow CFU-S induced by irradiation of mice could be 
prevented in a single limb protected from irradiation by a lead shield; indicating that 
control was exercised locally. Similarly, Rencricca et al (1970) observed a similar 
imbalance in the proliferation of CFU-S in the marrow and those which had migrated 
to the spleen after administration of the anaemia-inducing drug phenylhydrazine.
It was widely postulated at the time that these effects might be due to differential 
production of CFU-S-specific proliferation inhibitors, whose production would in 
turn be directly related to the proliferative state of the CFU-S compartment.
Several specific regulators of stem cell proliferation have now been described.
1.2.1 The Manchester Inhibitor.
The first specific inhibitor of CFU-S proliferation was described by Lord et al (1976) 
and subsequently became known as the Manchester Inhibitor after the city in which 
the work was carried out. This inhibitor is prepared by washing fresh, normal bone 
marrow (in which CFU-S proliferation is minimal) and obtaining a conditioned 
medium. Inhibitory activity is measured by the ability of the conditioned medium to
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block the entry of cycling CFU-S into the S-phase of the cell cycle as assayed by the 
ability to prevent the killing of CFU-S by cytotoxic drugs in vitro. The inhibitory 
material was not elaborated by regenerating bone marrow (in which CFU-S are 
proliferating rapidly); however a stimulatory, activity which could recruit quiescent 
CFU-S into S-phase, was demonstrated to be produced by this material (Lord et al 
1977).
Molecular ultrafiltration of the conditioned media consigned the inhibitory and 
stimulatory activities to separate molecular weight fractions; the inhibitory activity to 
between 50 and lOOkDa (fraction IV) and the stimulatory material to between 30 and 
50kDa (fraction III).
The inhibitor and stimulator display specificities of action which centre on the CFU-S 
compartment and which are reversible and non-cytotoxic. The exact cellular 
populations affected by these two molecules overlap but are not identical.
Tejero et al (1984) demonstrated that the action of the inhibitor was confined solely 
to the CFU-S population as the proliferative behaviour of committed progenitor cells 
was unaffected. BFU-E, GM-CFC and CFC-mix were unaffected. The stimulator 
increased the proportion of both CFU-S and CFC-mix in DNA synthesis but did not 
affect BFU-E or GM-CFC.
In addition, Wright et al (1985) have demonstrated differential sensitivity of 
components of the CFU-S compartment to actions of the stimulator and inhibitor. In 
general, more primitive cells (represented by CFU-S day 12) are much more sensitive 
to inhibitor than the stimulator, while the opposite is true for the more mature CFU-S 
day 8 cells.
The actions of both the inhibitor and stimulator on CFU-S are reversible. This 
reversal, however, requires the presence of the opposing factor as opposed to merely 
the absence of the original factor (Lord et al 1977). This indicates that the movement
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of CFU-S between quiescent and proliferative states is controlled by two separate 
mechanisms, rather than being dependent on one signal.
Very little is known about the mechanism of action of the inhibitor or stimulator; 
however, elegant studies by Lord et al (1979) suggest that the inhibitor acts by 
holding CFU-S in the GO phase of the cell cycle close to the Gl/S-phase transition 
point.
Knowledge of the cellular source of the inhibitor and stimulator is obviously 
important for a full picture of the biology of CFU-S proliferation and is essential if 
the mechanisms regulating the production of this molecule are to be investigated. A 
great deal of work to this end was carried out between 1979 and 1982 on fractionated 
cell populations of murine bone marrow and spleen by Wright and others.
Density separation of whole bone marrow on linear gradients of bovine serum 
albumin indicated that neither the inhibitor-producing nor stimulator-producing cells 
were likely to be the CFU-S cells themselves (Wright and Lord 1979, Wright et al 
1980a, Wright et al 1982). This was an important finding as it is possible to envisage 
models where the stem cell compartment could be completely self-regulating.
The source of the inhibitory activity was shown to be confined to the adherent . 
fraction of the bone marrow as removal of adherent cells of the bone marrow resulted 
in a loss of inhibitory activity. The inhibitory activity was also absent if bone marrow 
cells which had phagocytosed carbonyl iron were removed magnetically or if cells 
positive for the Fc receptor were removed by "panning" with immobilised 
immunoglobulin. Density separation showed that the inhibitor producing cells were 
confined to the fractions of density 1.052-1.062 g/ml (Wright et al 1980a, Lord and 
Wright 1982).
A similar series of experiments | was carried out in an attempt to identify the cellular 
source of the stimulatory activity in regenerating bone marrow (Wright et el 1982).
23
The results obtained were exactly the same except that the stimulator producing cells 
were contained in a slightly heavier density fraction (1.064-1.072 g/ml).
From these studies it would seem that the inhibitory and stimulatory activities could 
be consigned to the same cell-type, which from the diagnostic tests seemed most 
likely to be the macrophage, but to different subpopulations of this cell-type. 
Furthermore, Wright and Lord (1979) had shown using density fractionation that 
stimulatory material could be obtained on culturing cells of density 1.064-1.072 g/ml 
and that inhibitory material could be obtained on culturing cells of density 1.052- 
1.060 g/ml irrespective of the cycling status of the CFU-S in the source marrow. 
However, there was no evidence for the simultaneous presence of both factors; 
indeed, fraction IV from regenerating marrow was found to contain no inhibitor and 
fraction IE from normal bone marrow was found to contain no stimulator (Lord et al 
1977; Lord et al 1976).
It would seem, therefore, that the two activities are produced by separable 
macrophage populations which are present in the marrow regardless of the kinetic 
status of the CFU-S population but whose ability to produce their respective activities 
is directly related to the aforementioned. These data, then, argue for a role for both of 
these activities in the control of CFU-S proliferation and also that the production of 
these can be modulated by appropriate physiological conditions.
Simmons and Lord (1985) attempted to further characterise the inhibitor-producing 
cell by separation of low-density marrow cells based on expression of the murine 
macrophage-specific antigen F4/80 using a fluorescence activated cell sorter (FACS). 
The F4/80 positive population was found to have a 200-fold increased production of 
inhibitory material over unfractionated bone marrow. These cells were able to 
proliferate in the presence of conditioned medium from the cell lines L929 and 
WEHI3B which are sources of macrophage-colony stimulating factor (M-CSF) 
(Stanley and Guilbert 1981) and IL-3 plus M-CSF (Bazill et al 1983), respectively.
Proliferation was rapid in L929CM, but was more modest in WEHICM. The 
behaviour of these cells when cultured in the absence of conditioned media was not 
reported. Production of inhibitory material was enhanced a further 15 to 20-fold by 
culture of F4/80 positive cells in L929CM over several weeks. Morphologically, 
these cells resemble macrophages and have the ability to phagocytose latex particles. 
In addition to F4/80 they express the macrophage-specific antigen Mac-1 but not the 
neutrophil-specific 7/4 antigen. These cells are also negative for collagen types I and 
IV. In terms of enzyme histochemistry, these cells are positive for Acid-phosphatase, 
alpha-Napthyl acetate esterase and Myeloperoxidase but negative for Alkaline 
phosphatase.
Which population of bone marrow macrophages is represented by these sorted cells is 
not clear. The F4/80 antigen has been demonstrated by Austyn and Gordon (1981) to 
be present on "resident" macrophages ffom several tissues including lung, spleen and 
thymus as well as staining resident macrophages of the marrow in situ (Crocker and 
Gordon 1985), suggesting that the fixed stromal bone macrophages of the marrow 
would have been sorted by Simmons and Lord (1985). However, the antibody is also 
reactive with murine blood monocytes (Austyn and Gordon 1981) which makes it 
possible that the most mature cells of the developing mononouclear phagocyte series 
in the marrow might also be part of the experimental population.
The fact that stimulator and inhibitor producing macrophages were demonstrated to 
be different macrophage sub-types suggested that the expression of both these 
activities might be very different in different macrophage sub-types. Accordingly, 
Pojda et al (1988) investigated the abilities of macrophages freshly isolated and 
cultured from different sources to produce inhibitory material.
Normal bone marrow, as expected, and cultured bone marrow macrophages were 
very strong producers while material obtained ffom both fresh and cultured 
peritoneal macrophages were only mildly inhibitory in comparison to the marrow-
derived macrophages. Fresh splenic macrophages produced a level of inhibitor 
comparable to that ffom peritoneal macrophages but cultured splenic macrophages 
produced a much higher level. Macrophages from mouse peripheral blood also 
produced a fairly high level of inhibitor. Wright and Lorimore (1987) also 
demonstrated the ability of bone maiTOw macrophages to elaborate inhibitory 
material.
Production of inhibitory material ffom species other than mouse has also been 
demonstrated. Wright et al (1980b) have reported that fraction IV from fresh human 
bone marrow and from human long-term marrow culture elaborated inhibitory 
material while fraction ID from the same sources had no effect, either inhibitory or 
stimulatory. Pojda et al (1988) observed that the ability of cultured human blood 
macrophages to produce inhibitory material was variable. Cork et al (1981) also 
demonstrated that fraction IV ffom media conditioned by rat bone marrow was 
inhibitory to the proliferation of murine CFU-S while fraction III had no effect. The 
ultrafiltration characteristics of both the human and rat inhibitors were identical to 
that of the murine inhibitor. Material inhibitory to the proliferation of murine CFU-S 
has also been isolated from the bone marrow of pig and rabbit (Lord and Wright
1980).
It would appear, therefore, that the occurrence and activity of the inhibitor, at least, is 
not species specific. However, the vast majority of the investigations into the specific 
actions of both the stimulator and inhibitor have been carried out in the murine 
system.
Taken together, the data demonstrate that while both stimulator- and inhibitor- 
producing cells are present in the marrow at the one time, irrespective of the cycling 
status of the CFU-S, both stem-cell regulating activities can not be present in the 
marrow simultaneously. However, when inhibitor- or stimulator-producing cells are 
separated ffom each other they are able to resynthesise the appropriate factor
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irrespective of the CFU-S cycling status of the marrow of origin (Lord and Wright 
1982). Lord and Wright (1982) also demonstrated that, while the two factors are not 
mutually destructive, inhibitor could block the production of stimulator by cells of the 
appropriate density and vise versa. In addition, the active presence of the appropriate 
factor, not just the absence of the opposing factor, is necessary for changes in CFU-S 
proliferation state to take place (Lord and Wright 1982).
Clearly, any model for the regulation of CFU-S proliferation by the stimulator and 
inhibitor must take these factors into account. In addition to this, the predominance of 
either inhibitor or stimulator must be dependent on an appropriate physiological 
signal.
Lord and Wright (1982) and Lord (1988) have argued that this signal must come ffom 
the CFU-S compartment itself due to the heterogeneous nature of the maturing blood 
cells. A model for such an arrangement is illustrated in figure 1.3.
It can be seen that the proliferation of the CFU-S is dependent on the presence of 
either inhibitor (I) or stimulator (S). In the steady-state, where CFU-S are quiescent, 
the predominance of inhibitor is ensured by the production of a "feedback factor" 
from the CFU-S. The feedback faGtor acts to block the production of stimulator (S) 
ffom the appropriate macrophage subpopulation (ms), ensuring the production of 
inhibitor (I) from the appropriate cells (m j). Conversion to predominance of 
stimulator production is triggered by a decline in the production of the feedback 
factor from the CFU-S compartment, leading to the production of stimulator which 
then both induces proliferation of the CFU-S and blocks production of the inhibitor. 
The decline in inhibitor production could be caused simply by a reduction in CFU-S 
numbers or by a change in physiological state caused by, for example, the release of 
growth factors ffom the marrow microenvironment as a consequence of marrow 
ablation. Lending support to this model, Lord (1986) has reported the existence of an 
activity in medium conditioned by a purified population of CFU-S which is capable
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Figure 1.3 A model for the regulation of proliferation of 
myeloid stem cells by opposing inhibitory and stimulatory 
activities.
of blocking the production of stimulator, although it has not been characterised to any 
extent.
1.2.2 Other Negative Regulators of CFU-S
Other potentially physiologically important regulators of CFU-S proliferation have 
also been described and will be considered in this section.
1.2.2.1 The Terapeptide AcSDKP.
The tetrapeptide Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) was demonstrated by Lenfant 
et al (1989) to prevent the recruitment of marrow CFU-S into cycle by administration 
of the cell cycle-specific cytotoxic drug cytosine-arabinoside in vivo. The action of 
AcSDKP appears to be specific to the CFU-S compartment as the formation of GM- 
CFC colonies is not affected by its presence (Monpezat and Frindel 1989). 
Interestingly, studies on the mechanism of action of AcSDKP indicate that it is only 
capable of maintaining quiescent cells in the GO phase of the cell as it is unable to 
affect cells which are already actively cycling or indeed even cells at the G 1/S-phase 
boundary (Monpezat and Frindel 1989). This means that the tetrapeptide may exert 
its effects either early in G1 or at the G0/G1 boundary.
Administration of specific anti-AcSDKP antiserum to mice significantly increases the 
percentage of CFU-S in cycle, supporting a role for AcSDKP in the maintenance of 
CFU-S quiescence in normal bone marrow. Interestingly, if this was the case it would 
mean that the the CFU-S compartment is maintained in the quiescent state by only 
one molecule; while this is certainly possible it seems unlikely given that redundancy 
appears to be a predominant feature of the action of cytokines on primitive 
haemopoietic cells.
The AcSDKP sequence has so far been found in only three proteins, thymosin (34, 
TNFa and rat liver phenylhydrazine hydroxylase (Lenfant et al 1989). It is possible,
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therefore, that the tetrapeptide is produced by the proteolytic cleavage of one of these 
proteins; therefore the physiological activity of the tetrapeptide might be controlled 
by the secretion and/or activation of specific enzymes. Pradelles et al (1991,1990) 
have demonstrated the presence of both AcSDKP and thymosin (34 in extracts from a 
wide number of mouse tissues and in cultured human leukocytes. In addition, 
Wdzieczak-Bakala et al (1990) have demonstrated constitutive production of 
AcSDKP in long-term marrow culture, which again argues for a role for this 
molecule in haemopoietic regulation. Interestingly, Moscinski and Prystowsky (1990) 
have observed induction of expression of the thymosin P4 gene in GM-CSF induced 
myeloid differentiation, which raises the possibility of this molecule acting, via 
proteolytic cleavage to produce the tetrapeptide, as a negative feedback factor.
1.2.2.2 The Hemoregulatorv Peptide fHP5B)
The hemoregulatory peptide (HP5B) has the sequence pyroGlu-Glu-Asp-Cys-Lys 
(pEEDCK) (Laerum and Paukovits 1984a). This molecule is capable of inhibiting the 
formation of GM-CFC colonies in-vitro and CFU-S and GM-CFC in vivo, but has no 
effect on colony formation by erythroid progenitors (Laerum and Paukovits 1984a, 
Laerum and Paukovits 1984b, Laerum et al 1990). Paukovits et al (1987) have 
reported binding of ^H-labelled pEEDCK to bone marrow but not spleen or thymus 
cells, suggesting that the action of the haemoreulatory peptide may be specific to the 
marrow.
The inhibition of GM-CFC colony-formation in vitro can be achieved with 
concentrations of pEEDCK as low as 1 0 ' The molecule can dimerise through 
the formation of intermolecular disulphide bonds; intruigingly, this form of the 
molecule, rather than being inhibitory, is stimulatory for the both murine and human 
GM-CFC in the concentration range 1 0 '^  to 10"^M.
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Although the factor was initially identified in extracts of rodent bone marrow and 
human leukocytes, no further information has been reported on its cellular source in 
the marrow. Laerum et al (1990) have identified sequences similar to pEECDK in the 
G la  subunit of G proteins. The significance of this fact is unclear, however, as these 
are intracellular proteins.
1.2.2.3 Transforming Growth Factor J3 (TGFJ3).
TGFp is a multifunctional regulator of cell behaviour and has a wide variety of 
effects on a number of cellular systems. It is a member of a large family of 
structurally-related multifunctional cytokines (for review see Massague 1990). It is 
ubiquitously expressed in a latent form which is activated to form an active 25kDa 
homodimer of two 12.5kDa chains linked by disulphide bonds. Activation of this 
form is required for biological activity (Spom et al 1987). Mammals express three 
forms of TGFp (TGFp 1,2 and 3) which are highly homologous and more than 90% 
conserved between species (Massague 1990).
Membrane receptor labelling studies have identified at least nine membrane- 
associated proteins which bind TGFp. However, the significance of most of these is 
at the moment uncertain (for review see Massague 1992). At least two of these 
proteins TGFpR type I and TGFpR type II have are associated with the transmission 
of antiproliferative signals in a lung epithelial cell line (Laiho et al 1991). Many of 
the antiproliferative effects of binding to the TGFp receptors are thought to be 
mediated ultimately at the level of tumour suppressor genes, such as the 
retioblastoma gene product whose activity controls commitment to the cell cycle and 
by the inhibiting the expression of nuclear proto-oncogene c-myc (for review see 
Moses 1990). TGFP is also capable of down-regulating the expression of receptors 
for stimulatory growth factors as will be discussed below.
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All three of the mammalian forms of TGF(3 are active in the haemopoietic system, 
with slightly different potencies (Keller et al 1992).
In situ hybridisation and immunohistochemical studies have demonstrated that TGFP 
is produced in areas of active haemopoiesis such as bone marrow and fetal liver 
(Seyedin et al 1985, Wilcox and Derynck 1988). In vitro studies have also 
demonstrated it to have a wide variety of effects on haemopoietic cells, including the 
modulation of the differentiated functions of mature cells. For example, it is an 
extremely potent chemotactic factor for monocytes (Wahl et al 1987) and is also able 
to deactivate macrophages (Tsunawaki et al 1988). In addition, TGFP can inhibit the 
production of cytokines from both T cells and monocytes (Wahl et al 1987).
The major biological effect of TGFP on the haemopoietic system, however, is the 
reversible inhibition of proliferation (for review see Keller et al 1992). In general, 
TGFp appears to act as a selective negative regulator of primitive haemopoietic cells, 
while more committed progenitors are unaffected. For example, Keller et al (1988) 
have shown that TGFpl is a potent inhibitor of the formation of mixed myeloid 
lineage colony formation induced by IL-3 plus erythropoietin, while colony 
formation by the single lineage progenitors is completely unaffected. In addition, the 
formation of colonies in the HPP-CFC in vitro stem cell assay is inhibited by TGFpl 
in a dose-dependent manner as is the formation of colonies in response to IL-3 of 
primitive human progenitor cells sorted directly from the marrow (Keller et al 1990), 
suggesting that the negative regulatory effects of TGFp extend to the stem cell 
compartment and that these effects are direct rather than mediated by the production 
of other factors by accessory cells.
Eaves et al (1991) and Cashman et al (1990) have studied the role of TGFp in the 
control of proliferation of primitive progenitor cells in human long-term bone marrow 
culture. Antibody versus TGFp could prolong the period of proliferation of 
previously cycling, and activate the proliferation of quiescent, primitive progenitors,
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suggesting that TGFp has a role to play in the production and maintenance of the 
quiescent state in these cells.
The mechanism by which TGFp exerts its negative effects on the growth of primitive 
haemopoietic progenitors is unclear at present. However, Jacobsen et al (1991) have 
demonstrated that TGFp downregulates the numbers of the receptors for GM-CSF, 
IL-3 and G-CSF in factor-dependent and independent haemopoietic progenitor cell 
lines at concentrations similar to those which were inhibitory for proliferation; 
therefore it is possible that this mechanism could also operate on bone marrow 
progenitor cells.
It is now becoming apparent that TGFp can also display positive proliferative effects 
on haemopoietic progenitors in certain circumstances. For example, Keller et al
(1991) have demonstrated that the number and size of bone marrow colonies induced 
by murine GM-CSF is increased 3 to 5-fold in the presence of TGFp. This ability to 
act as a bipotential regulator of haemopoiesis is also seen with the haemoregulatory 
peptide and with SCI/MIP-la (Broxmeyer et al 1989,1990, 1991).
Given the ubiquity of expression of TGFP it is pertinent to ask how the activity of 
this molecule on the haemopietic system is controlled.
Most cell-types examined so far have receptors for TGFp (Massague 1992) so 
specificity of action is unlikely to be mediated by differential receptor expression.
One level of control is at the modulation of production from cell of origin. For 
example, human monocytes secrete 10-fold more TGFP activity after activation by 
LPS or ConA (Assoian et al 1987).
Yet another level of control could be the selective activation of TGFp from the latent 
form. Before use in the laboratory the molecule must be activated, usually by 
transient acidification (Lawrence et al 1985), however, it is not clear how the 
molecule might be activated in vivo. Plasmin has been shown to activate the molecule
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(Lyons et al 1988), so it is possible that selective release of specific proteases at sites 
of action could be an important controlling factor.
In addition, TGFp has been shown to form an inactivating complex with 0C2 - 
macroglobulin (Keller et al 1992) and it is possible that some of the differential 
effects seen TGFpl and TGFP2 in inhibiting the growth of haemopoietic cells (Keller 
et al 1992) could be due to the different affinities of these molecules for (X2 - 
macroglobulin.
1.3. Macrophage Inflammatory Protein-la.
1.3.1 Structure and Genetics of SCI/MIP-la and MIP-1J3.
Biochemical characterisation of the Manchester Inhibitor was hindered for many 
years by the lack of a suitable assay. This situation was remedied by the development 
of the CFU-A assay by Pragnell et al (1988). This allowed Graham et al (1990) to 
purify the active protein component of the Manchester Inhibitor which they termed 
Stem Cell Inhibitor (SCI). When partially sequenced, SCI was found to be 
functionally and antigenically identical to the alpha chain of a previously described 
protein, Macrophage Inflammatory Protein-1 (Graham et al 1990; Wolpe et al 1988). 
MIP-1 is one of the two major heparin-binding proteins secreted on LPS activation of 
a murine macrophage cell line (RAW 264.7) that are found to elute with 0.7M 
sodium chloride; the other major protein being named MIP-2 (Wolpe et al 1988). 
MIP-1 purifies as a doublet, both components of which migrate on SDS-PAGE as 
proteins of approximately 8,000 daltons. The cDNA sequences of both components of 
MIP-1 have been obtained and termed SCI/MIP-la (Davatelis et al 1988, Brown et al 
1989, Kwon and Weissman 1989) andM IP-lp (Sherry et al 1988).
Purified recombinant MIP-1 a, as tested in the CFU-A assay, was found to be 
functionally and antigenically j indistiguishable ffom the active component of the 
Manchester Inhibitor and purified natural SCI. Purified recombinant MIP-1 P was inactive in this
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respect at the concentrations tested (Graham et al 1990). The active component, or 
components, of the Manchester Stimulator have not been identified.
Although MIP-1 a  and MIP-1 (3 are very similar (see below) and co-purify, it is 
uncertain at the moment whether the two peptides would associate in vivo. MIP-1 
appears to form multimers in vitro of a  and p chains of varied molecular mass up to 
one million daltons; this is a non-covalent interaction which is most likely due to 
ionic interactions as high ionic buffers lessen the association (G.Graham personal 
communication).
The strong affinity of MIP-1 protein for heparin may have implications for the 
biological properties of both SCVMIP-la and MIP-1 p.
The cDNA for SCI/MIP-la (Davatelis et al 1988) predicts a mature peptide of sixty- 
nine amino acids with a molecular weight of 7,889 daltons, from a ninety-two amino 
acid precursor molecule, which contains no apparent sites for N-glycosylation. The 
cDNA for MIP-1 P also predicts a mature peptide of sixty-nine amino acids from a 
ninety-two amino acid precursor, containing one potential site for N-glycosylation at 
position 53 (Asn-Pro-Ser).
Glycosylation of MIP-1 P might explain its slightly greater apparent molecular weight 
on resolution of the MIP-1 doublet on SDS-PAGE.
The two cDNAs share 57% identity at the nucleotide level. The predicted amino acid 
sequences are 60% identical over their entire lengths and 69% identical in the 
sequences of the mature peptides. Both sequences contain typical hydrophobic signal 
sequences (which are involved in the secretion of proteins and are subsequently 
cleaved to produce the mature peptide). The hydrophilicity plots of the two sequences 
are almost superimposable (Sherry et al 1988). Both sequences contain single open 
reading frames and have AT-rich sequences in their 3' untranslated regions which 
correspond to the consensus sequences defined by Caput et al (1986) and which are
found in the mRNA of many immunomodulatory and other transiently expressed 
genes and are believed to confer instability (Shaw and Kamen 1986).
SCI/MIP-la 3’UTR contains four interspersed, imperfect copies of the TATTTAT 
sequence defined by Caput et al (1986), while MIP-1 P contains one element with 
perfect correspondence to the consensus.
The cells which have been shown to express mRNA for SCI/MIP-la and MIP-1 P are 
monocytic cell lines (Davatelis et al 1988, Orlofsky et al 1991, Widmer et al 1991, 
Martin andDorf 1991, T cell lines (Brown et al 1989, Kwon and Weissman 1989), 
mast cell lines (Burd et al 1989) and purified epidermal Langerhan's cells (G.Graham, 
K.Parkinson personal communication).
Human homologues of SCI/MIP-la and MIP-1 p have been cloned and characterised 
by several different groups. All of these cDNAs have been isolated as sequences 
induced on activation of haemopoietic cells. In addition, non-allelic variants of both 
of the human genes have been identified.
At least three different cDNAs for genes which appear to be human homologues of 
murine MIP-1 a  (Obaru et al 1986, Zipfel et al 1989, Nakao et al 1990, Irving et al 
1991, Siderovski et al 1990) have been isolated.
In addition, at least seven independent human cDNA sequences which display a high 
degree of identity to murine MIP-1 p have also been described (Lipes et al 1988, 
Zipfel et al 1989, Chang and Reinherz 1989, Miller et al 1989, Spom et al 1990).
The genomic sequences of SCI/MIP-la (Grove et al 1990, Widmer et al 1991), 
human MIP-1 a  (LD78) and human MIP-1 p (Act-2) have been obtained (Blum et al 
1990; Irving et al 1990; Nakao et al 1990). This area has recently been reviewed by 
Schall (1991).
All of these genes exhibit a three exon, two intron structure. The first exon codes for 
the 5’ untranslated sequence of the mRNA and the coding nucleotides for the leader 
sequence. The second exon codes for the amino-terminal end of the protein and the
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carboxyl end of the protein and the 3' untranslated region of the mRNA are coded for 
by the third exon. This organisation is typical of that of members of the MIP-1 family 
(see below).
The organisation of the genomic and cDNA sequences of SCI/MIP-la is represented 
schematically in figure 1.4.
1.3.2 The MIP-1 Family.
The murine and human versions of SCI/MIP-la and MIP-1 (3 belong to a family of 
cytokine genes entitled variously the MIP-1, the SCY or the 17q family (Wolpe and 
Cerami 1989; Schall 1991; Stoeckle and Barker 1990). Membership of this family is 
conferred by sequence conservation, in particular that of four position-invariant 
cysteine residues, the first two of which are located adjacent to each other near the 
amino-terminal end of the protein (for review see Wolpe and Cerami 1989; Schall 
1991).
The murine MIP-1 family has six members: MIP-1 a, MIP-1 p, JE (Cochran et al, 
1983; for review see Rollins 1991), TCA3, (Burd et al 1987), p500 (Brown et al
1989) and CIO (Orlofsky et al 1991). TCA3 and p500 are alternatively spliced forms 
of the mRNA ffom one gene (Wilson et al 1990A). All of the genes for this family 
have been mapped to the same locus (qll-q21) on mouse chromosome 11 (Wilson et 
al 1990a) except for CIO which has not yet been assigned to a locus. The SCI/MIP- 
l a  gene, at least, appears to be present as a single copy (Kwon and Weissman (1989). 
The human MIP-1 family has five members, four of which are homologues of the 
murine members: LD78/464.1/GOS 19-1 (human MIP-1 a), Act-2/744.1 (human 
MIP-1 p), MCP-1 (Rollins et al 1989), 1-309 (Miller et al 1989) and RANTES (Schall 
et al 1988). All of the known human MIP-1 genes have been mapped to chromosome
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Figure 1.4 Organisation of the SCI/MIP-la gene, messenger 
RNA and protein.
A SCI/MIP-la genomic organisation: Boxes designate the 
intronic sequences; filled and open boxes signify the protein- 
coding and 5' and 3' untranslated sequences, respectively.
B SCI/MIP-la mRNA: Hatched sections are protein-coding. 
Numbers 156 and 268 refer to position of splice sites; number 766 
refers to the polyadenylation signal.
C SCI/MIP-la protein: Hatched section designates leader 
sequence; open section, mature peptide. Numbers refer to the 
positions of the four conserved cysteine residues.
This figure is based on information contained in Davatelis et al
(1988) and Widmer et al (1991). The organisation of MIP-1 P 
mRNA and protein is essentially identical (Sherry et al 1988).
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17 (ql l-q21) (Donlon et al 1990; Irving et al 1990; Miller et al 1990; Mehrabian et al 
1991; Rollins et al 1991). The non-allelic variants of LD78/464.1/GOS 19-1 and Act- 
2/744.1 have also been shown to map to the same locus (Irving et al 1990).
Most of the cDNAs have been identified as sequences inducible on cellular 
stimulation which have been isolated by differential screening of haemopoietic cells 
(TCA3, LD78, Act-2,1-309) or fibroblasts (JE). RANTES and CIO, neither of which 
as yet has an identified cross-species homologue, were also isolated from 
haemopoietic cells but have a slightly different pattern of expression in that their 
mRNA tends to be decreased on stimulation.
1.3.3 MIP-2 Family.
The MIP-1 family of cytokines is one of two branches of a cytokine superfamily, the 
platelet factor four (PF4) superfamily. Membership of the other branch, the archetype 
of which is PF4 is also conferred by sequence conservation. Members of the MIP-2 
family also have four conserved cysteines. These are in similar positions to those of 
the MIP-1 family except that the first two cysteines are separated by a single amino 
acid rather than being adjacent (for reviews see Wolpe and Cerami 1989, Stoeckle 
and Barker 1990). The MIP-2 family contains both murine, human, rabbit and 
chicken members. The genes for the human proteins PF4, MGSA/gro and IP-10 have 
been mapped to the same locus (ql3-q21) on human chromosome 4 (Stoeckle and 
Barker 1990).
1.3.4 Biology of the MIP-1 Family.
Understanding of the biology of the MIP-1 family cytokines is still at an early stage 
and some members of the murine branch (JE, p500, CIO) have yet to be assigned any 
function. However, a body of evidence is beginning to emerge which is consistent 
with the members of the MIP-1 family acting as mediators responsible for attracting
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immune effector cells to sites of inflammation and injury (for review see Schall 
1991).
MIP-1 and TCA-3 have been shown to cause localised inflammation and swelling 
after injection into mouse footpads (Wolpe et al 1988, Wilson et al 1990b), 
suggesting that these proteins may play a role in mediating the inflammatory 
response. However, this may not be a specific effect of these proteins as very high 
protein concentrations and partially purified material, respectively were used by the 
investigators.
MCP-1 and 1-309 have been shown to be monocyte-specific chemoattractants 
(Rollins 1991) and RANTES has been shown to be a specific attractant for monocytes 
and a specific subset of T lymphocytes (Schall et al 1990).
The ability of several members of the MIP-2 family to attract neutrophils (Stoeckle 
and Barker 1990) has lead to suggestion that members of the MIP-2 family may be 
responsible for the early, acute inflammatory response associated with neutrophil 
infiltration while MIP-1 family members are responsible for the later, macrophage- 
borne chronic response. Further investigation of the biological properties of the MIP- 
1 family cytokines will enable the validity of this idea to be assessed.
The fact that mRNA and/or protein for MCP-1, RANTES, human MIP-1 a  and human 
MIP-1 p has been found to be associated with atherosclerotic plaques, rheumatoid 
joints and some tumours (Wilcox et al 1990, Schall 1991, Graves et al 1989) has also 
lead to suggestions that the proteins of the MIP-1 family could be involved in the 
pathology of these conditions; again these ideas await further experimental 
investigation.
Biology of MIP-1. SCI/MIP-la and MIP-lg.
The macrophage inflammatory proteins appear to occupy a special position within the 
MIP-1 family in that they appear to have effects on both the function of mature blood
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cells and also on the developmental process by which they are produced. In this 
section these functions will be described and discussed.
Effects on the Haemopoietic Progenitor Compartment
As has already been stated, SCI or the active component of the Manchester Inhibitor 
has been demonstrated to be antigenically identical to the alpha chain of MIP-1. 
Graham et al (1990) demonstrated that highly purified MIP-1 a  when added directly 
into the culture dish inhibited the formation of colonies by CFU-A. Purified MIP-1 a  
also reversibly reduced the proportion of CFU-A in DNA synthesis in regenerating 
bone marrow, while the proliferation of more mature progenitors such as granulocyte- 
macrophage colony forming cells (GM-CFC) were unaffected. These effects were 
seen at picomolar concentrations, which strongly indicates that the inhibition of 
primitive cell proliferation is a genuine property of SCI/MIP-la.
Studies with purified and recombinant material demonstrated that purified natural 
murine MIP-1 (nMIP-1) and recombinant murine MIP-1 a  (rmMIP-la) but not 
rmMIP-ip reversibly decreased the proportion of CFU-A in regenerating bone 
marrow in DNA synthesis, while neither rM IP-la nor rmMIP-lp had any effect on 
GM-CFC colony formation (Graham et al 1990). These results then indicated that the 
haemopoietic effects of SCI/MIP-la were confined to the more primitive 
progenitor/stem cells in a way which is directly analogous to the CFU-S specificity 
displayed by the Manchester Inhibitor (Tejero et al 1984). Furthermore, recombinant 
SCI/MIP-la was shown in the same study to have similar effects on CFU-S as on 
CFU-A. A neutralizing MIP-1 antiserum blocked the effect of both rM IP-la and 
purified SCI (Manchester Inhibitor) on CFU-S DNA synthesis, demonstrating that 
M IP-la and SCI are functionally and antigenically indistinguishable; although it 
should be borne in mind that the formal possibility still exists that SCI/MIP-la and
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the active protein component of the Manchester Inhibitor are distinct, although 
antigenically related, molecules.
Recently, Dunlop et al (1992) have demonstrated the ability both in vitro and in vivo 
of recombinant human MIP-1 a  (LD78) to reduce the proportion of CFU-A and CFU- 
S in cycle in the regeneration period after treatment of mice with two drugs (5- 
fluorouracil and phenylhydrazine) which induce rapid proliferation of these cells. 
More primitive CFU-S are apparently more sensitive to the action of human MIP-1 a  
which is in agreement with previous results obtained by Wright et al (1985) with the 
Manchester Inhibitor.
Human M IP-la (LD78) has also been assessed for its ability to protect CFU-S ffom 
the cytotoxic effects of cycle-specific drugs. Dunlop et al (1992) and Lord et al
(1992) have demonstrated protection of the CFU-S compartment from the effects of 
double injections of cytosine arabinoside and hydroxyurea, respectively, 
demonstrating that SCI/MIP-la has the capacity to act as a physiological mediator of 
CFU-S proliferation inhibition.
Investigations by other workers in the field have confirmed the ability of SCI/MIP-la 
to suppress the proliferation of primitive progenitors but have indicated that other 
haemopoietic compartments may also be affected.
Broxmeyer et al (1990) studied the effects of the murine MIP-1, SCI/MIP-la, MIP- 
ip  and MIP-2 proteins on primitive progenitor cells in mice and humans.
With murine bone marrow, they observed that natural murine (nm)MIP-l and 
recombinant murine (rm)MIP-la but not rmMIP-lp or rmMIP-2 inhibited murine 
CFU-GM colony formation stimulated by pokeweed mitogen spleen-conditioned 
medium (PWMSCM) and suppressed colony formation of both BFU-E and colony 
forming unit Granulocyte Erythroid Megakaryocyte Macrophage (CFU-GEMM) 
stimulated by Epo plus PWMSCM.
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With human cells, none of the MIP proteins suppressed the formation of BFU-E 
stimulated by Epo alone but nmMIP-1 and rmMIP-la, but not rmMIP-lp abrogated 
the enhanced formation of BFU-E stimulated by addition of rhIL-3 and rhGM-CSF to 
identical cultures. The formation of human CFU-GM colonies stimulated by rhGM- 
CSF plus rhIL-3 and of human CFU-GEMM by these growth factors plus 
eythropoietin was also affected in the same manner by the MIP proteins.
Bodine et al (1991) have also demonstrated that rmSCI/MIP-la is able to inhibit the 
increase in CFU-S numbers obtained on liquid culture of murine bone marrow with 
IL-3 and IL-6. This effect could be due either to inhibition of CFU-S self-renewal or 
by inhibition of the proliferation and differentiation of more primitive progenitors to 
produce CFU-S.
Taken together these data support the hypothesis that SCI/MIP-la, but not MIP-lp, 
displays suppressive activity for primitive myeloid progenitors, although its 
suppression of both mouse and human CFU-GEMM may indicate that the primitive 
compartment affected by the protein is not as restricted as first envisaged.
In addition to this, there may seem to be a contradiction between the findings of 
Graham et al and Broxmeyer et al concerning the inhibition of colony formation by 
the lineage committed progenitor cell CFU-GM. However, the CFU-GM grown by 
Graham et al were stimulated by iGM-CSF whilst Broxmeyer et al observed 
inhibition of colonies stimulated by PWMSCM. As PWMSCM has been shown to 
contain GM-CSF, IL-3, M-CSF and other growth factors, it is likely that the CFU- 
GM of Broxmeyer et al are derived ffom a more primitive cell. Thus, this result may 
support rather than detract from the above hypothesis.
The MIP-1 family members JE, MCP-1, RANTES and TCA-3 have all been shown to 
be ineffective in inhibiting the proliferation of CFU-A cells, demonstrating the 
specificity of SCI/MIP-la in this activity. (G.Graham personal communication.).
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Broxmeyer et al (1989,1990) have also presented evidence that rmMIP-la, rmMIP- 
lp  and MIP-2 can affect the proliferation of lineage-committed myeloid progenitors, 
namely CFU-GM, by enhancing rather than suppressing colony formation in the 
presence of suboptimal concentrations nmM-CSF or rmGM-CSF. These proteins also 
enhanced the plating efficiency of a purified population of human progenitors (BFU- 
E and CFU-GM) demonstrating that the enhancing effects were caused directly.
The ability to act as a bipotential regulator of progenitor cell proliferation has been 
seen with other inhibitors of haemopoiesis including transforming growth factor P 
(TGFP) (Keller et al 1992) and may have profound implications for the role played 
by SCI/MIP-la in the control of haemopoiesis. For example, it is possible that 
production of SCI/MIP-la in the haemopoietic microenvironment may lead to the 
proliferation of progenitors while at the same time affording protection, perhaps ffom 
extinction due to differentiation induced by growth factors, to stem cells.
It is possible that a further layer of complexity exists in the action of SCI/MIP-la and 
MIP-lp on the haemopoietic progenitor compartments. Broxmeyer et al (1991) have 
demonstrated the ability of rmMIP-lp (but not MIP-2) to abrogate the suppressive 
effects of
rmSCI/MIP-la on colony formation by BFU-E, CFU-GEMM and CFU-GM. A 4:1 
molar ratio of MIP-ip to SCI/MIP-la is required to block completely the 
myelosuppressive effects of SCI/MIP-la while a 1:1 ratio was ineffective in this 
respect. This fact presumably accounts for the myelosuppressive effects of the MIP-1 
protein (Graham et al 1990, Broxmeyer et al 1990) which apparently consists of 
equimolar amounts of SCI/MIP-la and MIP-ip (Wolpe et al 1988, Wolpe and 
Cerami 1989). This antagonistic effect of MIP-lp is seen even when bone marrow 
cells are exposed to the protein for only one hour before washing and subsequent 
addition of SCI/MIP-la suggesting that the effect of MIP-lp on primitive progenitor 
cells is achieved very rapidly and is not dependent on the continuous presence of the
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factor. The antagonistic effect of MIP-ip on the action of SCI/MIP-la appears to be 
specific as it does not affect the ability of another haemopoietic inhibitor, H-femtin, 
to suppress colony formation by the same primitive progenitor populations 
(Broxmeyer et al 1991).
The fact that MIP-lp has no effect on the more primitive haemopoietic cells itself and 
that the two MIP-1 proteins appear to be structurally closely related raises the 
possibility that MIP-1 p may exert its effects by acting as a direct antagonist of the 
receptor for SCI/MIP-la. Such an antagonist has recently been described for 
interleukin-1 (for review see Dinarello 1991).
It is also interesting to speculate that modulation of the relative levels of SCI/MIP-la 
and MIP-lp synthesised by producer cells could be a mechanism for controlling the
i
activity of SCI/MIP-la given that an excess of MIP-1 p can neutralise its inhibitory
\
I action.
I
Inflammatory Effects
MIP-1 protein was originally isolated as an inflammatory mediator (Wolpe et al 
1988) and when tested in a number of in vivo and in vitro assays appeared to behave 
as such. Wolpe et al (1988) demonstrated that MIP-1 induced a localized 
inflammatory response, characterised by infiltration of polymorphonuclear 
neutrophils (PMNs) when injected into the footpads of (endotoxin-resistant) C3H/HeJ 
mice. MIP-1 also appeared to be mildly chemotactic for human PMNs in vitro and 
induces them to undergo an oxidative burst after a one to two hour lag (Wolpe et al
1988). It also induces these cells to degranulate. (Wolpe and Cerami, 1989). 
Intracistemal injection of MIP-1 in rabbits causes a rapid influx of PMNs followed by 
monocyte infiltration (Wolpe and Cerami, 1989). The predominance of neutrophilic 
cells in the infiltrates attracted by MIP-1 as well as its apparent effect on human 
neutrophils led to the hypothesis that MIP-1 was a neutrophil-specific
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chemoattractant. However, other investigators have found purified MIP-1 to be 
ineffective in affecting the behaviour of neutrophils (Schall 1991, G.Graham personal 
communication).
It is interesting to note that the maximal activity of MIP-1 in the studies of Wolpe et 
al (1988) and Wolpe and Cerami (1989) was observed at relatively high 
concentrations of protein (greater than 1 fig/ml); these concentrations were thought to 
be necessary due to the propensity of the protein to aggregate. Schall (1991) has 
argued that the high concentrations used in these experiments make it possible that 
MIP-1 could be binding to a receptor on neutrophils for a related protein such as that 
for the MIP-2 family member Neutrophil Activating Peptide (IL-8); hence these 
activities might not reflect a true physiological role for MIP-1. As purified rather than 
recombinant material was used in these experiments it is also possible that neutrophil- 
activating contaminants could be giving misleading results. These issues could be 
resolved by using recombinant material or by the use of specific neutralising 
antibodies.
Schall (1991) have reported that human M IP-la (LD78) protein is able to attract 
killer T cells and B lymphocytes in a dose dependent manner in vitro while 
recombinant human MIP-lp preferentially attracts naive helper T cells in vitro.
In addition to this, Fahey et al (1992) have recently studied the effects of MIP-1, 
M IP-la and MIP-lp on its producer cell, the macrophage itself. Native MIP-1, at 
nanogram concentrations, had a modest, though significant proliferative effect on 
thyoglycollate broth-elicited peritoneal macrophages both alone and in combination 
with CSF-1. These macrophages also displayed enhanced antibody-independent 
cytotoxicity for tumour cells, which is a classic macrophage activation function 
(Adams and Hamilton 1984). On the other hand, MIP-1 was unable to trigger the 
oxidative burst, or to upregulate the expression of MHC antigens, which are normally
also associated with macrophage activation, suggesting that the macrophage response 
to MIP-1 may be complex.
In addition to these effects, Fahey et al (1992) observed that MIP-1 elicited the 
secretion of bioactive TNFa, IL-6 and immunoreactive IL -la  ffom peritoneal 
macrophages and these effects were greatly enhanced by IFNy. When the relative 
contributions of the two components of the MIP-1 doublet to these effects was 
assessed it was found that only SCI/MIP-la was active. Indeed, as with haemopoietic 
progenitors, an 8-fold excess of MIP-lp abrogated the response of macrophages to 
SCI/MIP-la which further strengthens the idea that MIP-lp may be a natural 
antagonist of SCI/MIP-la in some circumstances.
I
| It seems possible, therefore, that the SCI/MIP-la and MIP-lp proteins could play af
I role in the recruitment of immune defence cells to sites of infection which would
|
correspond with the fact that they can be produced by activated macrophages and T 
cells, although the actual subset(s) of effector cells mobilised by these proteins
I
remains unclear.
One interesting possibility is that the SCI/MIP-la secreted by macrophages may play
a part inj autocrine loop which could both increase the number of effector 
macrophages at sites of inflammation and augment some of the effector functions of 
these cells, including the secretion of other cytokines.
Further evidence of a role for SCI/MIP-1 a  and MIP-1P in the inflammatory response 
and in tissue remodelling has been reported by Fahey et al (1990) who studied the 
induction of expression of several cytokine mRNAs in inflammatory cells invading 
sterile subcutaneous implants in mice. Using the polymerase chain reaction 
technique, they demonstrated the appearance of mRNA for SCI/MIP-la and MIP-lp 
from day one to day seven after implantation. MIP-1 protein could also be detected 
by Western blotting. The fact that no SCI/MIP-la or MIP-lp mRNA could be
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detected in peripheral blood leukocytes indicates that these transcripts are specifically 
induced in response to injury.
In addition to its effects on inflammation in the periphery, SCI/MIP-la has been 
demonstrated to have inflammatory effects in the central nervous system.
Saukonnen et al (1992) observed the efficacy of SCI/MIP-la in promoting the influx 
of inflammatory cells into the subarachnoid space, a site sequestered behind the 
specialised vascular endothelium comprising the blood-brain barrier. The 
leukocytosis was associated with blood brain barrier permeability and brain edema. 
Interestingly, MIP-1(3 was found to be 100-fold less effective in generating these 
responses. These data suggest a possible role for SCI/MIP-la in the inflammatory 
response to and in the tissue damage associated with infections of the central nervous 
system such as bacterial meningitis.
Pvrogenic Activity of MIP-1.
MIP-1 appears to have a specific role to play in the systemic response to infection. 
Davatelis et al (1989) demonstrated that natural murine MIP-1, when injected into 
rabbits, induced a rapid monophasic fever which could not be suppressed by 
prostaglandin inhibitors. This febrile response was equal to those induced by the 
other known endogenous pyrogens, TNFa and IL-1, although the ability of MIP-1 to 
act independently of prostaglandin is unique among endogenous pyrogens.
Minano et al (1990) have demonstrated, using a direct injection technique on the rat 
that (murine) MIP-1 exerts its effects by acting directly on the hypothalamus. They 
observed that the potency of MIP-1 was in the femtomolar (10 '^M ) range, making it 
almost certain that this is a specific activity of MIP-1. Interestingly, Davatelis et al
(1989) injected a 300,000-fold higher dose sytemically into rabbits to achieve a 
febrile response comparable to that observed in rats by direct injection. One reason 
for this may be that most of the heparin-binding MIP-1 protein is sequestered by
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components of the vasculature when injected intravenously. It seems likely, therefore 
that MIP-1 acting on the hypothalamus would have to be released locally perhaps by 
blood-borne or brain-associated macrophages.
Given that the a  and p moieties of MIP-1 have been shown to have differential 
effects on haemopoietic progenitors and peritoneal macrophages, it will be interesting 
to see whether this is the case for the action of MIP-1 on the hypothalamus.
1.4 The Expression of Cvtokine Genes.
The cytokines and (colony stimulating factors) are extremely powerful biological 
regulators. As discussed in section 1.1 this means that activity of these proteins must 
be tightly regulated both physically and temporally. It has become apparent in the last 
few years that the expression of cytokine genes can be controlled at every possible 
level from mRNA transcription to translation and secretion of the final protein 
product. Cytokine genes can be expressed in a wide variety of cell types including 
leukocytes, fibroblasts, endothelial cells and smooth muscle cells (Taniguchi 1988, 
Arai et al 1990). It is now becoming apparent that mechanisms similar to those 
involved in the expression of cytokine genes are also involved in the regulation of 
expression of some nuclear proto-oncogenes, such as c-fos and c-myc. Therefore, 
some aspects of the regulation of expression of these genes will be considered where 
appropriate.
1.4.1 General Characteristics of Expression.
The two features of cytokine gene expression which are most striking are, firstly, the 
rapid and marked inducibility of expression and, secondly, the temporal control of 
that expression.
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In general, in resting cells (which have not been exposed to a stimulus), messenger 
RNA (mRNA) is usually barely detectable, if at all. However, on cellular stimulation, 
levels of mRNA can rise rapidly (within minutes to a few hours) to as much as 20- 
100 times that in the resting cells (Taniguchi 1988, Davatelis et al 1988, Brown et al
1989). The accumulation of cytokine mRNA following cellular stimulation is usually 
independent of de novo protein synthesis (Taniguchi 1988). This, along with the 
rapidity of induction, places such genes in the "immediate-early" group (Rollins and 
Stiles 1989); therefore the expression of these genes is often induced as part of the 
initial response of a cell to stimulation.
It is also often the case that the accumulation of cytokine mRNA following 
stimulation is transient, with levels peaking after a few hours and then falling to 
either basal levels or to a much lower level than that seen at the peak of expression. 
The mechanisms by which these patterns are achieved have been the subject of 
considerable investigation over the last few years and will be considered in the 
following sections.
1.4.2 Transcriptional Control.
Transcription is the process whereby an RNA molecule complementary to the coding 
region of a gene is produced in the nucleus. This process has three main stages: 1) 
Initiation, where RNA polymerase II becomes attached to the promoter sequences 5' 
of the gene and then begins to synthesis the new RNA. 2) Elongation, in which the 
synthesis of the new RNA molecule takes place. 3) Termination, where the process is 
ended. (Lewin 1987). Initiation is normally the rate-limiting step for determining the 
level of transcription (Komberg and Lorch 1991).
Transcription is directed by regulatory sequences lying closely 5* of (promoters) or at 
some distance from (enhancers) the gene (Lewin 1987, Ptashne 1988). RNA 
polymerase II does not directly bind to the gene on its own (Sowadogo and Sentenac
1990). Instead, usually several transcription factors, which recognise specific DNA 
sequences in the promoters and enhancers, must be present to facilitate the initiation 
of RNA synthesis. Other sequences, locus control regions (LCR), are responsible for 
the maintenance of an "open" chromatin structure which is important for the overall 
level of transcription (Komberg and Lorch 1991).
Promoters, enhancers and LCRs appear to be constructed in a modular fashion in that 
they may consist of binding sites for several transcription factors. In this way 
regulation of transcription may be dependent on the simultaneous binding of several 
transcription factors (Ptashne 1988). Hence, changes in the availability of, or ability 
of, transcription factors to bind to specific motifs in the regulatory elements of genes 
is the primary mechanism for modulating expression.
Some transcription factors are expressed by a wide variety of cell types and probably 
serve a general role in transcription; for example the transcription factor i FllD, 
which binds an AT-rich sequence situated about 25 nucleotides from the transcription 
start-site of many RNA polymerase II promoters, has been shown to be essential for 
the binding of RNA polymerase II and subsequent transcription in vitro. Myers et al 
(1986) have also demonstrated that this sequence is one of the main determinants of 
fidelity of transcriptional initiation in vivo (for review see Sowadogo and Sentenac
1990).
Other transcription factors are restricted in their expression to one or a few cell types 
and are likely to be responsible for tissue-specific expression of genes, including 
those encoding cytokines. For example, a number of cytokine genes contain putative 
binding sites for the transcription factor PU.l, the expression of which in normal, 
untransformed cells is restricted to B cells and macrophages (Pongubala et al 1992). 
Still other transcription factors are only activated to bind promoters after the cell has 
been exposed to an extracellular stimulus. It is highly likely that the expression of
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inducible genes could be specifically regulated by the control of activation of such 
transcription factors.
An example of such a transcription factor is NF-kB. This transcription factor is found 
in a number of cell types and activates transcription through binding as a heterodimer 
of two proteins of 50kDa (p50) and 65kDa (p65) to a decameric consensus sequence 
5'-GGGRNNYYCC-3\ This sequence is found in the 5' regulatory region of a number 
of genes including the cytokines IFNp, GM-CSF, G-CSF, IL-6, EL-2 and TNFa 
(Baeuerle 1991).
In resting cells, however, NFkB is present in an inactive form complexed with a 
labile inhibitory molecule, IkB. The NFkB heterodimer is released from the 
inhibitory effects of IkB, through a mechanism thought to involve changes in the 
phosphorylation state of IkB (Ghosh and Baltimore 1990), only after cellular 
stimulation. Following this, the free NFkB heterodimer can translocate to the nucleus 
where it is able to activate transcription of its target genes (for review see Baeurie 
1991, Blank et al 1992).
Monocytes and B cells contain a certain amount of free, nuclear NFkB which may be 
involved in the constitutive expression of some genes. Nevertheless, NFkB activity 
can be greatly increased in these cells following stimulation which suggests that, for 
inducible gene expression, the same concepts apply to monocytes as to other cells 
(Blank et al 1992, Vincenti et al 1992).
Various agents are able to activate NFkB including mitogens (phorbol esters, lectins), 
cytokines (IL-la, TNFa) and viruses (HTV-1, cytomegalovirus) andLPS (Bohnlein 
et al 1988, Sambucetti et al 1989, Collart et al 1990, Vincenti et al 1992), which 
makes activation of NFkB an obvious candidate for the activation of cytokine genes. 
The fact that the activation of NFkB can take place in the absence of new protein 
synthesis also makes this transcription factor a likely candidate for the activation of 
immediate early genes.
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Collart et al (1986) have demonstrated the transcriptional induction of mRNA for 
TNFa in elicited peritoneal macrophages by LPS, the protein synthesis inhibitor 
cycloheximide and EFNy. This induction appears to be mediated, in part, via NFkB as 
treatment of the same cells with these agents stimulates its activation and 
translocation to the nucleus from the cytoplasm and specific binding of NFkB to four 
NFkB-binding sites in the promoter region of this gene is necessary for the 
stimulation of transcription. (Collart et al 1990). It is possible that cycloheximide 
stimulates TNFa transcription by blocking synthesis of the labile IkB protein and 
hence leading to the production of free NFkB.
Promoter-binding of NF-kB has also been demonstrated to be involved in the 
transcriptional activation of the GM-CSF gene in T cells by PHA and phorbol ester 
(Schreck and Baeuerle 1990), the IL-6 gene by IL -la and TNFa (Shimizu et al 1990) 
and of the M-CSF gene in the human promyelocytic cell line HL-60 by TNFa 
(Yamada et al 1991).
One of the reasons for the transience of expression of mRNAs is the brevity of the 
enhancement of the rate transcription following cellular stimulation. For example 
LPS induces the transcription of the IL-1(3 gene in human monocytes within fifteen 
minutes. This activity reaches a peak at 3-4 hours, is sustained for 6 to 8 hours and 
then decreases rapidly (Fenton et al 1987, 1988).
There is evidence to suggest that transcription of the c-fos proto-oncogene, which 
reaches a peak 15 minutes after stimulation and has returned to basal levels by 1 hour 
(Greenberg et al 1986), is downregulated by binding of the gene product to specific 
sites on the c-fos promoter (Sassone-Corsi et al 1988, Rivera et al 1990), thus 
ensuring that expression of c-fos is self-regulating.
While such an auto-regulatory mechanism might operate in the control of cytokine 
gene transcription it seems improbable, considering that cytokines are secreted 
molecules. Studies by Fenton et al (1987,1988) suggest that LPS induces a repressor
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of IL-1|3 transcription in human monocytes which could be involved jn the temporal 
control of IL-lp transcription. Further studies will be required to determine whether 
this is a general mechanism for the control of cytokine gene transcription.
Inhibition of transcription is also a mechanism by which cytokine gene expression 
can be affected by downregulators. Various anti-inflammatory agents have been 
shown to be potent inhibitors of cytokine gene transcription. For example, 
glucocorticoids inhibit the accumulation of JE mRNA in fibroblasts in response to 
platelet-derived growth factor (PDGF) and of the IL-2 mRNA in T cells by phorbol 
ester and calcium ionophore by blocking the stimulation of gene transcription 
(Kawahara et al 1991, Vacca et al 1992).
Glucocorticoid transcriptional enhancement is known to occur through the interaction 
of the glucocorticoid receptor with specific DNA response elements (Yamamoto 
1985). However, the mechanism by which glucocorticoids repress transcription are 
less well defined. Vacca et al (1992) have reported evidence that the glucocorticoid- 
mediated repression of IL-2 transcription is mediated by the activated glucocorticoid 
receptor interfering with the synergistic cooperation between proteins binding to 
consensus binding motifs for the two inducible transcription factors AP-1 and NF- 
AT. Northrop et al (1992) have reported evidence which supports a similar 
mechanism involving a previously uncharacterised transcription factor.
1.4.3 RNA Processing.
The production of translatable mRNA from the primary product of gene transcription, 
termed heterogeneous nuclear (hn)RNA, requires that internal sequences (introns) 
which are not part of the protein-coding sequence be removed by a nuclear protein 
and RNA complex, the spliceosome. In addition, the RNA molecules are also given a 
3-methyl guanine cap at the 5' end, and a poly(A) tail at the 3' end of the molecule 
(Lewin 1987). These events take place before splicing.
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In general, the precursor molecules of mRNA are not detectable. This is thought to be 
for two reasons: firstly, intron splicing is an extremely efficient process and is not 
thought to be a rate-limiting step and secondly, a large proportion of nuclear RNA is 
rapidly degraded. Thus RNA processing is not generally considered to be an 
important control point in gene expression.
Nevertheless, several cases do exist where nuclear precursors of cytoplasmic mRNA 
can be readily detected after cellular stimulation. Gudas et al (1988), for example, 
have demonstrated the accumulation of precursors of murine thymidine kinase 
! mRNA in response to fetal calf serum in Balb/c 3T3 cells. This suggests slow
I maturation of the transcripts which could be a determining factor in the availability of
|
I mRNA for translation.
|
| Similarly, Weil et al (1990) have observed the accumulation of precursors of tumour
necrosis factor p (TNFp) mRNA in the nucleus of a murine T cell line CTLL-2 on
[
; stimulation by IL-2. The slow nuclear processing leads to a delay in the appearance
of cytoplasmic TNFp mRNA, suggesting that RNA processing could be a rate- 
limiting step in the expression of the murine TNFp gene. Similar results were 
obtained with ConA-stimulated splenocytes, indicating that this phenomenon is not a 
consequence of cell immortalisation.
These data suggest that mRNA processing is a limiting step, and hence could be a 
control point, for the accumulation of some mRNAs, including those for cytokines, in 
response to cellular stimulation.
1.4.4 Cvtokine mRNA Stability.
While the rate of production of mature mRNA molecules is an important control 
point for the regulation of expression of cytokine genes, posttranscriptional 
mechanisms also operate and can have profound effects on the overall level of 
expression.
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Cytokine mRNAs are very unstable in comparison to constitutively expressed genes, 
being measured in minutes or a few hours; for example, the half-life of GM-CSF 
mRNA in PHA-treated T cells is 30 minutes, while that for (3-globin mRNA is around 
17 hours (Shaw and Kamen 1986). The instability of cytokine mRNAs is a major 
determinant, in addition to the brevity of transcription, of the transience of 
accumulation of these molecules.
Caput et al (1986) have observed that a large number of cytokine mRNAs have 
conserved UA-rich elements in their 3'-untranslated regions consisting of interspersed 
repeats of the consensus AUUUA. This sequence is believed to destabilise molecules 
which contain it, as Shaw and Kamen (1986) have demonstrated that transfer of a 
portion of the 3'-untranslated region of the GM-CSF mRNA containing the conserved 
AU-rich sequence confers instability on (3-globin mRNA.
It is generally agreed that the first step in the degradation of mRNAs is the removal of 
the poly(A) tail which is then followed by the rapid endonuclease-mediated digestion 
of the mRNA in a general 3' direction (for review see Jackson and Standart 1990).
The description by Bernstein et al (1989) of a cytoplasmic 3' exoribonuclease in 
mammalian cells which in vitro readily degrades mRNA not protected by a 3' poly(A) 
tail lends credence to this idea.
Recent elegant work by Shyu and co-workers has lead to a partial elucidation of the 
mechanisms underlying the rapid degradation of the mRNA for the nuclear proto- 
oncogene c-fos. Wilson and Treisman (1988) observed that removal of the poly(A) 
tail of c-fos mRNA occurred much more rapidly than that for P-globin, suggesting 
that this may be related to then short c-fos half-life. Shyu et al (1991) have extended 
this observation by demonstrating that removal of the poly(A) tail (deadenylation) is 
a prerequisite for subsequent mRNA degradation. Furthermore, these two processes 
appear to be mediated by two distinct sequence elememts in the 3'UTR. Mutation of 
the AUUUA repeats demonstrated that deadenylation but not subsequent mRNA
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degradation is independent of these elements. Deadenylation is still, however, 
dependent on the presence of 3' AU-rich sequence.
You et al (1992) have recently described four proteins which specifically bind a 20 
nucleotide U-rich sequence in the 3'UTR of c-fos mRNA, the affinity of one of which 
is affected by agents shown to increase the stability of the c-fos mRNA. The binding 
of these factors is, however, independent of the presence of AUUUA 
pentanucleotides. This suggests that these four proteins may be involved in mediating 
the initial deadenylation of the c-fos mRNA.
Other investigators (Bohjanen 1991, Brewer, 1991, Vakalopoulou 1991) have 
described proteins which specifically bind the AUUUA pentanucleotides of several 
mRNAs. It is possible that these factors may be involved in regulating the mRNA 
degradation step.
Recent studies have indicated that the 3'AU-rich sequences are not the sole 
determinants of instability for labile mRNAs; other sequences within the coding 
region may be just as, if not more, important.
Han et al (1991a) have shown, using recombinant reporter constructs stably 
transfected into the macrophage cell line RAW 264.7 that decay of the mRNA for 
TNFa, after induction by LPS, is unaffected by the absence of a 3' UTR containing 
an AU-rich region. This suggests that other mechanisms for TNFa mRNA 
degradation, in addition to that mediated through the 3' AU-rich region, may operate. 
This "alternative" pathway is sensitive to the action of actinomycin D, whereas that 
mediated through the 3' AU-rich sequence is not which suggests that the two 
pathways operate through separate mechanisms.
Therefore, it appears that separate but superimposed mechanisms may determine the 
turnover of TNFa, and hence possibly other cytokine, mRNAs. Shyu et al (1989,
1991) have reported similar results for c-fos mRNA. In these studies, the "alternative" 
degradative pathway was located to the protein-coding region.
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Han et al (1991a) have argued that the "alternative" pathway is actually the major 
determinant for TNFa mRNA degradation as it apparently operates constitutively, 
whereas the pathway which operates through the 3' UTR has to be induced by LPS. 
Evidence to support this has come from the studies of Peppel et al (1991) who 
demonstrated that degradation of IFNp mRNA in the L929 fibroblast cell line was 
independent of the presence or absence of an AU-rich element in the 3'UTR.
However, the AU-rich element was shown to be necessary for the increased turnover 
of IFNP mRNA induced by glucocorticoids.
Recent studies have indicated that the stability of several labile mRNA species can be 
increased on cellular stimulation, increasing the level of mRNA accumulated above 
that which would be achieved through transcription alone, for example the induction 
of GM-CSF and IL-3 mRNA in the mast cell line PB-3c by calcium and phorbol ester 
(Wodnar-Filipowicz and Moroni 1990). Indeed the induction of several cytokine 
mRNAs, such as that of IL-2, GM-CSF, TNFa and IFNy in normal human T cells in 
response to mitogenic antibody and of GM-CSF (Thorens et al 1987) and JE (Koemer 
et al 1987) by LPS in murine peritoneal macrophages can take place in the absence of 
any change in transcriptional activity and hence are probably the result of increased 
mRNA stability.
Koeffler et al (1988) have demonstrated that the accumulation of GM-CSF mRNA in 
human fibroblasts by activators of protein kinase C, cycloheximide, IL-ip and TNFa 
is achieved by a similar mechanism. The mRNA sequence-dependency of the 
stabilising effects of these agents has been investigated by Akashi et al (1991). 
Removal of the 3'UTR AUUUA sequences completely abolished the ability of 
protein kinase activators and cycloheximide to confer increased stability, indicating 
that the AUUUA motifs may play a dynamic role in the regulation of mRNA 
stability. However, enhancement of GM-CSF mRNA instability by TNFa was 
independent of the presence or absence of the AUUUA motifs, demonstrating that
56
other mechanisms for stabilisation, presumably related to the utilisation of alternative 
degradative pathways may operate depending on the particular circumstance. 
Modulation of mRNA stability appears to be a target for some agents which 
downregulate the expression of cytokine genes. For example, Poon et al (1991) have 
demonstrated that the inhibition of platelet-derived growth factor (PDGF)-induced 
expression of JE mRNA by the synthetic glucocorticoid dexamethasone, is mediated 
through destabilisation of the mRNA. Similarly, Lee et al (1988) have demonstrated 
that down-regulation of phorbol ester-induced expression of IL-lp mRNA by the 
synthetic glucocorticoid dexamethasone is mediated through a reduction in the 
stability of cytoplasmic mRNA.
Further work on the molecular mechanisms underlying the modulation of labile 
mRNA stability is required to clarify the exact relationships between these competing 
effects.
1.4.5 Translational Control.
Another level at which the expression of cytokine genes can be regulated is that of 
the efficiency of translation into the protein product.
Various features of mature mRNA molecules are known to be necessary for the 
efficient translation of mRNAs in eukaryotes. For example, the presence of a cap 
structure, a favourable sequence surrounding an in-frame initiation codon at the 5' 
end of the molecule and the absence of stable secondary structures are all 
prerequisites for translation. In addition, the poly(A) tail at the 3f end of the mRNA is 
known to promote the initiation of translation. In yeast this effect is mediated through 
the poly(A)-binding protein whose gene is required for viability (reviewed in Jackson 
and Standart 1990).
Certain mRNAs, when injected into maturing and fully grown oocytes, such as that 
for tissue-type plasminogen activator (u-PA) in mouse oocytes (Huarte et al 1992)
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can be stored in a translationally silent form by specific shortening (from greater than 
150 to 15-90 nucleotides) of the poly(A) tail (de-adenylation) on entry to the 
cytoplasm. As the oocyte enters meiosis, re-adenylation takes place and the mRNA is 
translated (reviewed in Bacharova 1992).
Two sequence components of the mRNA 3' UTR have been shown to be necessary 
for readenylation to take place. First, the motif AAUAAA, which is also necessary 
for the polyadenylation of nascent RNA transcripts in the nucleus. Secondly, a signal 
known as the cytoplasmic polyadenylation element (CPE) or adenylation control 
element (ACE) which lies at a variable distance from the polyadenylation signal. The 
sequence element required for subsequent readenylation lies within the same ACE 
required for deadenylation to take place. The polyadenylation signal is not required 
for this process.
The consensus sequence for the ACE in the frog is UUUUUAU (Fox et al 1989, 
McGrew et al 1989). Huarte et al (1992) have demonstrated the sequence 
AUUUUAAU to be essential deadenylation and readenylation of both mouse and rat 
tissue-plasminogen activator mRNA. Therefore it seems likely that the AUUUUAAU 
sequence is the mouse and rat equivalent of the ACE sequence identified in the frog. 
This is strikingly similar to the (AUUUA)n consensus sequence of the AU-rich 
elements in the 3'UTR shown to be at least partly responsible for conferring 
instability on cytokine and nuclear proto-oncogene mRNAs and discussed in the 
previous section (Caput et al 1986, Shaw and Kamen 1986, Brewer and Ross 1988, 
Wilson and Treisman 1988).
It is possible, therefore, that these sequences of cytokine mRNAs might also V ?; play a 
role in the control of production of cytokine proteins through modulation of the 
ability of the mRNAs to translated.
Messenger RNAs which are labile in murine and human cells arc stable when 
injected into Xenopus oocytes. Kruys et al (1989) have used this system to
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demonstrate that the translation of IFNp and GM-CSF mRNA is precluded by the 
presence of the 3'AU-rich element.
Han et al (1990) have used the transfection of appropriate chimaeric TNFa genes in 
the macrophage cell line RAW 264.7 to demonstrate that the 3'UTR of TNFa mRNA 
suppresses its translation, specifically through AUUUA motif. This process is 
separate from mRNA degradation as the recombinant mRNAs generated in these 
studies were completely stable over the course of the experiment.
This translational suppression can be overcome by LPS. The presence of the AUUUA 
sequence is also necessary for derepression to take place, although the presence of 
other regions of the 3'UTR greatly increases the magnitude of the derepression.
The mechanism by which the modulation of translational efficiency is carried out is 
not clear; obviously reversible deadenylation is a likely possibility.
1.4.6 Control of Cvtokine Secretion.
It is axiomatic that cytokines must be secreted, or at least presented on the cell 
surface, by the producer cell before they can exert their effects on other cells.
Proteins to be secreted are synthesised in a precursor form which contains amino acid 
residues at the amino-terminal end additional to the mature form of the molecule. 
These additional residues represent a signal sequence which is involved in the 
secretion of the protein (Alberts et al 1989). The protein coding sequences in the 
mRNA of most cytokines encodes putative signal sequences, indicating that these 
proteins are secreted via a conventional route.
While macrophages, T cells and B cells do not appear to store preformed cytokine 
proteins, mast cells have been demonstrated to contain extensive preformed stores of, 
at least, TNFa that are available for immediate release on appropriate stimulation of 
the cell (Plaut et al 1989, Gordon et al 1990). Therefore, it is possible that control of
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secretion may play a part in the regulation of cytokine activity in certain 
circumstances.
EL-la and IL-lp are unusual cytokines with respect to processing and secretion in 
that they are synthesised as precursor (31kDa) forms which are approximately twice 
the size of the mature form (17.5kDa). Only the mature form is secreted, by a route 
separate from other cytokines, and is biologically active (Dinarello 1991). The 
production of the mature form of IL-lp in human cells has been shown to be 
dependent on the activity of a specific cytosolic protease, the IL-ip converting 
enzyme (Black et al 1989, Kostura et al 1989). Ray et al (1992) have recently 
demonstrated that the decrease in IL-ip activity seen on cowpox virus infection of 
human cells is mediated by a virally-encoded specific inhibitor of the IL-lp 
converting enzyme. So, it seems that the control of cytokine protein processing and/or 
secretion, at least in disease states, may play a role in regulating the production of 
these molecules.
1.5 Expression of the SCI/MIP-la and MIP-1 Genes
1.5.1 Expression of MIP-1 Family Genes.
In addition to the fact that the members of the MIP-1 family are structurally related, 
they also appear to display some similarities in their patterns of gene expression.
Most of the members of the MIP-1 family were initially described as sequences 
which are rapidly and greatly inducible on cellular activation and this property is one 
of the most noticeable features of the expression of these genes. In fact, on induction, 
the mRNA for these genes can represent about 1% of the poly(A)+ RNA in the 
stimulated cell (Davatelis et al 1988, Brown et al 1989). Murine JE and hMCP-1 
appear to be the most widely expressed in that mRNA and/or protein can be detected 
in a range of cell-types, including macrophage/monocytes, fibroblasts, and other
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connective tissue cells and cells associated with epithelial tissues. JE was first 
identified as a sequence inducible on platelet-derived growth factor (PDGF) 
stimulation of fibroblasts (Cochran et al 1983) and is a classical "immediate-early" 
gene in that accumulation of its mRNA is induced within minutes of stimulation and 
is independent of de novo protein synthesis (for reviews see Rollins and Stiles 1989, 
Rollins 1991).
The expression of the other members of the family appears to be exclusively 
restricted to leukocytes (for review see Schall 1991).
It should be noted, however, that RANTES and CIO do not conform to the general 
pattern for MIP-1 gene expression. Schall et al (1988) demonstrated that mRNA for 
RANTES was induced on stimulation of peripheral blood leukocytes but only 
reached a peak after 5 to 7 days, while antigen stimulation of a cytotoxic T cell line 
resulted in a decrease in message (Schall et al 1988). The expression pattern of CIO is 
also context dependent (Orlofsky et al 1991).
1.5.2 Expression of MIP-1 a  and MIP-1 jl
The murine SCI/MIP-la and MIP-1 p genes appear to be generally co-expressed and 
so far their expression appears to be confined to haemopoietic cells, more particularly 
macrophage and monocytic cell lines (Davatelis et al 1988, Orlofsky et al 1991, 
Widmer et al 1991, Martin and Dorf 1991) T cell lines (Brown et al 1989), mast cell 
lines (Burd et al 1989) and purified epidermal Langerhan's cells (G.Graham, 
K.Parkinson personal communication).
A similar pattern of expression appears to be emerging for the human equivalent 
genes. Both of these genes have been shown to be expressed in human monocytes, 
human monocytic cell lines, peripheral blood mononuclear cells (PBMCs), human 
peripheral blood T cells, human T cell lines, human B cells and freshly harvested
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leukemic cells. There is one report of expression in cultured primary human 
fibroblasts and a human glioma cell line treated with PMA (Nakao et al 1990) but it is 
possible that this represents cross-hybridisation from a related member of the MIP-1 
family which may possibly have not yet been described.
Expression in monocvtes and macrophages.
A cDNA clone for SCI/MIP-la was first isolated by Davatelis et al (1988). Using 
this sequence as a probe for the expression of SCI/MIP-la mRNA they demonstrated 
that the message was barely detectable in unstimulated macrophage cell line RAW
264.7 but was rapidly induced (within one hour) after stimulation with LPS with the 
level of SCI/MIP-la mRNA reaching a peak at around 8 hours and staying elevated 
for at least 16 hours. The level of mRNA obtained after six hours was shown to be 
dependent on the dose of LPS. Orlofsky et al (1991) and Widmer et al (1991) 
reported similar kinetics in the same cell line. Widmer et al (1991) also reported that 
the level of MIP-lp mRNA, while following similar kinetics to that of SCI/MIP-la, 
declined to a lower level after the early peak although it still remained above the 
basal level. No data other than the kinetics of mRNA accumulation was reported by 
these investigators.
The most extensive study of the expression of both SCI/MIP-la and MIP-lp genes in 
murine macrophages so far has been carried out by Martin and Dorf (1991) in the 
macrophage cell line J774.1 and in the monocytic cell line P388D1. They 
demonstrated that LPS, used at a suboptimal 50ng/ml, increased the expression of 
mRNA for both SCI/MIP-la and MIP-1 P 4 to 7-fold above constitutive levels after 
six hours. The level of mRNA for JE was equally elevated by the same treatment.
The kinetics of accumulation was not reported.
The macrophage activating factor interferon-y (IFNy) only slightly increased (1.5- 
fold) levels of mRNA for both SCI/MIP-la and MIP-lp but increased the levels of
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mRNA for JE approximately 7-fold in both cell lines. IFNy also augmented the 
increase in JE mRNA induced by LPS but was ineffective in respect of SCI/MIP-la 
and MIP-lp. Neither IL -la  nor TNFa had any effect on the expression of MIP-1 a, 
MIP-1 P or JE in these cells nor did they enhance the increase in mRNA levels 
stimulated by LPS.
Martin and Dorf also investigated the effects of pharmacological agents on the 
accumulation of these mRNAs. Prostaglandin E l (PGE1), which is produced by 
macrophages in response to various agents including LPS, IL -la  and TNFa and has 
immunosuppressive properties (Phipps et al 1991) was able to reduce both 
constitutive and LPS-induced levels of SCI/MIP-la and MIP-lp mRNA by 50-70% 
and JE mRNA levels by 43%. This suggests the possibility of PGE1 playing a 
feedback role in the controlling the accumulation of these mRNAs.
The effects of PGE1 could be almost exactly duplicated by dibutryl cyclic AMP 
(dcAMP), the soluble analogue of cyclic AMP (cAMP), save for the fact that dcAMP 
was ineffective in reducing constitutive levels. Increases in the levels of the three 
mRNAs induced by PMA were also inhibited by dcAMP. The effects obtained with 
PGE1 and dcAMP are consistent as the effects of prostaglandins of the E series are 
mediated through increases in intracellular cAMP (Phipps et al 1991).
Interestingly, in the same study, the expression of both mRNA and protein for IL-6 
and TNFa was investigated. It was found that while LPS, PMA and IFNy could 
increase the expression of mRNA for these genes, this was accompanied by an 
increase in protein secretion only with LPS. Such effects have also been reported for 
the expression of IL -la and EL-lp (Dinarello 1991). It would obviously be of great 
interest to find out whether the expression of SCI/MIP-la, MIP-1 P and JE is similar 
in this respect.
The expression of hMIP-ip (Act-2) mRNA has been shown to be rapidly inducible in 
isolated primary human monocytes, but not lymphocytes, by LPS, EL-7, calcium
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ionophore and PMA (Lipes et al 1988, Ziegler et al 1991, Spom et al 1990). Spom et 
al (1990) also observed that mRNA for hMIP-ip (MAD-5) was rapidly induced on 
adherence of human monocytes to plastic, type I collagen, immune complex and 
fibronectin. These data again demonstrate the ability of stimuli associated with the 
activation of macrophages to induce accumulation of one of the MIP-1 mRNAs. 
Ziegler et al (1991) demonstrated the ability of IL-4 to down-regulate both the LPS 
and the IL-7-induced rise in hMIP-lp mRNA. Despite the fact that they identified 
three glucocorticoid response elements in the 5' regulatory region of this gene, they 
found that dexamethasone was unable to inhibit the induction of hMIP-lp mRNA by 
LPS. However, in this study, the concentration of LPS used was 10|ig/ml, which is 
almost certainly a vast excess when it is considered that murine MIP-lp gene 
expression can be elevated by as little as 50ng/ml LPS; therefore it is possible that 
dexamethasone may successfully oppose the action of lower concentrations of LPS. 
Three investigators have studied the expression of either both human MIP-1 a  and 
MIP-lp (Zipfel et al 1989) or human M IP-la alone (Nakao et al 1990, Yamamura et 
al 1989) in human monocytic cell lines.
In the promyelocytic cell line HL60, Zipfel et al (1989) found that although 
expression of neither hMIP-lcc or hMIP-lp could be detected in untreated cells, 
treatment with PMA, which induces a monocytic phenotype, induced expression of 
both transcripts when measured at both 4.5 and 72 hours. Treatment of HL60 with 
dimethyl sulphoxide, which induces a granulocytic phenotype, did not induce these 
mRNAs. It is possible, therefore, that accumulation of these transcripts following 
treatment with PMA is mediated indirectly through the differentiation of the cell 
rather than by a direct action on gene expression. However, as PMA has been shown 
to increase expression of (murine) SCI/MIP-la and MIP-1 P mRNA in J774.1 cells it 
is also possible that PMA is regulating both processes independently.
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Both Yamamura et al (1989) and Nakao et al (1990) followed the kinetics of 
expression of human MIP-1 a  (LD78) in the promonocytic cell line U937 after 
treatment with both PMA (to induce a mature monocytic phenotype) and PMA plus 
LPS. In both cases mRNA was detected after 2 hours with a peak of expression at 4- 
12 hours and then declined. A similar pattern was observed in the promyelocytic cell 
line HL60 by Nakao et al (1990) after treatment with PMA and the protein synthesis 
inhibitor cycloheximide. It should be noted, however, that Yamamura et al (1989) 
detected expression of hM IP-la mRNA in untreated HL60 cells. Expression was 
abolished completely by the transcriptional inhibitor actinomycin D which suggests 
that the mRNA is labile and that its presence is dependent on continuous 
transcription. Cycloheximide, however, induced a higher level of expression at one 
hour which then declined and had returned to resting levels by six hours.
Nakao et al (1990) found that addition of cycloheximide did not inhibit the induction 
of hM IP-la (LD78) mRNA by PMA plus LPS which indicates that this induction is 
independent of de novo protein synthesis and indeed cycloheximide increased over 
four-fold the level of message obtained after treatment with PMA.
Expression in Lvmphocvtic Cells.
Brown et al (1989) have demonstrated that mRNA for both SCI/MIP-la (TY5) and 
MIP-lp (H400) are induced on ConA-mediated activation of murine T helper cell 
lines. Similarly, Kwon and Weissman (1989) described SCI/MIP-la as a sequence 
induced on ConA stimulation of the T cell line L2.
Expression of the human genes in lymphocytic cells has been more extensively 
studied.
Zipfel et al (1989) demonstrated using isolated peripheral blood T cells that hM IP-la 
(pAT464) and hMIP-ip (pAT744) were co-induced by four and a half hours by 
cycloheximide, PHA, PHA plus PMA, and PHA plus PMA plus cycloheximide in
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ascending order of effectiveness. While PMA synergised with PHA it had no effect 
on the expression of these genes on its own. The immunosuppressant drug 
cyclosporin A (CsA) completely abolished the induction of the two messages by PHA 
plus PMA.
Chang and Reinherz (1989) observed that antibody versus the cell surface 
determinant CD2 induces a characteristic pattern of expression of hMIP-ip mRNA in 
peripheral blood lymphocytes and in human peripheral blood T cells. Induction is 
rapid, peaks within two hours, and then decreases. A second peak of expression is 
seen at around twenty-two hours.
Taking these data together, it can be seen that T cell activation is necessary for the 
accumulation of hM IP-la and hMIP-lp mRNA. On activation, accumulation is 
rapid, suggesting that expression of these genes, as in macrophages, is part of the 
early response to cellular stimulation.
Several groups have also investigated the expression of the two human genes in 
human peripheral blood mononuclear cells (PBMC) which consist mainly of 
lymphocytes with some monocytes (Lipes et al 1988, Chang and Reinherz 1989,
Blum et al 1990, Siderovski et al 1990) and in human T cell lines (Lipes et al 1988, 
Chang and Reinherz 1989, Zipfel et al 1989). The characteristics of expression in 
these cells are, not surprisingly, extremely similar to that in isolated human T cells 
and serve to reinforce the idea of the expression of the two genes being induced early 
in T cell activation.
Yamamura et al (1989) have also demonstrated that both mRNA and protein for 
hM IP-la (LD78) is constitutively expressed in the human T-lymphotrophic virus 1- 
infected T cell line MJ. The level of mRNA was not reduced on exposure to 
actinomycin D for upto six hours which suggests that the mRNA may be fairly stable 
in this cell line which was in contrast to the observation made in the promyelocytic 
HL60 cell line by the same authors.
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Schall et al (1992) have demonstrated that both hM IP-la and hMIP-lp are induced 
rapidly and transiently by the T cell line HA 1.7 upon activation by either anti-CD3 
antibody or anti-CD3 antibody plus IL-2. This rise in mRNA is mirrored by levels of 
secreted protein. However, when this cell line is made anergic (non-responsive to 
antigen) by exposure to the superantigen Staphylococcus Aureus enterotoxin B the 
levels of hM IP-la and hMIP-ip induced are higher and these levels are sustained. 
Interestingly, the mRNA levels are not reflected in the level of MIP-1 protein 
secreted which suggests that there may be an uncoupling of mRNA expression and 
either translation or protein secretion in anergic cells.
Expression in Mast Cells.
There has so far been one report of expression of the MIP-1 mRNAs in mast cells. 
Burd et al (1989) demonstrated the expression of mRNA for both SCI/MIP-la and 
MIP-lp in three out of four cloned murine mast cell lines in response to activation by 
specific antigen and Immunoglobulin E (IgE). This induction was blocked by the 
anti-inflammatory agent cyclosporin A (CsA). The expression of mRNA for TCA3 
was identical to that of the MIP-1 genes. Levels of mRNA for JE, which is expressed 
constitutively in these cells, was unaffected by these treatments, indicating that the 
mechanisms underlying the expression of JE and the MIP-1 genes may be 
overlapping judging by the similarity of their expression patterns but they are not 
identical.
The characteristics of the accumulation of the MIP-1 mRNAs in mast cells again 
reinforces the idea of rapid accumulation of SCI/MIP-la and MIP-1 P mRNA being 
associated with cellular activation. The fact that the genes can be expressed in mast 
cells, adds to the number of processes in which the gene products could potentially be 
involved.
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Expression in Leukemic Samples.
Yamamura et al (1989) found that mRNA for hM IP-la (LD78) was expressed in 8 
from 8 fresh maiTOw sample from patients with Acute Non-Lymphoblastic 
Leukaemia (ANLL). ANLL samples with the most monocytic morphology expressed 
the highest levels. Two from three acute lymphocytic leukaemia (ALL) samples, 
eight from nine B cell-ALL samples and one of three T cell-ALL samples expressed 
detectable mRNA for hMIP-la. LD78 protein could be detected by Western blot in 
two out of four of the ATL cases but in no other samples.
Interestingly, the expression of a number of cytokine genes (Arai et al 1990, Chan et 
al 1986) including hM IP-la as discussed above (Yamamura et al 1989) have been 
shown to be upregulated in adult T cell leukemia (ATL) and derived cell lines. The 
etiological agent of this condition is human T lymphotropic virus 1 (HTLV1).
A nuclear.protein encoded by the HTLV-1 genome, p ^ ^ * ,  functions as a positive 
regulator of the promoters of a number of genes including those of IL-2 and GM-CSF 
(Maruyama et al 1987, Miyatake et al 1988), possibly through activation of NFkB. It 
is possible that such a mechanism might also be responsible for the upregulation of 
hM IP-la expression.
Whether similar mechanisms might operate in other leukeamic cells is unclear, 
however it is highly likely that cytokine genes including hM IP-la and MIP-1 P are 
dysregulated in some way in transformed cells.
1.5.3 Summary
The characteristics of expression of both the murine and human M IP-la and MIP-lp 
genes follows a pattern which now appears to be typical for most of the members of 
the MIP-1 family. Expression appears to be restricted to haemopoietic cells and the
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accumulation of mRNA is either induced or greatly enhanced by the appropriate 
activating stimuli.
In all cases, the accumulation of mRNA appears to be extremely rapid following 
stimulation and, at least in primary cells, accumulation is transient. In several reports, 
the mRNA accumulation was unaffected by the presence of cycloheximide, 
indicating that this is independent of de novo protein synthesis. These characteristics 
are indicative of the expression of these genes being a part of the early response to the 
activation of either macrophages, T cells, B cells or mast cells.
It is interesting to note that mRNA accumulation can be downregulated by an 
immunosuppressant agent in macrophages, T cells and mast cells. Presumably this 
reflects the inflammatory role of the products of these genes. This may be a major 
physiological route for downregulating the expression of these genes.
It should also be noted that studying expression of the MIP-1 genes in cell lines may 
give very different results from using primary cells. For example, a high level of 
unstimulated expression of hM IP-la mRNA is seen in the T cell line MJ and in 
HL60 cells (in one report). The fact that some leukemic cells also express high levels 
of hM IP-la mRNA suggests that the expression of this gene might be dysregulated in 
transformed cells. For this reason, it is likely that primary cells would be most 
appropriate for the study of the regulation of expression of these genes.
1.6 Bone Marrow-Derived Macrophages.
The Resident Bone Marrow Macrophage (RBMM) population is believed to be quite 
distinct from the rapidly proliferating, immature, developing members of the 
monocyte/macrophage lineage of the haempoietic system (monoblasts, 
promonocytes, monocytes) which outnumber the RBMM by five to one (Crocker et al
69
1988). In contrast to the developing haemopoietic cells RBMM appear to be non- 
replicating end cells (Crocker and Gordon 1985).
RBMM have been identified in situ by criteria such as morphology, ultrastructure, the 
presence of phagocytic inclusions and enzyme histochemistry and appear to be 
evenly distributed throughout the marrow (Hume et al 1984). It is thought that the 
stromal macrophages of the marrow are predominantly of this type.
In vitro, functional, studies have, unfortunately, been hampered by the inability of 
investigators to purify RBMM (Crocker et al 1988). As experimental surrogates, 
therefore, other types of recruited and cultured ex vivo populations of macrophages 
have been used to study macrophage function both as inflammatory macrophages and 
as surrogates for RBMM (Pojda et al 1989, Rich 1988).
1.6.1 Bone Marrow-Derived Macrophages and their Proliferation.
One cultured population which has been used to study macrophage gene expression 
and effector function and the biochemistry of the colony stimulating factors is the so- 
called bone marrow-derived macrophage (BMDM or BMM) population. This 
population is cultured directly from normal unfractionated bone marrow in vitro 
using a source of Colony Stimulating Factor 1 (CSF-1). The BMDM are derived 
directly from progenitors of the monocytic lineage in the marrow and more than 
ninety five percent of this population expresses the CSF-1 receptor (Tushinski et al 
1982, Tushinski and Stanley 1985). Tushinski et al (1982) observed that the cells 
were dependent on a source of CSF-1 for survival and proliferation. Submitogenic 
concentrations of CSF-1 were still able to promote survival of BMDM. They also 
demonstrated, using iodinated CSF-1, that the molecule is selectively degraded by the 
BMDM over the range of concentrations which stimulate both cell survival and 
proliferation.
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The proliferative response of BMDM to CSF-1 has been analyzed by Tushinski and 
Stanley (1985) who demonstrated, using tritiated thymidine labelling of nuclei, that 
93-98% of the BMDM were in cycle when cultured in the presence of both CSF-1 
and serum (15% fetal calf serum). Tushinski and Stanley (1985) reported that in the 
presence of serum, but in the absence of CSF-1, DNA synthesis was reduced by 98%. 
This was concomitant with a 35% reduction in total cellular protein synthesis, a 76% 
reduction in ribosomal protein synthesis and a 96% reduction in the synthesis of 
histones compared to exponentially growing cells. When cells deprived of CSF-1 (in 
15% serum) for 10-12 hours were refed with CSF-1 they entered DNA synthesis after 
a lag period of approximately 12 hours in a concentration-dependent manner 
(Tushinski et al 1982; Tushinski and Stanley 1985).
Assessment of labelled nuclei after treatment of BMDM with tritiated thymidine 
indicated that these cells had a doubling time of 24-28 hours and an S-phase time of 
8-9 hours. The continuous presence of CSF-1 up until the end of G1 phase is required 
for DNA synthesis to take place, indicating that the early programme of events 
induced by CSF-1 is insufficient on its own to induce proliferation. However, once 
cells have begun to synthesise DNA they can complete the cell cycle in the absence 
of CSF-1.
Matsushime et al (1991a) reported similar observations in the BMDM-like cell line 
BAC1.2F5, which is dependent on either CSF-1 or GM-CSF for survival, in response 
to CSF-1 using flow cytometric analysis of cellular DNA content.
In other systems in which cellular proliferation in response to growth factors has been 
studied, such as the Balb/c 3T3 fibroblast system, the sequential action of more than 
one growth factor is required to drive the cell from the resting quiescent (GO) state 
through early and late G1 and onto DNA synthesis (Rollins and Stiles 1989). 
Tushinski and Stanley (1985) have cited the fact that the presence of CSF-1 is able to 
induce progression from the resting state to S-phase to argue that in the BMDM
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system, this process can be driven by CSF-1 alone. However, two qualifications must 
be made to this statement. Firstly, BMDM, because of their dependence on CSF-1 for 
survival do not enter a GO quiescent state on the removal of growth factor but arrest 
in G1 and then die (Sherr 1991). Therefore, CSF-1 may be driving cellular 
proliferation from a different point in the cell cycle. Secondly, it should be borne in 
mind that all of the studies of BMDM proliferation described above were carried out 
in the presence of serum (15% FCS) which means that a component(s) of serum 
could be contributing to the induction of proliferation. Indeed, two reports have 
demonstrated a need for the presence of serum for the optimal mitogenic response to 
CSF-1. Hume and Gordon (1984) reported that the proliferation of BMDM was dose- 
dependent on serum even with optimal CSF-1. In the absence of serum, but in the 
presence of optimal CSF-1, proliferation was negligible. Tushinski and Stanley 
(1985) also reported that CSF-l-induced proliferation was reduced by approximately 
60% in the absence of serum. Tushinski and Stanley argued that this was due to non­
specific trophic effects. However, this issue can only be resolved by restoration of a 
full proliferative response to CSF-1 by BMDM in a defined serum-free medium 
which has not yet been achieved. It would appear, therefore, that the proliferation of 
BMDM is absolutely dependent on the presence of CSF-1 but that other factors (as 
yet unidentified) may play an auxiliary role.
Interestingly, the initiation of BMDM cultures from normal bone marrow can be 
achieved using partially purified but not pure CSF-1 (even in the presence of serum) 
which suggests that additional factors to CSF-1 may be involved in the development 
of BMDM as well as in their proliferation.
Hamilton et al (1988) have also investigated the ability of other growth factors to 
stimulate the proliferation of BMDM, both alone and in combination with CSF-1. 
They observed that recombinant murine Granulocyte Macrophage-Colony 
Stimulating Factor (rmGM-CSF) could induce incorporation of tritiated thymidine in
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BMDM with approximately one fifth of the efficiency of murine placental CSF-1. 
Recombinant murine interleukin-3 (rmEL-3) and the phorbol ester, and protein kinase 
C activator 12-O-tetradecanoyl-phorbol-13-acetate (TPA) were weak mitogens. 
Purified murine G-CSF had no detectable effect.
These cytokines also displayed synergy in their ability to induce proliferation in 
BMDM. In addition, TPA displayed dramatic synergy with each of CSF-1, GM-CSF 
and IL-3.
The macrophage activating factors LPS and ConA were not mitogenic for BMDM 
and indeed LPS almost completely inhibited the CSF-1 induced proliferation of 
BMDM, even at optimal CSF-1 concentrations.
Vairo et al (1991) have shown that the inhibition of CSF-1-stimulated BMDM 
proliferation by TNFa, EFNy and LPS is not due to a general loss of responsiveness to 
CSF-1; the ability of all three of these agents to also inhibit proliferation stimulated 
by GM-CSF and IL-3 suggests that they act at a post-receptor level.
The synthetic glucocorticoid dexamethasone and also prostaglandin E2 (PGE2) have 
also been shown to inhibit CSF-l-induced DNA synthesis in BMDM; this effect can 
however be overcome at higher concentrations of CSF-1 ( Hamilton et al 1988; Hume 
and Gordon 1984; Hamilton et al 1991). Agents which increase the intracellular 
levels of cyclic AMP (e.g. cholera toxin and PGE2) have been shown to inhibit the 
proliferation of BMDM late in G1 (Vairo et al 1990).
1.6.2 Macrophage Effector Functions and BMDM.
The ability of BMDM to carry out the effector functions of macrophages has also 
been investigated. Phillips and Hamilton (1989) and Hamilton et al (1989) have 
demonstrated that BMDM can be induced to produce the superoxide anion by TPA 
after they have been primed first by the growth factors GM-CSF and IL-3 (but not 
CSF-1) and macrophage activating factors such as LPS.
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Knight et al (1992) have demonstrated the stimulation of fluid-phase pinocytosis by 
BMDM after stimulation by CSF-1, GM-CSF, IL-3 and LPS. Again, this function can 
be dissociated from the proliferation of these cells.
1.7 Gene Expression in Bone Marrow-Derived Macrophages.
Bone marrow-derived macrophages have proved a suitable system for the 
investigation of the inducible expression of several genes.
The genes expressed in BMDM in response to stimuli can be assigned to two groups; 
those coding for products involved in cell maintenance and the mitogenic response 
and those coding for products involved in the functional activities of macrophages. 
Gene expression in an SV40-transformed cell line BAC1.2F5, which has similar 
properties to BMDM, which have very similar growth properties to BMDM will also 
be considered where appropriate.
1.7.1 Genes involved in the mitogenic response, 
c-fos. c-mvc
The proto-oncogenes c-myc, c-fos and c-jun have been implicated in the proliferative 
response to growth factors in a number of cell types. All three gene products appear 
to be transcription factors; c-myc protein on its own and c-fos and c-jun as a dimer 
known as AP-1. These products appear to exert their effects on the cell cycle by 
affecting the expression of other genes, most probably those responsible for 
progression through the later stages of the cell cycle.
Hamilton et al (1989) demonstrated transient expression of mRNA for c-fos and c- 
myc in BMDM which had been starved of CSF-1 in response to a variety of 
mitogenic agents (CSF-1, GM-CSF, IL-3, TPA, exogenous phospholipase C). 
Messenger RNA for c-fos was detectable after 20 minutes and then declined rapidly, 
while c-myc mRNA had its maximum level of expression at one hour and declined
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thereafter. The level of mRNA for both genes is dependent on the dose of CSF-1. The 
observed kinetics place these expressions in the "immediate early" time frame which 
is in agreement with that seen in other cell types (Rollins and Stiles 1989).
Agents which "activate" macrophages by other criteria but were not mitogenic 
(ConA, Zymosan, FMLP and calcium ionophore) did not stimulate expression of c- 
fos or c-myc. These results are consistent with expression of c-fos and c-myc playing 
an essential role in the proliferation of BMDM.
Orlofsky and Stanley (1987) demonstrated a similar pattern of expression for c-fos 
and c-myc in response to CSF-1 or GM-CSF stimulation in BAC1.2F5 cells.
1.7.2 Genes encoding secreted molecules.
Macrophages play roles in the response to infection and in tissue remodelling (Adams 
and Hamilton 1984) as well as being an important component of the haemopoietic 
microenvironment (Rich 1988, Greenberger 1991). One of the ways in which 
macrophages exert an effect on other cell types is by the secretion of signalling 
molecules which can affect the behaviour of other cell types. One recent review 
estimated the number of secretory products produced by macrophages to be over 
three hundred (Nathan 1987). Not all of these products are secreted by a given 
macrophage at any one time which indicates that heterogeneity within the 
macrophage population may be an important consideration of the biology of any 
secreted product (Rich 1988).
JE and KC
Orlofsky and Stanley (1987) demonstrated that mRNA transcripts for the MIP-1 
family member JE and the MEP-2 family member KC were inducible by the action of 
CSF-1 on BAC1.2F5 cells.
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The protein products of JE and KC are secreted and can affect the behaviour of 
monocytes (Rollins 1991) and tumour cells (Schall 1991), respectively.
The kinetics of expression of these genes was similar to that observed in PDGF- 
stimulated 3T3 cells (Cochran et al 1983) in that accumulation of mRNA was seen 
within twenty minutes and reached a peak after 4 hours and was still elevated at eight 
hours. The levels of expression at times later than eight hours was not reported.
The expression of JE, but not KC, could be similarly induced by GM-CSF which 
suggests differences in the pathways for the signals leading to the induction of these 
genes. This result also demonstrates that expression of KC is not essential for 
proliferation of BAC1.2F5 cells as these cells proliferate in response to GM-CSF as 
well as CSF-1.
Although the expression of JE, KC and c-fos and c-myc (see above) is temporally 
associated with the early response to proliferation, Orlofsky and Stanley (1987) 
demonstrated that induction of these genes could be dissociated from the cellular 
response to a mitogen. All four of these genes could be induced by CSF-1 in a 
BAC1.2F5 variant (Autl) which can proliferate independently of exogenous growth 
factor which suggests that the pathways mediating progression through the cell cycle 
and the early expression of genes are different. In addition to this, all four genes can 
be greatly elevated by CSF-1 in cells previously made asynchronous with respect to 
the cell cycle by prolonged culture in GM-CSF; this again demonstrates that the early 
gene programme can be induced independently of the induction of mitogenesis.
It should be noted, however, that these experiments do not disprove a role for c-fos or 
c-myc (or JE for that matter) in the early stages of cell cycle progression, although 
Rollins and co-workers have been unable to demonstrate any role for JE in the 
proliferative response (Rollins 1991).
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IL-la. IL-1J3 and IL-lra
IL -la  and (3 are pro-inflammatory cytokines which exert effects on practically every 
tissue of the body, including induction and suppression of gene expression, and 
cellular activation. The genes for IL -la  and IL-lp are expressed in a wide variety of 
cell-types. A natural inhibitor of the action of these molecules, IL-1 receptor 
antagonist (IL-1 ra) has been identified and the cDNA cloned in the mouse 
(Matsushime et al 1991b). This field has recently been reviewed by Dinarello (1991). 
Matsushime et al (1991b) also demonstrated that CSF-1 induces the expression of 
murine EL-Ira mRNA within an hour in BAC1.2F5 cells and the level of this message 
continues to increase for five hours. This induction is unaffected by cycloheximide 
indicating that the induction is independent of de novo protein synthesis. In BMDM, 
expression of IL-lra mRNA was induced within 45 minutes by CSF-1. The level of 
the mRNA continued to rise with time and peaked at around ten hours after which 
they declined. Messenger RNA for IL -la  and IL-lp, on the other hand, was induced 
early and peaked at around 6 hours and had returned to undetectable levels by twenty 
hours. Induction of IL -la  was inhibited by cycloheximide whereas it increased the 
level of IL-lp induced by CSF-1. In this study, all three of the mRNAs were also 
induced in BMDM by LPS. These data would put place expression of IL-ip and IL-1 
ra in the immediate early category whereas the expression of EL-la mRNA may be 
dependent on the expression of other genes.
Urokinase-tvpe Plasminogen Activator
The expression of mRNA and protein for urokinase-type plasminogen activator (u- 
PA) has also been studied in BMDM (Hamilton et al 1991). Plasminogen activators 
are serine proteases that cleave plasminogen to create plasmin, another serine 
protease. They are expressed by a large number of cell types and appear to be
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associated with processes such as tissue remodelling and cell migration (for review 
see Saskela et al 1985).
Expression of u-PA mRNA and activity by BMDM deprived of a source of CSF-1 for 
18 hours was negligible. However, CSF-1 induced expression of u-PA mRNA after 
one hour and peak levels were seen between two and eight hours. By thirteen hours u- 
PA mRNA had declined to a lower, but still detectable, level and was still at this level 
twenty four hours after stimulation. The level of u-PA mRNA expressed after three 
hours was dependent on the dose of CSF-1 as was the production of u-PA activity in 
the culture medium. The CSF-1-mediated production of u-PA activity was abrogated 
by the addition of the transcriptional inhibitor actinomycin D to the culture which 
suggests that transcription is necessary for CSF-1 induced expression of this gene. U- 
PA mRNA and activity was also induced by treating BMDM with GM-CSF or IL-3 
but G-CSF was ineffective at inducing u-PA activity in the culture medium. The 
macrophage activator ConA also induced u-PA mRNA; therefore it seems that u-PA 
expression can be induced both by specific cytokines and by non-specific 
macrophage activating agents. The synthetic glucocorticoid dexamethasone also 
inhibited CSF-1 induced production of mRNA and u-PA activity. A direct causal 
relationship between macrophage proliferation and u-PA gene expression has been 
proposed by both Hume and Gordon (1984) and Grimaldi et al (1986). However, 
despite the fact that the gene is expressed as part of the early response to growth 
factors, Hamilton et al (1991) identified conditions where gene expression was 
induced in the absence of proliferation (such as induction by ConA) and those in 
which proliferation took place in the absence of u-PA expression as the down- 
reguatory effect of dexamethasone on BMDM proliferation but not on u-PA mRNA 
expression could be overcome by high levels of CSF-1. Therefore, it appears that, 
like the expression of JE and KC, the expression of this gene can be induced 
separately from the induction of proliferation.
78
Taken together, the work discusssed in this and the last section indicate that bone 
marrow-derived macrophages constitute a system suitable for the study of the 
regulation of gene expression in primary macrophages.
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Aims of Thesis and Plan of Investigation
Identifying and understanding the signals and mechanisms underlying the production 
of negative and positive regulators of haemopoietic stem cell proliferation is essential 
for a full appreciation of the role played by these factors in the regulation of 
haemopoiesis and in other processes.
The central aim of this thesis was to study the regulation of expression of the gene for 
a negative regulator of haemopoietic stem cell proliferation, Stem Cell Inhibitor/ 
Macrophage Inflammatory Protein-la (SCI/MIP-la), which has recently shown to be 
functionally and antigenically identical to a previously described regulatory activity, 
Manchester Inhibitor, and that for a closely related molecule Macrophage 
Inflammatory Protein-lp (MIP-lp) in the context of haemopoietic regulation and 
other processes. The objectives were: a) to identify the characteristics of expression 
and to determine whether the expression of these genes was capable of being 
regulated by physiological signals, b) to identify the likely mechanisms underlying 
the observed behaviour, c) to identify putative physiological regulators of the 
expression of these genes, d) to investigate the relationship between the expression 
of these genes and the regulation of haemopoiesis and other processes.
The main approach taken was to study the regulation of expression of mRNA for 
SCI/MIP-la and MIP-lp in a cell population approximating as closely as possible to 
the putative producers of the Manchester Inhibitor in the bone marrow.
The first step in this approach was to set up an in vitro cell culture system consisting 
of a defined population of macrophages cultured directly from normal murine bone 
marrow. This population was demonstrated by Northern and Western blotting, to 
express mRNA for SCI/MIP-la and MIP-ip and SCI/MIP-la protein, respectively. 
Bacterial endotoxin was used as a model inducer, and hydrocortisone as a model 
downregulator, of the accumulation of both mRNAs. It was observed that the 
induction of accumulation of both SCI/MIP-la and MIP-lp mRNA have
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characteristics typical of genes expressed as part of the early phase of the response of 
macrophages to stimulation. These experiments, which helped define the parameters 
of the system, led to further studies aimed at testing candidate regulators of SCI/MIP- 
l a  and MIP-lp gene expression in vitro. These experiments also allowed the 
relationship between the expression of SCI/MIP-la and MIP-lp and the proliferation 
of this population to be investigated.
A complementary study was also carried out to investigate the relationship between 
SCI/MIP-la gene expression in vivo and the regulation of haemopoiesis by 
comparing the accumulation SCI/MIP-la mRNA in normal, unperturbed murine 
bone marrow to that in the marrow of animals treated with drugs demonstrated to 
have profound effects on the proliferation of haemopoietic stem cells.
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Chapter 2
Materials and Methods
2.1 Mice.
All mice were housed within the animal facility of the Beatson Institute, twelve to a 
cage, and were fed water and mouse chow ad libitum. Female mice were used at age 
8-12 weeks for all experimental procedures. For the culture of macrophages, bone 
marrow and spleens from normal untreated mice of the outbred strain CD1 (Charles 
River, UK) were used. For experiments involving drug treatment of animals, strain 
B6D2F1 mice, an FI hybrid of C57B1/6 (females) and DBA2 (males) strains 
(Harl -Olac, UK) were used.
2.2 Harvesting of Bone Marrow and Spleen Cells.
Bone marrow was obtained from the femora of mice. Mice were killed by either 
cervical dislocation or by suffocation with carbon dioxide. Femora were removed 
from the animal and cleaned of surrounding muscle tissue using a tissue soaked in 
75% ethanol. Both ends of the femur were removed using scissors and the bone 
marrow plug expelled from the central cavity by inserting a 21 gauge needle into one 
end of the femur and flushing through 2ml of SLM/FCS (Table 2.1). The bone 
marrow plug was collected in a sterile container. The cells were then dispersed into a 
single cell suspension by vigorous pipetting and nucleated cells counted using a 
haemocytometer. Cells were diluted 1 in 10 with 0.23% methylene blue in 22% 
ethanol to enable discrete visualisation of nucleated cells. Ten to twenty million 
nucleated bone marrow cells were routinely obtained per femur. For experimental 
estimates of marrow cellularity, the cells from at least three pooled femurs were 
electronically counted using a Coulter Counter (Coulter Electronics, England).
82
The adherent fraction of normal bone marrow was prepared according to the method 
of Wright et al (1980a). Bone marrow cells were suspended in Fischer’s medium 
(Table 2.1) at 5.10^ cells/ml and allowed to adhere to plastic for 2 hours at 37°C. The 
supernatant was then removed and fresh Fischer's medium added to the plate, after 
which the adherent cells were detached using a disposable cell scraper and 
resuspended in the medium.
Spleens were carefully removed under sterile conditions using scissors and forceps. 
Spleens were disaggregated in SLM/FCS by passage through a 0.1mm, sterilised, 
stainless steel gauze and a single cell suspension obtained after repeated vigorous 
pipetting steps. Nucleated cells were counted as for bone marrow. Approximately 
1.10^ cells were obtained per normal spleen. For experimental determinations of 
spleen weight, spleens were weighed on an electronic balance and data presented as 
the mean of at least four spleens +/-1 standard deviation.
2.3 Maintenance of Cell Lines and Production of Conditioned Media.
All cell lines were obtained from the frozen stocks of the Beatson Institute and were 
maintained in SLM/FCS. Cells were maintained in T75 tissue culture flasks (Nunc, 
Denmark). On reaching semi-confluence, cells were replated in fresh medium at one- 
fifth of the number at semi-confluence. Fibroblastic cell-lines were detached from the 
surface of the flask using trypsin (Gibco) diluted 1:10 in PE (Table 2.1). Macrophage- 
and monocyte-like cell lines were detached using a disposable cell scraper (Costar). 
For the production of conditioned media, the L929 (Stanley and Heard 1977), WEHI 
3B (Ihle et al 1982) and AF1-19T (Franz et al 1985) cell lines were grown in roller 
bottles in SLM/FCS to half-confluence. Spent medium was then removed, replaced 
with fresh medium, and the cultures allowed to grow for another three days. The 
conditioned medium was then removed, passed through 0.45 and 0.22|im filters and 
stored at -20°C.
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2.4 Culture of Monocvte/Macrophages from Normal Bone Marrow and Spleen.
The methods used in this section were adapted from Pojda et al (1988) and Tushinski 
et al (1982). For the culture of bone marrow-derived macrophages (BMDM) and 
spleen-derived macrophages (SDM), a single cell suspension was obtained from the 
appropriate tissue of female CD1 mice as described in section 2.2.
Normal bone marrow cells were plated at a concentration of 5.10~7ml in alpha-MEM 
medium (Table 2.1) containing 25% Donor Horse Serum (DHS) and 20% L929 
conditioned medium (L929CM). Two methods were used for culture after this initial 
step. 1) Cells were cultured under these conditions for seven days. After seven days 
non-adherent cells were removed by aspirating the spent medium and washing the 
adherent cells twice in warm PBS (Table 2.1). The cells remaining attached were then 
used as BMDM. 2) Alternatively, the non-adherent cells were removed after three 
days of culture and replated in fresh alpha medium as before. The adherent fraction 
present after a further four days in culture was then used as BMDM.
Normal spleen cells were plated at a concentration of l.iofyml in the same culture 
conditions. The adherent fraction present after seven days of culture was used as 
SDM. The cells were identified as monocyte/macrophages by morphology and by 
positive staining for the enzyme alpha-napthyl acetate esterase (as described in 
chapter 3).
2.5 Cvtospin Preparations and Non-Specific Esterase Assay.
Cultured and sorted bone marrow cells were prepared for morphological examination 
by centrifugation onto glass slides. Approximately 2.5-5.10^ cells were placed in a 
Cyto-tek chamber (Cyto-tek, France) and centrifuged at 500rpm for 5 minutes in a 
Cyto-tek cytocentrifuge. The slides were air-dried and fixed with methanol for ten 
minutes. After air-drying, the slides were stained in Giemsa's stain (BDH, UK) (10%
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v/v in distilled water) for ten minutes and then rinsed under running tap water until 
the water ran clear. After drying, the slides were mounted with DPX mountant (BDH, 
UK) and glass coverslips (BDH, UK) and the slides examined by microscopy. 
Morphological observations were confirmed by an experienced histologist. 
Non-specific esterase assays were performed using a kit (diagnostic kit 91-A) 
supplied by Sigma (UK) and were performed as recommended by the manufacturer. 
Immediately prior to fixation, 1ml of sodium nitrite solution was added to 1ml of Fast 
Blue BB solution in a test tube. The contents were mixed gently and allowed to stand 
for 2 minutes. The resulting solution was then added to 40ml of distilled water 
prewarmed to 37°C. To the solution was added 5ml TRIZMAL 7.6 buffer 
concentrate (Sigma) and 1ml a-napthyl acetate solution. The solution was then mixed 
well and poured into a Coplin jar.
Cells were cytocentrifuged and fixed for 30 seconds in Citrate/ Acetone/ 37.5% 
Formaldehyde (25:65:8) fixative at room temperature. The slides were then rinsed for 
60 seconds in running distilled water and placed, without drying, in the Coplin jar. 
The Coplin jar was then incubated in a 37°C water bath, protected from light. After 
incubation, the slides were removed, rinsed in tap water and air dryed. Cells of the 
monocytic lineage were identified by brown/red staining of the cytoplasm. A 
macrophage cell line (J774.2) and a fibroblastic cell line (NRK) were used as positive 
and negative controls, respectively. On all occasions, BMDM were found to be 
greater than 95% positive for non-specific esterase. Non-specific esterase assays on 
the BMDM population derived in this study were also performed independently by 
the Department of Haematology of Glasgow University School of Veterinary 
Medicine and confirmed the observations of the author.
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2.6 BMDM Growth Curves.
For the assessment of their growth properties, BMDM were replated at a 
concentration of 2.5.10^/ml in alpha-MEM medium containing 25% DHS in the 
presence or absence of either L929CM or WEHICM in T25 (5ml) Flasks (Nunc, 
Denmark). Cells were allowed to adhere, to the surface of the culture flask for 48 
hours and after this time were counted either daily or every two days. For counting, 
medium was aspirated and the remaining adherent cells washed twice with warm PBS 
to remove any remaining non-adherent cells. The adherent cells were then detached 
from the culture flask using a disposable cell scraper (Costar, USA) and counted 
using a haemocytometer. Six counts were performed per flask and the contents of 
four flasks were counted per time point. Data was presented as the average count 
from four flasks.
2.7 DNA Synthesis Assays.
DNA synthesis was measured by incorporation of ^H-thymidine (^H-TdR) into 
trichloroacetic acid precipitable material. The method used in this section was 
adapted from Vairo et al (1990). BMDM, in T25 (5ml) flasks were "starved" 
overnight in alpha-MEM containing 25% DHS in the absence of any additional 
growth factors to reduce proliferation to a minimum. The quiescent BMDM were 
then cultured in fresh alpha-MEM in the presence or absence of the putative 
mitogenic stimulus at 37°C. Thirty minutes before the appropriate time point, the 
medium was removed and the cells washed twice with SLM/FCS. Two ml SLM/FCS 
supplemented with ^H-TdR (10 fiCi/ml) (NEN, UK) were then added to the flask and 
the flask incubated at 37°C for thirty minutes. After this, the medium was removed 
and the cells washed once with ice cold PBS. Three ml of ice cold trichloroacetic acid 
(10%) was then added and the flask left on ice for 60 seconds. The cells were then 
detached from the culture flask using a disposable cell scraper and the samples
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filtered through a Millipore harvester using cellulose filters (Whatman GF/A). The 
filters were washed twice with ice cold 10% trichloroacetic acid and once with 
ethanol before P scintillation counting in an LKB 1215 Rackbeta scintillation counter. 
For a single time-point, ^H-TdR incorporation was measured after twenty hours. Data 
were presented as the mean of triplicate cultures +/- 1 standard deviation.
2.8 Metabolic Labelling of Cvsteine-Containing Proteins in BMDM and RAW264.7 
Cells.
For the metabollic labelling of cells with ^S-cysteine, BMDM or the cell line 
RAW264.7 were replated in 100mm tissue culture dishes (Falcon UK) at a 
concentration of 10^ per ml in alpha-MEM medium plus 20% L929CM or SLM/FCS, 
respectively and the cultures incubated for 24 hours. Medium was then aspirated and 
the plates washed once with 7ml PBS, after which the plates were incubated for 
twenty minutes at 37°C for 20 minutes in 7ml PBS. Medium was then aspirated and 
lml of cysteine-free medium supplemented with 300|iCi -^S-cysteine was added to 
each plate. The plates were then placed in a closed equilibrated box at 37 °C and 
rocked every 30 minutes to ensure even distribution of medium. After four hours, the 
medium was removed and both cells and medium stored at -20°C for analysis (see 
section 2.20).
2.9 ClQnQgenig Assays,
a) CFU-A Primitive Progenitors (Pragnell et al 19881.
For the detection of CFU-A, 10^ normal bone marrow cells in alpha-MEM medium 
containing 25% DHS and 0.3% agar (Difco, USA) were seeded on top of an 
underlayer of the same medium containing 0.6% agar, 10% L929CM and 10% 
AF1CM in a 60mm petri dish (Sterilin, UK). Cultures were incubated at 37°C in a 
fully humidified atmosphere of 10% CO2 , 5% O2  and 85% N2  for 11 days. Colonies
87
were stained with INT (2-(4 Iodophenyl)-3-(nitophenyl)-5-phenyltetrazolium 
chloride) [Table 2.1] overnight (Bol et al 1977). Colonies with a diameter greater 
than 2mm were scored as CFU-A.
hi CFU-M Progenitor Assay (Pragnell et al 19881.
For the detection of CFU-M, 7.5.10^ normal bone marrow cells in 1ml alpha-MEM 
medium containing 25% DHS and 0.3% agar were seeded on top of an underlayer of 
the same medium containing 0.6% agar and either L929CM or recombinant human 
CSF-1 (rhCSF-1). Cultures were incubated as for CFU-A. After seven days the 
colonies were stained with a solution containing 0.13% methylene blue and 20% 
glutaraldehyde in PBS (Table 2.1). Colonies with greater than 50 cells were scored as 
CFU-M.
cl Cvtosine-Arabinoside Suicide Assay (Dunlop et al 19921.
The proportion of CFU-A cells in S-phase was estimated using a "suicide" assay. 
Before plating bone marrow cells in a CFU-A assay, cells were divided into two 
aliquots of 2.10^ to 5.10^ cells each in 1ml Fischer's medium containing 20% DHS. 
Cytosine arabinoside (Ara-C) (Sigma, Poole, UK) was then added to one tube to a 
concentration of lCT^M and both tubes gassed with 5% CO2 / air and incubated for 
lhour at 37°C. After incubation the cells were washed four times in 2ml fresh 
Fischer's medium containing 20% DHS to remove any remaining Ara-C, resuspended 
to appropriate cell concentrations and plated as for CFU-A assay. CFU-A numbers 
were calculated by averaging the counts from ten plates. The CFU-A proliferative 
status was derived by comparison of the plus or minus Ara-C data to calculate the 
proportion of progenitors sensitive to Ara-C and hence the proportion in S-phase at 
the time of assay (Dunlop et al 1992). For time courses of CFU-A cycling a normal,
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untreated control was assayed in parallel for each time point to take into account the 
large daily fluctuations seen in CFU-A cycling with normal untreated animals.
2.10 5-Fluorouracil and Phenvlhvdrazine Treatment of Mice.
5-fluorouracil (Sigma, USA) was dissolved in PBS to a concentration of 6mg/ml. 
Each B6D2F1 mouse was then given a single intravenous injection of 0.2ml (a dose 
of 150mg/kg in accordance with the method of Harrison and Lemer 1991). 
Phenylhydrazine (PHZ) (Sigma, USA) was used according to the method of 
Rencricca et al (1970). B6D2F1 mice were injected subcutaneously with PHZ 
(60mg/kg) in PBS on days 0, 1 and 3 of experiments.
2.11 PolvmixinB.
Carrier-fixed polymixin B (Boehringer Mannheim, UK), used to remove LPS from 
culture media, was used according to the method of Issekutz et al (1983). Polymixin 
B was added to media under sterile conditions to a concentration of 2mg/ml and the 
solution stirred at room temperature for twenty four hours. The polymixin B was then 
removed by centifugation and the media used as normal.
2.12 Hvbridoma Culture and Antibody Production.
The RA3-3A1 hybridoma cell line (Coffman and Weissman 1983) was used as a 
source of monoclonal antibody against the B220 antigen. The cells were grown in 
RPMI 1640 (Table 2.1) containing 15% FCS and insulin, transferrin, selenium 
supplement (Sigma, UK) plus penicillin (30pg/ml) and streptomycin (30}ig/ml). A 
growth curve was plotted to find the concentration at which the cells would be 
growing exponentially (data not shown). Logarithmically growing cells were then 
centifuged at 1500rpm for 30 minutes and the cells resuspended in 3-4 times their 
original volume in serum-free RPMI. The cells were harvested 4 days later and 
centrifuged at 10,000rpm for 15 minutes. The supernatant was decanted and
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powdered ammonium sulphate added to 50% (331 grams/litre) and the solution 
stirred overnight at 4°C. The next day the solution was centrifuged at 10,000rpm for 
60 minutes. The pellet was then resuspended in the smallest volume of PBS in which 
it would dissolve and dialysed overnight against PBS in dialysis tubing with a 
molecular weight cut-off of 12.5 KDa.
2.13 Bead Separation of Cells.
All manipulations were carried out in Falcon 2097 centrifuge tubes (Beckton 
Dickinson, USA). Magnetic beads with attached goat anti-rat Fc antibody were 
purchased from Metachem Diagnostics (England).
Bone marrow cells were suspended in SLM/FCS at a concentration of 5.10^/ml and 
either an appropriate dilution of primary antibody or an appropriate concentration of 
Bovine Serum Albumin (as a control) added. The tubes were then gassed with 5% 
CC>2 in air and incubated at 37°C for 30 minutes with agitation. Next, the secondary 
(bead-attached) antibody was added to the tube and the tube incubated as before.
After this step, the tubes were exposed to a powerful magnetic field (Magnetic 
Separator, Metachem Diagnostics) which caused the beads to adhere to the side of the 
tube. According to the nature of the experiment, either the supernatant or the bead- 
bound fraction was harvested (see chapter 3).
2.14 Isolation of Total RNA.
For RNA isolation from adherent cells, cells were washed twice with PBS and 5ml 
RNAzol B (Biogenesis, England) added directly to the flask. The resulting mixture 
was then decanted to Falcon 1059 polypropylene centrifugation tubes. Non-adherent 
cells were transferred to a sterile universal container, pelleted by centrifugation, 
washed once in PBS, re-pelleted and resuspended in 250pl PBS and the contents 
transferred to Falcon 1059 tubes. Five ml of RNAzol B were then added to tube and
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the solution pipetted vigorously and 1ml of chloroform added to tube and the contents 
again pipetted vigorously. The tops of the tubes were then covered with parafilm 
(American National Can, USA) and left on ice for at least ten minutes to allow phase 
separation to take place. After this the tubes were spun at 10,000rpm for 15 minutes 
in an HB-4 rotor in a Sorvall RC-5B superspeed centrifuge. After centrifugation, the 
upper aqueous phase was removed from the tube and placed in a fresh identical tube 
to which an equal volume of propan-2-ol was added. The tube was then shaken using 
a whirlymixer before being stored for at least one hour at -20°C to allow precipitation 
of RNA. After precipitation, the tube was centrifuged as before and the pellet rinsed 
with 6ml ethanol (75% in DEPC-treated water [ Table 2.2]) and centrifuged as 
before. The pellet was then resuspended in DEPC-treated water to give an RNA 
concentration of approximately 2mg/ml as estimated by optical density. An equal 
volume of ethanol was then added to give a stock solution of 1 mg/ml and the sample 
stored at -20°C.
2.15 Isolation of PolvfAVH and PolvfAV Fraction of Total RNA.
Total RNA was isolated as described in the previous section by the author and the 
poly(A)+ and poly(A)- fractions isolated by Dr.E.Barone of the Beatson Institute.
This was done using a kit manufactured by Promega (USA). Total RNA was 
incubated in an eppendorf tube with a buffer containing magnetic beads with attached 
poly(T) moiety, which specifically binds the poly(A)+ fraction, which was then 
adhered to the side of the tube by application of a strong magnetic field. The poly(A)- 
fraction was then decanted and the poly(A)+ fraction eluted by incubation in water at 
65°C. RNA yield was determined by spectrophotometry.
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2.16 Agarose Gel Electrophoresis.
Agarose gel electrophoresis was used to check the integrity of prepared RNA samples 
and to prepare RNA for Northern blot transfer. 1.4% (w/v) agarose gels (150ml total 
volume) were prepared by dissolving 2.8g agar (Gibco, Scotland) in 160ml water in a 
microwave oven. When cooled to 60°C, 20.4 ml of formaldehyde (37.5% solution) 
and 20ml lOxMOPS (Table 2.2) buffer were added and the gel poured under a 
chemical fumehood.
RNA samples were freeze-dried and redissolved in 15|il of RNA sample loading 
buffer (Table 2.2) plus lp.1 of ethidium bromide (lmg/ml), heated to 65°C for 15 
minutes, chilled on ice for 1 minute and then loaded on the gel. For determination of 
the size of mRNA species detected, 2pg of an RNA ladder (BRL, UK) containing 
RNA molecules of sizes 0.24, 1.4, 2.4,4.4,7.5 and 9.5kb in 15pl of RNA sample 
loading buffer plus lpl of ethidium bromide (lmg/ml) was also run in on the agarose 
gel.
Electrophoresis was carried out with the gel fully submergered in lxMOPS 
electrophoresis buffer at 50V (250mA) for 3-4 hours until the dye-front had travelled 
approximately half the length of the gel.
2.17 Northern Blot Transfer of RNA.
RNA samples were size separated as described in the previous section. The loading 
and integrity of the RNA was checked by visualisation under U. V. light and a 
photograph of the gel taken.
The gel was washed twice in lOxSSC (Table 2.3) for 15 minutes. Transfer was 
performed overnight in lOxSSC on to a Genescreen (Dupont NEN, USA) membrane 
which had previously been hydrated in DEPC-treated water and soaked once in 
lOxSSC for 15 minutes. After transfer, the membrane was removed and the gel
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visualised under U. V. light to ensure efficient transfer. The membrane was then 
baked at 80°C for 2-3 hours to fix the RNA.
2.18 Preparation of Radiolabelled Probes.
The SCI/MIP-la-specific probe was generated as an in vitro transcription product of 
the coding sequence of SCI/MIP-la cDNA sequence cloned into the pBluescript II 
SK" (pSK') plasmid. The cDNA was generated as a PCR product whose synthesis 
involved the generation of additional Xhol and EcoRI restriction sites. This product 
was then cloned into the multiple cloning site in the pSK" plasmid in the appropriate 
orientation to allow the generation of an antisense SCI/MIP-la RNA sequence by in 
vitro transcription from the T3 promoter contained within the plasmid. Before the in 
vitro transcription reaction was carried out, the plasmid was cut with Xho I to 
enhance the efficiency of reaction. A plasmid allowing the generation of a MIP-1 p- 
specific anti-sense RNA was generated in an identical fashion. Both of these plasmids 
were obtained from Dr. Mark Plumb, Institute for Cancer Studies, Leeds. 
Forriboprobes, approximately 0.5|ig of the appropriate DNA transcription template 
was added to a reaction mixture containing 2|il 10xT3 buffer (400nM Tris, 50mM 
M gC^, pH8), 2fil DTT (50mM), 2|il spermidine (40mM), 2fil ATP,CTP,GTP 
(5mM), l|il RNAguard, 0.5jil T3 polymerase, 50|iCi -^P UTP (Amersham, UK code 
PB20383), and 5|il DEPC-treated water. The mixture was agitated gently and 
incubated at 37°C for one hour.
The 7S RNA-specific probe is a 0.4kb Hinf I fragment of the plasmid pAT153 
containing 150bp of a 190bp portion of of the 7S cDNA which had been cloned into 
the plasmid at EcoRI site 375. The plasmid was obtained from Frances Fee (Beatson 
Institute). This probe hybridises with an RNA message of approximately 280bp, 
which is the size of the 7S RNA (reference for plasmid Balmain et al 1982).
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For DNA probes, approximately lOOng of DNA fragment was added to 20|il of 
water, boiled for 10 minutes to denature the DNA and then cooled on ice. To the tube 
was added ljil each of dATP, dGTP, dTTP (0.5mM), 2|il reaction mixture 
(hexanucleotide mixture in lOx reaction buffer), ljil Klenow enzyme and 50|iCi ^ P  
dCTP (Amersham, UK code PB10205). The mixture was agitated gently and 
incubated at 37 °C for one hour.
For both types of reaction, unincorporated nucleotides were removed by size 
fractionation on a NICK column (Pharmacia, Sweden). The specific activity of the 
probe was calculated after scintillation counting and sufficient probe added to the 
hybridisation buffer to give a concentration of 1.10^ cpm/ml. DNA probes were 
always boiled for five minutes and chilled quickly on ice before use.
2.19 Hybridisation Analysis of RNA.
The solutions used for hybridisation are shown in table 2.3. Membranes were pre­
hybridised in hybridisation buffer in the absence of probe in plastic boxes with 
agitation for at least six hours. Then radiolabelled probe was added and hybridisation 
carried out overnight with agitation. For riboprobes the hybridisation was carried out 
at 65°C, while hybridisation with DNA probes was carried out at 42°C. The 
following day, membranes were washed twice for 30 minutes with agitation at room 
temperature and then washed twice for 30 minutes at the probe hybridisation 
temperature with the approriate wash buffers (Table 2.3). Membranes were dried on 
Whatman 3MM paper and and sealed in thin polythene bags.
Sealed membranes were then exposed to Kodak X-OMAT AR film at -70°C and the 
films processed in an X-ray processor.
Membranes were stripped of bound probe by boiling for ten minutes in either 
Northern blot wash buffer (A) (Table 2.3) or in distilled water.
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2.20 SDS-Polvacrvlamide Gel Elecrophoresis.
A 15% agarose gel with a 5.5% stacking gel (Table 2.4) was poured in a minigel 
system (Atto, UK). Protein samples were boiled for ten minutes in protein sample 
buffer (Table 2.4) and chilled on ice immediately prior to loading. Radiolabelled 
(l^C) molecular weight markers of 200,97, 69,46, 30,21 and 14kDa were also 
loaded (Amersham UK). Electrophoresis was carried out in SDS-PAGE 
Elecrophoresis Buffer (Table 2.4) at 150V until the dye-front was close to the end of 
the gel.
For the analysis of the media conditioned by -^S-cysteine labelled cells, the gel was 
fixed in SDS-PAGE Gel Fixative (Table 2.4) for 30 minutes and then washed in 
Amplify (Amersham, UK) for 20 minutes to increase the sensitivity of detection of 
radioactivity. The gel was then placed on Whatman 3MM paper, covered in Saran 
Wrap (Dow, USA) and dried on a gel drier. The dried film was then exposed to 
Kodak X-OMAT AR film at -20°C.
2.21 Western Blotting.
SCI/MIP-la content of media conditioned by BMDM or RAW264.7 cells was 
analysed by Western blotting. Twenty |il of conditioned medium was boiled in an 
equal volume of protein sample buffer and separated by SDS-PAGE (3% stacker, 
17.5% gel). Ten ng of pure recombinant SCI/MIP-la protein was also run as a 
positive control as described in section 2.20.
The contents of the gel were then transferred on to a nitrocellulose membrane (BA 
85; Schleicher and Schuell) using a minigel electroblotting apparatus (Biotech 
Instruments Ltd., UK) driven by a current of 50mA for 30 minutes. The membrane 
was then removed and washed in multiple changes of "blotto" (PBS, 5% dried milk, 
0.1 % NP40) for 1 hour to block non-specific binding sites. The membrane was then 
incubated in blotto containing a 1 in 1000 dilution of goat anti-mouse SCI/MIP-la
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antibody (R and D Systems, USA). The membrane was then washed in blotto for 30 
minutes, with multiple changes before the addition of a horse radish peroxidase- 
conjugated horse anti-goat antibody (Vector Labs, UK) in blotto. The membrane was 
then washed for 15 minutes in blotto before multiple washes in PBS/1 %  Tween. 
Antibody binding was visualised using an Enhanced Chemiluminescence (ECL) kit 
(Amersham, UK). The membrane was incubated in ECL solutions for 60 seconds and 
then exposed to X-OMAR AR X-ray film.
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Reagent Tables.
Table 2.1 Tissue Culture
Special Liquid Medium (SLIM
Supplemented modified Eagles medium (SLM, Gibco cat. no. 043-01136M) 
10% fetal calf serum (FCS, Gibco).
2mM L-Glutamine
Dulbecco's/SF12 (for 1 litrel
lOx Dulbecco's medium 50ml
lOx SF12 medium • 50ml
L-Glutamine (200mM) 10ml
Pyruvate (lOOmM) 5ml
Penicillin (750|ig/ml) 5ml
Double distilled water 840ml
Nutridoma 10ml
Sodium bicarbonate (7.5%) 41ml
(Gibco cat. no. 042-0251 M) 
(Gibco cat. no. 041-01765M)
MEM Alpha Stock (Gibcol
Dissolve 5 litre pack (Gibco) in water, add 50ml MEM xlOO vitamins (Gibco) and 
lOOmg gentamycin sulphate. Make up to 1500ml and filter sterilise.
MEM Alpha x2 (for lOOmL
Alpha stock 21ml
L-Glutamine (200mM) 1ml
Sodium bicarbonate (7.5%) 3ml
Donor Horse Serum 25ml
(For MEM Alpha xl add an equal volume of distilled water and check osmolarity in 
osmometer [range 300+/- 10 mOs] or add to equal volume of agar for clonogenic 
assays.)
Fischer's Medium
Distilled water 
lOx Fischer's Stock
87ml
10ml (Gibco cat. no. 042-01735M)
L-Glutamine (200mM) 
Sodium bicarbonate (7.5%) 
Donor Horse Serum
lml
1.5ml
20ml
RPMT 1640
Distilled water 
RPMI xlO stock 
L-Glutamine (200mM) 
Sodium bicarbonate (7.5%)
860ml
100ml I (Biol. Industries cat. no. 06-1100-01-5A)
10ml
1.5ml
Dulbecco's phosphate-buffered saline, solution A (PBS).
KC1
k h 2p o 4
NaCl
2.68mM
1.47mM
0.137mM
Na2HP04.7H20  8.06mM
Trvpsin diluent. PBS/EDTA (PE) 
PBS
ImM EDTA
Trvpsin
0.25% trypsin in PE
INT Stain.
For the preparation of INT stain, 50mg 2-(4-Iodophenyl)-3-(4-nitrophenyl)-5- 
phenyltetrazolium chloride (INT) (BDH, UK) was added to 50ml PBS and the 
mixture heated to allow dissolution of the solid. After cooling, the INT solution was 
filtered to remove any undissolved solid and sterilised through a 0.22|im filter.
Methvlene Blue Progenitor Stain (for 23mD.
Methylene Blue (0.23%) lml
Glutaraldehyde (25%) 4.6ml
PBS 17.4ml
Table 2.2 Agarose Gel Electrophoresis.
MOPS buffer xlO pH7 (for 1 litre)
Sodium Acetate 
EDTA
MOPS (Sigma) 41.8g (0.4M)
6.8g (0.1M)
3.72g (0.01M)
RNA Sample Loading Buffer
Formamide 
lOx MOPS 
Formaldehyde
Water
Glycerol
55%
11%
17.9%
7.5%
7.5%
Bromophenol Blue to colour
DEPC-treatment of HoO (for 400ml>)
Distilled H20 500ml
Diethyl Pyrocarbonate (DEPC) 500|J.l
Mixture was left at room temperature overnight and then autoclaved.
Table 2.3 Transfer and Hybridisation Buffers
Northern Blot Hybridisation Solution (for 50mL.
Formamide 25ml
50x Denhardt's Solution 2.5ml
20xSSPE 12.5ml
polyA (lmg/ml) 50|il
polyC (lmg/ml) 50pl
Herring Sperm DNA (lOmg/ml) 0.5ml 
10% SDS 0.5ml
Complete to 50mls with dH20
20x SSC nH7. (for 1 litre")
Sodium chloride 175.3g (3M)
Sodium citrate 88.4g (0.3M)
20x SSPE pH7.4. (for 1 litre).
Sodium chloride 175.3g (3M)
Sodium citrate 88.2g (0.3M)
EDTA 7.4g (0.02M)
50x Denhardt's Solution.
Ficoll-400 1% (w/v)
Polyvinylpyrrolidine 1% (w/v)
Bovine Serum Albumin 1% (w/v)
(Pentax Fraction V)
Northern Blot Wash Buffers
A) 25°C Wash: 2x SSC, 0.1% SDS.
B) Hybdn. Temp. Wash O.lx SSC, 0.1% SDS
Table 2.4 SDS Polyacrylamide Gel Electrophoresis
15% Acrvlamide Running Gel.
30% Acrylamide 7.5ml
1 % .Bis-acrylamide 1.3ml
Tris (1.5M) 3.75ml
SDS (20%) 0.075ml
Distilled Water 2.2ml
Ammonium persulphate 0.1ml
TEMED 0.01ml
5.5% Acrvlamide Stacking Gel
Acrylamide (30%) 3.3ml
Bis-acrylamide (1%) 2.9ml
Tris (1M) 2.5ml
SDS (20%) 0.1ml
Distilled Water 8.8ml
Ammonium persulphate (10%) 0.1ml
TEMED 0.01ml
Protein Sample Buffer for SDS-PAGE (for 20mlV
Tris-HCl 0.5M, pH6.8 2ml
Glycerol 6ml
SDS (10%) 5ml
Distilled Water 7ml
p-mercaptoethanol 2% (immediately prior to use)
SDS Gel Fixative (for lOOmll
Propan-2-ol 25ml
Distilled Water 65ml
Acetic Acid 10ml
5x SDS PAGE Electophoresis Buffer (Tor 1 litre)
Glycine 144g
Tris.HCl 30g
10% SDS 50ml
Make up to 1 litre with dl^O .
Table 2.5 Sources and Storage of Selected Reagents
Purified LPS from Salmonella Typhinurium was obtained from Sigma (UK) and was 
dissolved in PBS to a concentration of 2mg/ml, aliquoted and stored at -20°C.
Recombinant murine EFNy and recombinant human CSF-1 were obtained from 
Genzyme (UK), aliquoted and stored at -20°C in alpha-MEM containing 25% DHS.
Hydrocortisone was obtained from Sigma (UK) dissolved in 5% alcohol in PBS to a 
concentration of 10'^M, aliquoted, and stored at -20°C.
Actinomycin D and cycloheximide were obtained from Sigma (UK) and stored at - 
20°C in distilled water at a concentration of 5mg/ml.
Anti-F4/80 antibody was obtained as a hybridoma tissue culture supernatant from 
Serotec (UK), aliquoted and stored at -20°C.
Chapter 3
Culture, Growth Properties and Demonstration of SCI/MIP-la mRNA and 
Protein Production by Bone Marrow-Derived Macrophages.
3.1 Attempted Sorting of Macrophages
Understanding the expression of the gene for SCI/MIP-la is important for a full 
appreciation of the role played by the Stem Cell Inhibitor/Macrophage Inflammatory 
Protein-la in the control of haemopoiesis and in other biological processes. The 
central aim of this thesis was to investigate SCI/MIP-la gene expression in an in 
vitro model system representing as far as possible the SCI/MIP-la-producer cell of 
the marrow. It was first necessary, therefore, to devise and then characterise that 
system.
It was reasoned that the best in vitro model for the in vivo SCI/MIP-la producer cell 
would be to use macrophages isolated directly from murine bone marrow.
The Manchester Inhibitor-producing cell had already been shown to be most probably 
a macrophage/monocyte by Wright et al (1980a); however, although Wright et al 
characterised the cell to a great extent and enriched for it greatly, they did not 
<  actually obtain a pure population.
Simmons and Lord (1985) sorted a population of monocyte/macrophages from 
normal murine bone marrow, using density fractionation and fluorescence activated 
cell sorting on the basis of expression of the macrophage-specific cell surface marker 
F4/80, which produced the Manchester Inhibitor. After an input of 40 femora 
(approximately 4-8.10^ bone marrow cells), Simmons and Lord sorted a total of fifty 
thousand F4/80-positive cells (or 0.15% of the total starting population). This 
approach was considered but it was concluded that it would prove to be impractical as 
the numbers of producer cells generated per sort was incompatible with the
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magnitude of some of the experiments envisaged. For example, it was envisaged that 
multiple time and concentration points would be necessary for a full analysis of 
SCI/MIP-la gene expression and an assay population of tens of thousands of cells 
would be insufficient for any one experiment. In addition, it was considered that the 
extremely lengthy, labour intensive process of electronic sorting would have limited 
the number of experiments able to be completed.
A related experimental approach, immunomagnetic sorting, was therefore initially 
adopted. The basis of this approach, in this study, is to bind antibodies raised against 
a lineage-specific antigen to bone marrow cells. A second anti-Fc antibody, which is 
covalently linked to a magnetic bead is then attached to the Fc region of the primary 
antibody. The secondary antibody is attached to a magnetic bead. This allows the 
separation of the bound and unbound cells by exposure to a strong magnetic field.
At first, a negative selection process was attempted, i.e. antibodies specific for non- 
monocytic cells were used as the primary antibody, in the same fashion as the CFU-S 
separation methods of Sprangude et al (1988). A monoclonal IgM antibody specific 
for the surface determinant B220, which is produced by the hybridoma RA3 3A1 
(Coffman and Weissman 1981) was employed. The B220 glycoprotein is restricted in 
its expression to cells of the B lymphoid lineage and is expressed on approximately 
30% of bone marrow cells (Coffman and Weissman 1981). It was considered that 
removal of cells bearing the B220 surface antigen might provide a reasonable first 
enrichment step towards isolating SCI-producing macrophages from bone marrow. 
Using a rat anti-B220 antibody produced by the hybridoma RA3-3A1 in conjunction 
with a goat anti-rat Fc antibody linked to magnetic beads on unseparated normal bone 
marrow it was possible to remove 30-40% of the total marrow cells as illustrated in 
figure 3.1. It was not possible to determine by morphology whether B-lineage cells 
had actually been removed as they were obscured by being linked to the beads. 
Attempts to remove the beads by culture and by mild protease (tiypsin) treatment
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Figure 3.1 Reduction in bone marrow cell number using anti-
6220 antibody.
Normal, unfractionated bone marrow was manipulated as described 
in chapter 2. Additions to tubes were as follows:
1) Nil no additions
2) l/40AbNB anti-B220 diluted 1 in 40;
no beads
3) lOOulB no antibody; 100ml beads;
lOOfig/ml BSA
4) l/40AbB anti-B220 diluted 1 in 40;
lOOp.1 beads
5) l/80AbB anti-B220 diluted 1 in 80;
100|il beads
6) l/160AbB anti-B220 diluted 1 in 160;
100|il beads
Cells were counted using a haemocytometer and data presented as 
the mean determination of two tubes.
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were unsuccessful. As fairly standard culture conditions (Special Liquid Medium and 
10% fetal calf serum, SLM/FCS), not specially suited to B cells, were employed it is 
highly likely that attached cells did not stay viable long enough for the removal of 
beads to be effective and subsequent culture to take place.
As indicated, a general problem with these experiments was that it was not 
determined whether the population removed by the beads was specific. This was an 
important consideration as it was possible that cells could be removed via a non­
antigen-specific interaction with the primary antibody such as binding to Fc receptors 
which are expressed on both lymphocytes and macrophages (Mellman et al 1988). 
Attempts to assess whether the unbound population in these experiments was 
specifically depleted of B220-positive cells compared to unfractionated bone marrow 
by immunofluorescence were uninformative due to technical difficulties.
Attempts were made to increase the depletion using antibodies directed against 
antigens expressed specifically on other lineages (such as the granulocytic lineage- 
specific antigen Gr-1) in combination with anti-B220. Unfortunately, these attempts 
did not result in an increase in the numbers of cells removed (data not shown), and 
the problems of positive identification of the sorted populations continued. It was 
concluded that this approach would not be suitable for the isolation of bone marrow 
macrophages.
It was considered that positive selection of macrophages might constitute an 
alternative method of obtaining the desired population. Attempts were made to do 
this using the immunomagnetic depletion with a commercially obtained IgG2b 
monoclonal antibody versus the macrophage-specific antigen F4/80.
The surface determinant F4/80 is a 160 KDa glycoprotein which is specifically 
expressed on cells of the mononuclear phagocyte system (Hume et al 1984).
It was found that use of this antibody in conjunction with magnetic beads resulted in 
a depletion of about 40% of the cells in the plastic-adherent fraction of bone marrow
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cells as illustrated in figure 3.2. Approximately 10-20% of unffactionated bone 
marrow cells adhere to plastic and indeed Wright et al (1980a) had demonstrated that 
the Manchester Inhibitor-producing cells were confined to the adherent fraction of 
normal bone marrow; this therefore serves as a pre-enrichment step for macrophages 
which are readily adherent to plastic. However, it was again impossible to identify the 
selected population due to inability to remove it from the beads despite the fact that 
culture conditions suitable for the survival of monocytes and macrophages (alpha 
MEM medium containing 25% donor horse serum and a source of macrophage 
colony stimulating factor) were used.
It was clear that sorting the macrophage population straight from the marrow was not 
a feasible option as the results obtained with the antibody and magnetic beads 
approach were highly variable, it was not possible at that time to verify the specificity 
of removal and on reflection it had become apparent that the problem concerning the 
small number of producer cells generated by any direct isolation method had not 
actually been addressed by this particular approach. It was concluded, therefore, that 
an alternative strategy would have to be employed.
3.2 Culture of Macrophages from Normal Bone Marrow and Spleen.
Pojda et al (1988) and Wright and Lorimore (1987) had previously demonstrated that 
macrophages cultured from murine bone marrow and spleen were good producers of 
the Manchester Inhibitor and therefore it was thought possible that a similar strategy 
could be employed to provide a model for studying the expression of the SCI/MIP-la 
gene.
It should be noted that using macrophages cultured from haemopoietic tissues is in 
many respects a compromise as any cultured population is almost certain to be 
derived in vitro from progenitors of the monocyte/macrophage lineage and exposed 
to exogenous growth factors and can not therefore, by definition, be truly
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Figure 3.2 Reduction in bone marrow cell number using anti-
F4/80 antibody.
Normal bone marrow was adhered to plastic in Fischer’s medium 
and manipulated as described in chapter 2. Additions to tubes were
as follows:
1) Nil no additions
2) l/5AbNB anti-F4/80 diluted 1 in 5; no beads
3) lOOulB no antibody; lOOfil beads;
lOOfig/ml BSA
4) l/5AbB anti-F4/80 diluted 1 in 5; 100|Hl
beads
5) 1/lOAbB anti-F4/80 diluted 1 in 10; lOOjil
beads
6) l/20AbB anti-F4/80 diluted 1 in 20; lOOfil
beads
Bone marrow cells were counted using a haemocytometer and data 
presented as the mean percentage of adherent bone marrow cells 
remaining from three tubes plus or minus one standard deviation.
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representative of the bone marrow stromal population or resident bone marrow 
macrophage (RBMM) population or any other macrophage population in the bone 
marrow. RBMM have been studied morphologically and are usually found associated 
with developing haemopoietic cells. They are apparently widespread throughout the 
marrow and are present at about 20% of the incidence of committed monocytic 
progenitors (Crocker et al 1988).
A major difference in the behaviour of the two populations is the fact that RBMM 
appear to be a non-proliferating end cell population as no mitotic figures ov'thymidine 
incorporation can be demonstrated for these cells whereas the monocytic progenitor 
cells are a rapidly dividing and differentiating population (Crocker and Gordon 
1985). Crocker et al (1988) have argued that subtle but important aspects of the 
phenotypes of RBMM are conferred by virtue of their interactions with developing 
haemopoietic cells. Obviously, a cultured monocyte/macrophage population would 
not be exposed to these influences.
It is clear, therefore, that the differences between cultured and in vivo macrophages 
have to borne in mind when discussing the haemopoietic implications of any 
experimental results obtained with cultured macrophages. Evidence will be presented 
in this section, however, to show that the behaviour of the cultured macrophages used 
in this study is very similar to that of the Manchester Inhibitor-producing population 
sorted by Simmons and Lord (1985) which validates the use of this population in the 
light of previous studies.
Murine bone marrow and spleen were cultured in conditioned media from three 
different cell lines; L929, a fibroblastic line and a source of M-CSF (Stanley and 
Guilbert 1981); WEHI3B, a myelomonocytic line and a source of M-CSF and IL-3 
(Bazill et al 1983) and AFI-19T, a retrovirally-transformed variant of the NRK 
(normal rat kidney) cell line which is a source of, at least, M-CSF and GM-CSF 
(Franz et al 1985; Pragnell et al 1988).
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Normal, unfractionated bone marrow and spleen cells were cultured in the presence 
of various concentrations of these conditioned media (CM) in alpha-MEM containing 
25% donor horse serum for seven days.
L929CM has been used widely in the culture of macrophages and therefore was an 
obvious choice; for example Tushinski et al (1982) and Gordon and Hume (1984) 
have used this conditioned medium to culture bone marrow derived macrophages 
(BMDM).
Wright et al (1980a, 1982) had demonstrated that the Manchester Inhibitor-producing 
cell was confined to a distinct subset of adherent bone marrow cells (on the basis of 
buoyant density) and an attempt was therefore made to culture macrophages of 
slightly different phenotypes using AFICM and WEHICM to ascertain whether this 
would affect SCI/MIP-la gene expression.
On morphological examination, after staining with Giemsa's stain, it was found that 
both the bone marrow and spleen cultures in which L929CM was used consisted 
almost entirely of cells with the characteristic appearance of mature 
monocyte/macrophages. Figure 3.3 (A and B) shows cytospin slides of preparations 
of both bone marrow- and spleen-derived macrophages. In both cases, the 
overwhelming majority of the cells display the round nucleus and high cytoplasmic to 
nuclear ratio characteristic of mature cells of the monocytic lineage. In culture, under 
light microscopy, the cells also display the stellate morphology characteristic of 
mature monocyte/macrophages.
Tushinski et al (1982) have used a slightly different culture technique in that bone 
marrow was cultured in L929CM-containing medium for three days and then the non- 
adherent cells transferred to a fresh identical culture. This was done to produce as 
uniform a culture as possible and presumably to minimise any possible contamination 
by other adherent cell types such as fibroblasts. Macrophages were also cultured in 
this way for comparison. It was found that the adherent cells produced in these
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Figure 3.3A Morphology of normal murine bone marrow 
cultured for 7 days in alpha-MEM medium containing 25% 
DHS plus 20% L929CM (Bone Marrow-Derived 
Macrophages).
Normal, unfractionated murine bone marrow was cultured at a 
concentration o f  5.10^ cells/ml in alpha-MEM medium containing 
25% DHS plus 20% L929CM. After 7 days, non-adherent cells 
were removed and adherent cells (Bone Marrow-Derived 
Macrophages) fixed with methanol and stained with 10% 
Giemsa's. Figure shows 100X magnification.
Figure 3.3B Morphology of normal murine spleen cultured for 
7 days in alpha-MEM medium containing 25% DHS plus 20% 
L929CM (Spleen-Derived Macrophages).
Normal, unfractionated murine spleen was cultured at a 
concentration of 5.10^ cells/ml in alpha-MEM medium containing 
25% DHS plus 20% L929CM. After 7 days non-adherent cells 
were removed and adherent cells (Spleen-Derived Macrophages) 
fixed with methanol and stained with 10% Giemsa's. Figure shows 
100X magnification.
cultures were morphologically indistinguishable from the cultures in which the 
replating step was not performed. In the present study the former technique was used 
for initial gene expression experiments (chapter 4) and the latter used for later 
experiments (chapters 5 and 6). It is unlikely that there was any significant fibroblast 
contamination in the cultures used in chapter 4 as they were morphologically 
indistinguishable from the cultures derived from the three day non-adherent cells; 
furthermore it is unlikely that any contaminants would contribute to data obtained on 
the expression of the SCI/MIP-la or MIP-ip gene as no mRNA for either of these 
genes has been detected in fibroblasts and futhermore Plumb et al (1991) have 
reported structural analysis of the SCI/MIP-la gene which suggests that the gene is 
in an inactive conformation in epithelial and fibroblastic cell lines. In addition to this, 
no SCI/MIP-la mRNA could be detected in two fibroblastic cell lines analysed for 
SCI/MIP-la expression in this study (figure 3.14).
Positive staining for the monocytic lineage-specific enzyme alpha-napthyl acetate 
esterase (non-specific esterase) identified the cells derived from bone marrow using 
both culture techniques as being overwhelmingly (>95%) monocytic (figure. 3.4). 
The spleen and bone marrow cultures incubated with AF1CM and WEHICM 
contained cells with a variety of morphologies representing both monocytic and 
granulocytic lineages and so were not considered further as sources of macrophages. 
Figures 3.5 and 3.6 show the morphology of normal bone marrow cells after culture 
for seven days in medium containing 20% AF1CM or WEHICM, respectively. The 
morphological heterogeneity of the cultures can be seen clearly and cells of an 
immature appearance can be seen in both cultures.
It was concluded that L929CM, as expected, was the most suitable conditioned 
medium for promoting the growth of macrophages in vitro from bone marrow. The 
monocyte/macrophage cells cultured using L929CM will be referred to as Bone
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Figure 3.4 Alpha-napthyl acetate esterase (non-specific 
esterase) staining of bone marrow-derived macrophages.
Bone marrow-derived macrophages were stained as described in 
chapter 2. Figure shows 100X magnification.
Figure 3.5 Morphology of normal bone marrow cultured for 7 
days in alpha-MEM medium containing 25% DHS plus 20% 
AF1CM.
Normal, unfractionated murine bone marrow was cultured at a 
concentration o f 5.10^ cells/m l in alpha-M EM  medium containing 
25% DHS plus 20% AF1CM . After 7 days non-adherent cells were 
rem oved and adherent cells fixed with methanol and stained with 
10% Giemsa's. Figure shows 100X m agnification.
Figure 3.6 Morphology of normal murine bone marrow 
cultured for 7 days in alpha-MEM medium containing 25% 
DHS plus 20% WEHICM.
Norm al, unfractionated murine bone m arrow was cultured at a 
concentration o f 5.10** cells/ml in alpha-M EM  medium containing 
25% DHS plus 20% W EHICM . After 7 days non-adherent cells 
were rem oved and adherent cells fixed with methanol and stained 
with 10% Giemsa's. Figure shows 100X magnification.
Marrow Derived Macrophages (BMDM) or Spleen Derived Macrophages (SDM) in 
the rest of this manuscript.
Parenthetically, morphological examination of L929CM-stimulated cultures at day 
three contained cells with the characteristic appearance of primitive progenitor cells 
of the monocyte/macrophage lineage. In retrospect it may have been possible to 
culture macrophages of a different phenotype by culturing normal bone marrow in 
L929CM for three days and then replating in either AF1CM or WEHICM.
3.3 Growth Characteristics of Bone Marrow-Derived Macrophages 
The growth characteristics of the BMDM were investigated. This was done for three 
reasons: 1) While the proliferative capacity of cells of the monocytic lineage has 
long been a subject of much controversy, it appears that the resident macrophages of 
the bone marrow, which are potential producers of SCI/MIP-la in vivo do not 
proliferate (Crocker et al 1988). If the BMDM population was to act as a surrogate 
for these cells it was necessary to characterise the differences between these 
populations as fully as possible so that any data obtained on gene expression could be 
interpreted in the light of these. 2) Simmons and Lord (1985) had reported some 
observations on the growth properties of the F4/80-positive Manchester Inhibitor- 
producing population which they had sorted from density fractionated bone marrow 
and it was considered that the ability to compare the growth characteristics of these 
two populations would be informative in allowing comparison of the data from that 
study with the present one. 3) A population of macrophage/monocyte cells cultured 
using L929CM and recombinant human Colony Stimulating Factor 1 (rhCSF-1) had 
been described previously by Tushinski et al (1982) and their proliferative 
characteristics and their relationship to gene expression investigated in a series of 
publications (for review see Vairo and Hamilton 1991). A comparison of the growth 
characteristics of the two populations was, therefore, considered to be essential if the
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characteristics of gene expression in the BMDM population used in this study was to 
be discussed in the context of previous studies.
Simmons and Lord had reported that the sorted F4/80 positive population would 
proliferate in L929CM and WEHICM while Hume and Gordon (1984) had observed 
that both L929CM and recombinant CSF-1 could induce DNA synthesis in BMDM 
as assessed by incorporation of tritiated thymidine.
The response of the BMDM population cultured in this study to L929CM and 
WEHICM were investigated. Initial experiments had indicated a high degree of 
variability in the growth properties of SDM and so this aspect of these cells was not 
investigated further.
Bone marrow-derived macrophages were re-plated at a density of 2.5.10^ cells/ml in 
alpha-MEM medium containing 25% donor horse serum (DHS) in the presence or 
absence of either 20% L929CM or WEHICM.
Without a source of growth factor (other than those contained in DHS) the BMDM 
did not adhere to the surface of the plastic culture dish and by 72 hours very few cells 
could be observed in the culture dish, indicating cell death. When an established 
culture was refed with alpha-MEM medium (containing 25% DHS) without any other 
source of growth factor, the vast majority of the BMDM had become detached from 
the surface of the culture dish within forty-eight hours, again indicating cell death. It 
was concluded, therefore, that BMDM can not survive in alpha-MEM medium 
containing 25% DHS alone and hence possibly require an additional source of growth 
factor(s) to be present.
Tushinski et al (1982) had reported that the BMDM cultured by them could survive 
and proliferate in the presence but not the absence of either CSF-1 or L929CM, 
therefore the ability of the BMDM population cultured in this study to survive and 
proliferate in L929CM, and also in WEHICM, was assessed.
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When BMDM were replated at a concentration of 2.5.10^ cells/ml in alpha-MEM 
medium containing 25% DHS plus 20% L929CM, containing either 20% L929CM or 
20% WEHICM, the cells were observed to have adhered to the bottom of the culture 
dish within twenty-four hours. As shown in figure 3.7 the growth kinetics of BMDM 
in 20% L929CM as monitored over seven days demonstrated exponential growth at a 
concentration of 1.25.10^-1.10^ cells/ml with a doubling time of approximately 24 
hours after a lag phase of about three days. Twenty percent WEHICM, on the other 
hand, only had a modest effect on the growth of BMDM with the number of cells in 
the culture on day seven after replating being typically one and a half to two times 
initial number. This is consistent with the results of Simmons and Lord (1985) who 
found that sorted macrophages grew well in L929CM and that WEHICM could also 
support growth but at a slower rate. They did not, however, report the ability of these 
cells to survive and proliferate in absence of conditioned medium.
Interestingly, Simmons and Lord (1985) reported that many of the F4/80-positive 
cells "disintegrated" on replating in 20% L929CM and did not begin to proliferate 
until three days later. This effect was also observed on every occasion in this study 
(four experiments) in which a growth curve for BMDM in L929CM was performed. 
The reason for this behaviour is not clear and can not be due merely to experimental 
manipulation as BMDM replated in 20% WEHICM did not exhibit the same initial 
decline.
The BMDM could be scraped and replated in 20% L929CM at 2.5.10^ cells/ml and a 
healthy confluent culture re-established three to four times before the proliferative 
ability of the cells was markedly compromised. The population sorted by Simmons 
and Lord (1985) behaved similarly.
The ability of BMDM to respond to the growth-promoting activity of L929CM was 
further confirmed by measuring the ability of L929CM to stimulate DNA synthesis in 
these cells. This was measured by the ability of BMDM to incorporate tritiated
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Figure 3.7 Growth of BMDM in medium containing L929CM 
and WEHICM.
BMDM were plated at a concentration of 1.25.10^ per 5ml flask in 
alpha-MEM containing 25% DHS plus either 20% L929CM or 
20% WEHICM as indicated. Adherent cells were counted using a 
haemocytometer and data presented as the mean determination 
from four flasks.
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thymidine into trichloroacetic acid precipitable material. Figure 3.8 shows thymidine 
incorporation in BMDM after twenty hours in the presence or absence of various 
concentrations of L929CM or WEHICM. It can be seen that L929CM induces 
thymidine incorporation in a dose-dependent manner while no incorporation above 
background is detectable both in the absence of conditioned medium and with 
WEHICM even at a concentration of 40%. These data can be compared to those of 
Tushinski and Stanley (1982), Hume and Gordon (1984) and Hamilton et al (1988) 
who demonstrated that DNA synthesis in BMDM can be induced by L929CM and 
CSF-1.
The inability of WEHICM to promote the incoiporation of thymidine during the time 
of exposure in this experiment (30 minutes) is consistent with the slow rate of 
proliferation observed with this conditioned medium (figure 3.7). Fetal calf serum 
could substitute for donor horse serum in this system; however, the magnitude of 
tritiated thymidine incorporation induced by L929CM in this system was consistently 
less than that observed with donor horse serum, as illustrated in figure 3.8, and hence 
donor horse serum was used in all subsequent experiments, unless otherwise 
indicated.
The kinetics of the induction of proliferation of BMDM in response to 20% L929CM 
was also investigated. It had been observed in initial experiments that the BMDM in 
untreated cultures after seven days could be proliferating moderately as assessed by 
tritiated thymidine incorporation (data not shown). In order to make the interpretation 
of data as straightforward as possible, BMDM were starved of L929CM for 12-16 
hours to reduce proliferation to a minimum and then refed with alpha-MEM 
(containing 25% DHS) in the presence or absence of 20% L929CM and rates of DNA 
synthesis measured at various times after refeeding. It can be seen from figure 3.9 
that there is a synchronous increase in tritiated thymidine incorporation from 
background to approximately fifty-thousand counts per minute between 12 and 16
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Figure 3.8 Tritiated thymidine incorporation in BMDM following 
treatment with L929CM and WEHICM.
BMDM were starved overnight in alpha-MEM medium containing 
25% DHS in the absence of any other additions. Medium was then 
removed and BMDM refed with alpha-MEM containing either 25% 
DHS (columns 1, 2, 3, 4, 5, 8 and 9) or 25% FCS (columns 6 and 7) 
plus the following additions:
1) Nil no additions
2) 20LCM 20% L929CM
3) 10LCM 10% L929CM
4) 5LCM 5% L929CM
5) 1LCM 1% L929CM
6) Nil/F no additions
7) 20L/F 20% L929CM
8) 20WCM 20% WEHICM
9) 40WCM 40% WEHICM
Tritiated thymidine incorporation was measured after 20 hours and the 
data presented as the mean determination of triplicate cultures plus or 
minus one standard deviation.
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Figure 3.9 Time course of tritiated thymidine incorporation in 
BMDM following refeeding with alpha-MEM containing 25%
DHS plus or minus 20% L929CM.
BMDM were starved overnight in alpha-MEM medium containing 
25% DHS in the absence of any other additions. Medium was then 
removed and the cultures refed with alpha-MEM medium containing 
25% DHS plus (crosses) or minus (diamonds) 20% L929CM. Tritiated 
thymidine incorporation was measured at the appropriate time points 
and data presented as the mean determination of triplicate cultures plus 
or minus one standard deviation.
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hours, compared to control cultures, in the absence of L929CM, where thymidine 
incorporation did not rise above background. The kinetics of the increase in tritiated 
thymidine incorporation suggest a synchronous entry of the BMDM into the S-phase 
of the cell cycle on refeeding with L929CM after starvation.
Although BMDM have been shown to be dependent on a source of CSF-1 for both 
survival and proliferation, at least two reports have demonstrated that both L929CM- 
and CSF-1-induced proliferation is affected by the presence or absence of serum. 
Hume and Gordon (1984) demonstrated that L929CM- and CSF-1-induced BMDM 
DNA synthesis was dose-dependent on the presence of (fetal calf) serum with 
proliferation being negligible even in the presence of a concentration of CSF-1 or 
L929CM which was optimal for proliferation. Tushinski and Stanley (1985) had also 
observed that incorporation of thymidine into BMDM nuclei was reduced by 
approximately 60% in the absence of fetal calf serum.
Accordingly, in order to further characterise the growth requirements of the BMDM 
population used in this study, the effect of serum on the ability of the BMDM 
population in this study to proliferate in response to L929CM, as measured by 
tritiated thymidine incorporation, was investigated. BMDM cells were cultured in a 
prepared serum-free medium (Dulbecco's/SF12 medium or SF12) in the presence or 
absence of donor horse serum (DHS) and/or 20% L929CM and DNA synthesis 
assessed by measuring the incorporation of tritiated thymidine by the cells after 
twenty-four hours. From figure 3.10A it can be seen that tritiated thymidine 
incorporation is negligible in serum-free medium alone and in alpha MEM plus 25% 
DHS as was expected. A level of thymidine incorporation comparable to that 
achieved with alpha MEM plus 25% DHS plus 20% L929CM was only seen after 
addition of both 20% L929CM and 25% DHS to SF12 medium and not with either of 
these alone. It was therefore concluded that the presence of both DHS and 20% 
L929CM was required for proliferation of the BMDM population used in this study.
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Figure 3.10 Tritiated thymidine incorporation in BMDM in SF12 
medium.
Figure 3.10A: BMDM were taken as a healthy growing culture 6 days 
after initial bone marrow inoculation, washed twice with PBS and 
refed with either SF12 medium (columns 1-4) or alpha-MEM medium 
(columns 5 and 6) plus the following additions:
Tritiated thymidine incorporation was measured after 24 hours and 
data presented as the mean determination of triplicate cultures plus or 
minus one standard deviation.
Figure 3.10B: Cultures, treated as in figure 3.10A, had medium 
removed after 24 hours and all were refed with alpha-MEM containing 
25% DHS plus 20% L929CM.
Tritiated thymidine incorporation was measured after 24 hours and 
data presented as the mean of triplicate cultures plus or minus one 
standard deviation.
SF No additions 
20% L929CM 
25% DHS
20% L929CM plus 25% DHS 
20% L929CM plus 25% DHS 
25% DHS
SF+L
SF+D
SF+D+L
MEM+D+L
MEM
250
c p m  3HT ( thousands)
2 0 0  -
1 5 0
100 u
SF+L SF+D SF+D+L MEM + D+L MEM
F i g u r e  3.10A
c p m  3HT ( t h o u s a n d s )
2 5 0
200
1 5 0
100
5 0
0
SF SF+L SF12+D SF+L+D MEMMEM+L
F i g u r e  3.10B
The ability of these cells to survive in the various culture conditions was assessed in 
the same experiment by their subsequent ability to incorporate tritiated thymidine in 
response to 25% DHS-containing alpha-MEM medium with 20% L929CM. It can be 
seen (figure 3.10B) that while thymidine incorporation is reduced in all cases, this is 
more likely to be due to experimental manipulation than cell death as even those cells 
which had been cultured in the conditions optimal for growth had reduced thymidine 
incorporation on the second refeed. However, incubation in SF12 with either 20% 
L929CM or 25% DHS alone clearly enhances cell survival compared to that achieved 
with SF12 alone. This effect was seen in several separate experiments.
3.4 Detection of SCI/MIP-la mRNA in Bone Marrow Derived Macrophages.
Normal Bone Marrow and Cell Lines.
An essential consideration with setting up the BMDM system was that SCI/MIP-la 
gene expression should be measured in some way.
One approach would have been to measure the ability of conditioned media from 
BMDM to inhibit the proliferation of CFU-A or CFU-S cells, as had been done with 
other cultured macrophage populations by Simmons and Lord (1985) and Pojda et al 
(1988), but this idea was rejected for two reasons. Firstly, these are both cumbersome 
assays and are not suitable for screening a large number of samples. Secondly, many 
molecules which could have an effect on primitive haemopoietic cells may be 
secreted by BMDM; Matsushime et al (1991b) have, for example, demonstrated that 
BMDM express IL -la, IL-ip and the IL-1 receptor antagonist. The purpose of the 
present study, on the other hand, was to specifically study the expression of the 
SCI/MIP-la, as opposed to a haemoregulatory activity, in the context of 
haemopoiesis.
One way of ensuring that any assayed inhibitory activity from BMDM was in fact 
SCI/MIP-la would have been to block its activity by the use of a specific neutralising
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antibody or antisera. Unfortunately no such reagent was available at any time during 
this study.
As Davatelis et al (1988) had previously isolated a cDNA sequence for SCI/MIP-la, 
it was clear that one way of evaluating expression of the SCI/MIP-la gene would be 
to measure levels of its messenger RNA by Northern blot analysis.
A radioactive antisense RNA molecule (riboprobe) was generated by using an in vitro 
run off transcription method. The template for this transcription reaction was an Xhol 
cut plasmid with the SCI/MIP-la cDNA sequence linked to a promoter from the 
bacteriophage T3. This allowed the production of an a-32P-UTP-labelled riboprobe 
complementary to the mRNA for SCI/MIP-la which could be used to detect steady- 
state SCI/MIP-la levels by Northern blot analysis.
The SCI/MIP-la riboprobe was hybridised to total RNA (extracted from BMDM, 
SDM and the murine macrophage-like cell line J774.2) which had been separated by 
denaturing agarose gel electrophoresis and transferred and fixed onto a nylon 
membrane (Northern blotting). The J774.2 cell line had been used as a source of 
SCI/MIP-la protein by Graham et al (1990) and was therefore used as a positive 
control.
The integrity of the RNA loaded onto the gel was assessed by inspecting the 
ribosomal RNA (rRNA) bands, which could be visualised by staining with the 
fluorescent nucleic acid intercalating agent ethidium bromide under ultra violet light. 
Figure 3.11 shows a Northern blot demonstrating that BMDM, SDM and J774.2 cells 
contain an RNA species which hybridises to the SCI/MIP-la riboprobe. This 
transcript has a size of about approximately 800 nucleotides (as measured against 
RNA size markers) which corresponds to the size of the SCI/MIP-la transcript 
previously detected by Davatelis et al (1988). Furthermore, the levels of this 
transcript are increased approximately 50-fold (as measured by scanning 
densitometry) by treatment of both BMDM and SDM with 2|ig/ml endotoxin from
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Figure 3.11 Northern analysis of the expression of SCI/MIP- 
la  mRNA in BMDM, SDM and J774.2 cells.
Total RNA was isolated and blotted in equal amounts (20|ig) onto 
nylon m em brane. Lane 1, untreated BM DM ; lane 2, BMDM 
treated for 6 hours with LPS (2 |ig/m l); lane 3, untreated SDM; lane 
4, SDM  treated for 6 hours with LPS (2|ig/m l); lane 5, untreated 
J774.2 cells. Equal loading was ensured by ethidium  bromide 
staining o f the gel.
S.Typhimurium for six hours. This observation is in agreement with the work of 
Davatelis et al (1988) with the macrophage-like cell line RAW264.7.
To ascertain whether the RNA species detected in BMDM was in fact a messenger 
RNA, the poly(A)+ fraction of total RNA prepared from BMDM before and after 
treatment with LPS for four hours was analysed by Northern blot. From figure 3.12 
(lane 1) it can be seen that a specific band hybridising to the SCI/MIP-la riboprobe 
can be detected in BMDM poly(A)+ RNA, indicating that the species detected in total 
RNA is in fact SCI/MIP-la mRNA. Lane 2 of the same figure shows that the extent 
of this hybridisation is increased by treating BMDM with LPS, demonstrating that 
LPS treatment increases the representation of SCI/MIP-la mRNA in BMDM.
Much of the RNA hybridising to the SCI/MIP-la-specific riboprobe in lanes 2 and 4 
of figure 3.11 lies outside the 0.8kb size level. This is probably due to the fact that the 
level of SCI/MIP-la mRNA in the samples from cells treated with LPS is many 
times greater than that in control samples, where a discrete band of the expected size 
is seen; presumably due to the fact that only a certain amount of RNA can be 
contained at a particular level in a gel. In addition to this, two extra bands of 
approximately 5 and 2kb can also be seen in lanes 2 and 4. These sizes correspond to 
those of the two higher molecular weight ribosomal RNA (rRNA) bands. Non­
specific hybridisation to rRNA is a common problem with riboprobes; however, it is 
unlikely that this is the case in these particular experiments for two reasons: 1) The 
hybridisation conditions for these experiments are extremely stringent and this should 
preclude non-specific effects. 2) The additional bands are only seen in the lanes 
containing RNA from cells in which the level of SCI/MIP-la-specific hybridising 
sequences has been greatly elevated. If non-specific hybridisation to rRNA was 
taking place these bands would have been seen with all samples as ethidium bromide 
staining of the gel showed that equal amounts of rRNA was loaded. A more likely 
explanation is that the level of SCI/MIP-la mRNA in samples from the LPS-treated
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Figure 3.12 Northern analysis of the distribution of SCI/MIP- 
la-specific hybridising sequences in the poly(A)+ and poly(A)- 
fractions of total cellular RNA from BMDM.
Total cellular RNA was isolated and separated into poly(A )+ and 
poly(A)- fractions and blotted onto nylon m em brane. Lane 1, 
poly(A)+ RNA from untreated BM DM; lane 2, poly(A)+ RNA 
from BM DM  treated for 4 hours with LPS (2pg/m l); lane 3, 
poly(A)- RNA from untreated BMDM; lane 4, poly(A)- RNA from 
BM DM  treated for 4 hours with LPS (2|j.g/ml).
BMDM and SDM is so great that some of it is complexed in some way with the 
hugely abundant ribosomal bands, due to incomplete denaturation. Hence the 
hybridisation to the additional higher molecular weight bands is specific for 
SCI/MIP-la mRNA; it is merely the position of hybridisation which is artefactual. 
Evidence to support this explanation can be gained by Northern blot analysis of both 
the poly(A)+ and poly(A)- RNA fractions of LPS-treated BMDM. It can be seen from 
figure 3.12 that the SCI/MIP-la-specific riboprobe hybridises to only one discrete 
band in the poly(A)+ fraction (lane 2) indicating that only one size of SCI/MIP-la 
mRNA is expressed on LPS treatment. In addition, it can be seen from lane 3 that no 
SCI/MIP-la-specific sequences are contained in the poly (A)- fraction, nor are any 
induced on treatment of cells with LPS, as seen in lane 4 of figure 3.12, indicating 
that the SCI/MIP-la-specific riboprobe only hybridises to mRNAs.
Hence, the most likely explanation for the presence of the additional bands 
hybridising to the SCI/MIP-la-specific riboprobe on LPS-treatment of BMDM and 
SDM is the complexing of SCI/MIP-la mRNA with rRNA.
It was concluded, therefore, that Northern analysis of total cellular RNA was a 
suitable method for the determination of SCI/MIP-la mRNA levels in BMDM (and 
SDM).
As the main aim of this project was to investigate the expression of the SCI/MIP-la 
gene in relation to its possible role in in vivo haemopoiesis, the ability to detect the 
expression of SCI/MIP-la mRNA in normal bone marrow was also investigated. 
Figure 3.13 shows a Northern blot in which total RNA from normal unfractionated 
bone marrow and the J774.2 cell line was hybridised to the SCI/MIP-la-specific 
riboprobe. It can be seen that a low level of SCI/MIP-la mRNA, approximately one 
twentieth of the level of that seen in unstimulated J774.2 cells (as assessed by 
densitometry), is detectable in normal, unfractionated bone marrow. This is an 
interesting finding in that mRNA for several other cytokines has not been reported as
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Figure 3.13 Northern analysis of the expression of SCI/MIP- 
la  mRNA in normal murine bone marrow and in the J774.2 
cell line.
Total cellular RNA was isolated and blotted in equal amounts 
(20|ig) onto nylon m em brane. Lane 1, normal m urine bone 
m arrow; lane 2 untreated J774.2 cells.
being detectable in normal untreated marrow (Troutt and Lee 1989) and Fahey et al 
(1990) have reported inability to detect mRNA for SCI/MIP-la in unstimulated 
murine peripheral blood leukocytes. This observation demonstrates expression of the 
SCI/MIP-la gene in normal, unperturbed murine bone marrow and hence is strongly 
suggestive of a role for SCI/MIP-la in the biology of normal, unperturbed marrow.
In addition to this, and in an attempt to assess the cellular specificity of expression, 
the ability to detect SCI/MIP-la mRNA in cell lines representing the monocytic 
(RAW264.7, J774.2, WEHI3B, P388.1), fibroblastic (STO, L929), erythroid (F4), B 
lymphocytic (RA3 3A1) and T lymphocytic (DA2) lineages was assessed. It can be 
seen from figure 3.14 that mRNA could only be detected in the four cell lines 
representing the monocytic lineage and in a Moloney murine leukemia virus- 
transformed T cell line (DA2) (Ihle et al 1990), which was not unexpected 
considering that SCI/MIP-la mRNA has been demonstrated to be present in 
activated murine T cell lines by Brown et al (1989). No mRNA for SCI/MIP-la was 
detectable in any of the other cell lines even on prolonged exposure (six weeks) of the 
blots to X-ray film.
The ability to readily detect SCI/MIP-la mRNA in monocytic cell lines and in 
BMDM suggests, but not fibroblastic cells that macrophages are the main producers 
of SCI/MIP-la in the bone marrow. Although T cells and mast cells have been 
shown to express SCI/MIP-la mRNA, both of these cell-types are present at 
extremely low levels in the marrow (Kincaide 1990, Gordon et al 1990) and have to 
be specifically activated before SCI/MIP-la mRNA can be detected (Brown et al 
1889, Burd et al 1989); it is therefore likely that they make little or no contribution to 
the level of SCI/MIP-la mRNA detectable in normal murine bone marrow, which 
indicates that the regulation of expression of SCI/MIP-la gene expression in the 
macrophage is most pertinent to marrow haemopoiesis.
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Figure 3.14 Northern analysis of the expression of SCI/MIP- 
la  mRNA in 9 cell lines.
Total cellular RNA was isolated from nine different cell lines and 
blotted onto nylon membrane. Lane 1, RAW 264.7 (R); lane 2, 
J774.2 (J); lane 3, W EHI 3B (W); lane 4, P388.1 (P); lane 5, STO 
(S); lane 6, L929 (L); lane 7, F4 (F); lane 8, RA3-3A1 (R); lane 9, 
DA-2 (D). Different amounts o f RNA were added to each lane; 
therefore the level of mRNA is not representative o f the relative 
levels expressed by the cell lines but does dem onstrate the 
presence or absence o f expression.
3.5 Detection of SCI/MIP-la Protein Secretion bv Bone Marrow-Derived 
Macrophages.
Although mRNA for SCI/MIP-la had now been detected in BMDM it was also 
necessary to demonstrate that the cells translated and secreted mature SCI/MIP-la to 
gain a complete picture of SCI/MIP-la gene expression.
For most of the time of this investigation no specific tools were available for the 
detection of SCI/MIP-la protein, such as an antibody or a simple specific bioassay; 
therefore, an alternative method was sought.
Brown et al (1989) and Chang and Reinherz (1989) had isolated the cDNA sequences 
for SCI/MIP-la and human MIP-ip ignorant of their function. Both of these 
investigators demonstrated that these were secreted proteins by exploiting the fact 
that both proteins contain cysteine. The proteins were detected in conditioned 
medium of fibroblastic cell lines which had been transfected with the appropriate 
cDNA in an expression vector and grown in culture media containing radioactive 
(35S) cysteine. The presence of the secreted ^S-labelled protein was then detected 
by SDS-polyacrylamide gel electrophoresis and autoradiography.
A similar approach was attempted to detect the presence of SCI/MIP-la (or MIP-1), 
expressed from the endogenous gene, in the media conditioned by BMDM. BMDM 
cells were cultured for four hours in cysteine-free medium supplemented with ^ S -  
labelled cysteine in the presence and absence of LPS. The proteins secreted into the 
medium by the cells were fractionated on an SDS-PAGE gel and the presence of ^ S -  
containing proteins resolved by autoradiography.
Figure 3.15 shows the ^^S-cysteine-containing proteins secreted by both RAW264.7 
cells and BMDM in the presence or absence of LPS (2pg/ml). LPS was added four 
hours before the culture medium was changed for medium supplemented with -^S- 
cysteine (as this had been shown to be the time when SCI/MIP-la mRNA is 
maximally induced by LPS, see figure 4.1) and additional LPS was added with the
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Figure 3.15 SDS-PAGE of ^S-Iabelled proteins in medium 
conditioned by BMDM and RAW264.7 cells with and without 
stimulation by LPS (2|ig/ml).
Lane 1, ^ C -la b e lle d  m olecular weight markers; lane 2, untreated 
RAW 264.7 cells; lane 3, RAW 264.7 cells treated with LPS for 4 
hours; lane 4, untreated BM DM ; lane 5, BM DM  treated with LPS 
for 4 hours.
new medium. MIP-1 protein migrates with an apparent molecular weight of 8kDa on 
SDS-PAGE (Wolpe et al 1988). There are a few bands which are induced by LPS and 
secreted by RAW264.7 which could correspond to MIP-1. However, the same region 
in the lanes containing medium conditioned by BMDM with or without being treated 
with LPS is very blurred, possibly due to protein degradation, and contains a large 
number of minor bands situated very close together and is therefore impossible to 
interpret. This culture technique was repeated twice and the samples run on SDS- 
PAGE several times.
Wolpe et al (1988) and Graham et al (1990) had demonstrated that MIP-1 protein 
binds heparin; therefore a way of improving this detection method may have been to 
enrich for heparin-binding proteins before electrophoresis. Alternatively, the timing 
of the endotoxin treatment (when mRNA levels were maximal) may not have been 
optimal for the translation or secretion of MIP-1 protein.
Extracts of intracellular proteins from these experiments were also made and run on 
SDS-PAGE in case MIP-1 was translated by the BMDM but not secreted into the 
culture medium. However, no discrete bands could be detected on autoradiography, 
presumably because of the large number of cysteine-containing intracellular proteins. 
One of the main problems with using this technique may be related to the fact that 
macrophages secrete over three hundred proteins (Nathan 1987) which means that the 
conclusive identification of a distinct band is difficult. Although this technique could 
possibly have been refined using perhaps chromatography, or a detailed analysis of 
the kinetics of protein translation and secretion, the technique was abandoned due to 
constraints of time.
Toward the end of this study, a polyclonal anti-sera raised against murine SCI/MIP- 
l a  protein in the goat became available. When used at a high titre in conjunction with 
the luminol detection kit this allowed sensitive detection of SCI/MIP-la protein by 
Western Blot. Figure 3.16A shows a Western Blot of the proteins secreted by both
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Figure 3.16 Western analysis of SCI/MIP-la protein levels in 
media conditioned by BMDM and RAW264.7 cells in the 
presence or absence of LPS (2|ig/ml).
Panel A W estern analysis: Cells were plated at a concentration of 
lOfyml; BMDM in alpha-M EM  medium containing 25% DHS plus 
20% L929CM , RAW 264.7 in SLM / 10% FCS. A fter 24 hours cells 
were refed with the appropriate medium plus or m inus LPS 
(2pg/m l) for a further 24 hours, after which conditioned medium 
was harvested and analysed as described in chapter 2.
Lane 1, pure recom binant S C I/M IP -la  (lOng); lane 2, untreated 
NBM ; lane 3, BM DM  treated with LPS; lane 4, untreated 
RAW 264.7 cells; lane 5, RAW 264.7 cells treated with LPS 
(2 |ig/m l).
Panel B Northern analysis o f the same cultures (Note that the 
lanes do not correspond): Total cellular RNA was isolated and 
loaded in equal amounts (20jig) onto nylon m em brane.
Lane A, untreated RAW 264.7 cells; lane B, RA W 264.2 cells 
treated with LPS (2p,g/ml) for 24 hours; lane C, untreated BM DM ; 
lane D, BM DM  treated with LPS (2|ig/m l) for 24 hours.
RAW264.7 cells and BMDM with or without treatment with 2|ig/ml endotoxin from 
S.Typhimurium for twenty four hours. It can be seen that unstimulated RAW264.7 
cells secrete detectable SCI/MIP-la protein and that this level can be increased 3-4- 
fold (as estimated by laser densitometry) by treating the cells with LPS for twenty- 
four hours. On the other hand, no SCI/MIP-la can be detected from BMDM until 
they are treated with LPS for twenty-four hours.
Changes in SCI/MIP-la mRNA levels of the cultures described in figure 3.16A were 
also assessed by Northern blotting as seen in figure 3.16B. It can be seen that the 
level of SCI/MIP-la mRNA is increased greater than fifty-fold in RAW264.7 cells 
twenty-four hours after LPS (lanes A and B), demonstrating that induction of 
SCI/MIP-la mRNA accumulation in BMDM by LPS is mirrored in protein secretion. 
It can be seen from lanes C and D of the same figure that the level of SCI/MIP-la 
mRNA in BMDM is the same before and after the same treatment; however, this does 
not mean that LPS-induced secretion of SCI/MIP-la protein by BMDM is 
unaccompanied by changes in SCI/MIP-la mRNA levels as will be discussed in 
chapter 4.
3.6 Summary of Chapter 3
Attempts were made to isolate macrophages directly from murine bone marrow using 
immunomagnetic depletion. This approach was discontinued as: 1) the reproducibility 
of the technique was highly variable, 2) positive identification of isolated populations 
was difficult due to practical problems, 3) the yield of separated populations was 
inadequate for the experiments envisaged.
An alternative approach was followed by culturing macrophages from normal bone 
marrow and spleen using medium conditioned by the fibroblastic cell line L929, 
which is a source of CSF-1.
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These culture conditions produced an essentially homogeneous population of 
macrophages as identified by morphology and by positive staining for the 
macrophage-specific enzyme alpha-napthyl acetate esterase.
The growth properties of the bone marrow-derived macrophage (BMDM) population 
were investigated and were found to be extremely similar to a macrophage population 
sorted directly from murine marrow which is a producer of the Manchester Inhibitor 
and to previously cultured macrophage populations.
In the absence of a method for readily detecting SCI/MIP-la protein, Northern 
blotting was used to detect expression of mRNA for SCI/MIP-la in BMDM (and also 
in spleen-derived macrophages). This level was found to be increased greatly by 
exposure of these cells to bacterial endotoxin. Fractionation of total cellular RNA 
from BMDM into poly(A)+ and poly(A)- pools demonstrated that the SCI/MIP-la- 
specific hybridising sequence was a messenger RNA.
A low level of SCI/MIP-la mRNA was also detectable in total cellular RNA 
prepared from normal, unfractionated murine bone marrow, demonstrating expression 
of the SCI/MIP-la gene in normal, unperturbed murine bone marrow.
SCI/MIP-la mRNA was also readily detectable in monocytic cell lines and in a 
transformed T cell line but not in cell lines representing other haemopoietic lineages 
or fibroblasts.
Metabolic labelling of proteins secreted by BMDM did not prove to be a suitable 
method for the detection of the SCI/MIP-la protein.
Towards the end of the study it was demonstrated that SCI/MIP-la protein could be 
detected in media conditioned by BMDM after treatment with bacterial LPS by 
Western Blotting using a specific goat polyclonal anti-SCI/MIP-la antiserum.
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Chapter 4
Induction of mRNA for SCI/MIP-la and MIP-1J3 in BMDM by Bacterial 
Endotoxin (Lipopolysaccharide): Kinetics of Expression and Initial Mechanism 
Studies.
4.1 Introduction.
It had been demonstrated in chapter 3 that the level of SCI/MIP-la mRNA expressed 
in BMDM could be greatly increased by treating the cells with bacterial endotoxin. In 
order to form a clearer picture of the ways in which SCI/MIP-la mRNA levels are 
modulated, this induction was investigated in more detail. To this end, bacterial 
lipopolysaccharide (or endotoxin), which had been demonstrated in chapter 3 to 
induce accumulation of SCI/MIP-la mRNA in BMDM and the glucocorticoid 
hormone hydrocortisone were used a model inducer and downregulator of SCI/MIP- 
l a  gene expression, respectively.
Expression of the closely-related Macrophage Inflammatory Protein-1(3 (MIP-1 (3) 
gene, whose protein product has no detectable effect on the proliferation of 
haemopoietic stem cells in vitro (Graham et al 1990) but is apparently able to 
modulate the activity of SCI/MIP-la (Broxmeyer et al 1991) was also investigated 
for comparison. Messenger RNA for MIP-1 (3 is approximately the same size as that 
for SCI/MIP-la (Sherry et al 1988). It was reasoned that any differences in the 
expression of the two genes which could be demonstrated may be informative and 
make a contribution to both our understanding of the regulation of expression of these 
genes and the relationship of this to the biology of SCI/MIP-la and MIP-1|3. 
Endotoxin, or Lipopolysaccharide (LPS), is a complex glycolipid which is the major 
component of the outermost coat of Gram-negative bacteria. The biologically active 
component of LPS is the lipid A moiety, which is highly conserved between the LPS
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of many bacterial species (for review see Raetz 1990). LPS has pleiotropic effects on 
leukocytes, especially monocytes/macrophages, including adherence to endothelial 
cells (Spom et al 1990) and priming for oxidative burst (Hamilton et al ^989) and 
has also been shown to induce the expression of the genes for, and promote the 
release of, a number of cytokines including IL-la, IL-ip and TNFa as discussed in 
chapter 1 .
It is generally agreed that LPS stimulates cells by binding to specific receptors, 
thereby initiating a signal transduction event.
Several LPS-binding proteins have been identified on macrophages and evidence 
suggests that these may be involved in several functions involving the recognition of 
LPS including the activation of macrophages, the uptake and detoxification of free 
LPS and the attachment of whole Gram-negative organisms prior to phagocytosis (for 
review see Lynn and Golenbock 1992). LPS can also prime macrophages for more 
complex cytotoxic behaviour such as tumour cell killing (Adams and Hamilton 
1984). Candidate LPS receptors responsible for the activation of macrophages 
include the cell surface determinant CD 14, a 55KDa phosphoinositol-linked protein 
which binds LPS complexed with a serum-binding protein (Schumann et al 1990, 
Wright et al 1990) and a 55KDa/65KDa protein dimer found on the surface of the 
J774.1 macrophage cell line (Hara-Kuge et al 1990) which appears to be essential for 
activation of these cells by LPS.
The signalling pathways activated by LPS in macrophages are, at the moment, 
unclear (Raetz 1990); however, the ability of LPS to activate inducible transcription 
factors, such as NFkB (Baeurle 1991, Vincenti et al 1992)) and to alter mRNA 
stability (Thorens et al 1987, Koemer et al 1987) and to induce secretion of cytokines 
(Han et al 1990) in macrophage cell lines has been demonstrated.
The presence of MIP-lp mRNA was detected by Northern blotting using a specific 
cDNA riboprobe in the same manner as SCI/MIP-la mRNA. As before, the integrity
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of the total RNA and equal loading between lanes was ensured by ethidium bromide 
staining of the RNA samples. As an additional control to ensure equal loading of 
RNA, Northern blots were hybridised to a radioactive DNA probe specific for the 
murine 7S RNA species. 7S RNA is a component of the signal recognition particle of 
the ribosome and is highly conserved among eukaryotes (Lewin 1987). It has a size of 
280 nucleotides (Balmain et al 1982).
Probes for RNA Polymerase II-transcribed "housekeeping" genes such as the gene for 
the cytoskeletal component actin were also considered as loading controls; however, 
Mufson (1990) has recently demonstrated that level of p-actin mRNA changes on 
stimulation of human peripheral blood macrophages when measured in relation to the 
level of ribosomal RNA visualised by ethidium bromide staining under ultraviolet 
light. In the light of this, it was considered that expression of the 7S mRNA would be 
less likely to fluctuate, with it being a component of the nuclear RNA splicing 
apparatus.
A probe for the P2 -microglobulin gene was initially used as a loading control, 
however this probe hybridises to a mRNA which is approximately the same size as 
the SCI/MIP-la and MIP-lp mRNA transcripts which meant that reprobing for P2 - 
microglobulin necessitated stripping the membrane at high temperature and low salt 
which might result in the loss of some of the transferred RNA. In addition to this it 
has recently been demonstrated that levels of P2 - microglobulin mRNA can be 
altered by interferon-y (Sen and Lengyell 1992). The difference in size between the 
RNA transcripts of 7S and the two MIP-1 mRNAs was useful as it allowed 
hybridisation membranes to be sequentially probed without stripping. In all 
experiments in this study for which the level of 7S RNA was assessed differences in 
levels between samples corresponded to differences between the levels of ribosomal 
RNA visualised by ethidium bromide staining; hence it was concluded that 
hybridisation to 7S RNA was a suitable loading control for this study.
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4.2 Kinetics of Expression of SCI/MIP-la and MIP-lj3 mRNA.
If analysis of the modulation of SCI/MDP-la and MIP-lp mRNA levels was to be 
carried out it was essential that the kinetics of accumulation and turnover of the 
mRNA transcripts be established given that lymphokine genes tend to be expressed in 
fairly short time frames in response to stimuli (Taniguchi 1988; Arai 1990). It was 
also necessary to demonstrate that BMDM expressed mRNA for MIP-lp.
Northern blot analysis of the expression of both SCI/MIP-la and MIP-lp mRNA 
transcripts in BMDM at various times after stimulation with 2|ig/ml LPS was 
therefore carried out. Figure 4.1 shows the results of one of four different 
experiments. It can be seen that the levels of both mRNA transcripts are greatly 
elevated at four hours post treatment with LPS. This increase was found to be 
approximately 50-150-fold, for both mRNAs, by scanning laser densitometry. Levels 
of both mRNAs peak at 4-8 hours and decline thereafter. By twenty four hours the 
level of MIP-lp mRNA has returned to the same level as the time zero control while 
that of SCI/MIP-la mRNA is still at approximately 5-10 times the level of the 
controls (as estimated by densitometry). In the experiment shown (figure 4.1), MIP- 
lp  mRNA levels did not decline as rapidly as those of SCI/MIP-la mRNA but this 
feature did vary between experiments. It can also be seen from lanes 1 and 2 of figure
4.3 that the levels of both SCI/MIP-la and MIP-lp mRNA are elevated by one hour 
after addition of LPS which indicates that the onset of accumulation of these 
transcripts after stimulation is extremely rapid.
One explanation for the difference in the levels of the two transcripts at the later time 
points might be related to the fact that the 3' untranslated sequence of MIP-lp mRNA 
has a complete copy (Sherry et al 1988) of the AU-rich sequence (consensus 
sequence TTATTTAT) which is present in many rapidly induced mRNA transcripts 
(Caput et al 1986) and are thought to confer instability (Shaw and Kamen 1986) and
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Figure 4.1 Northern analysis of the time course of 
accumulation of SCI/M IP-la and M IP-lp mRNA in BMDM 
treated with LPS (2fig/ml).
Total cellular RNA was isolated and blotted in equal am ounts 
(20 |ig) onto nylon m em brane. Lanes 1-7, BM DM  treated with LPS 
for 0, 4, 8, 12, 16, 20 and 24 hours. Equal loading was confirm ed 
by hybridisation with a 7S probe.
may also be necessary for the modulation of that instability (Akashi et al 1991); MIP- 
l a  only has incomplete copies of this consensus sequence (Davatelis et al 1988; 
Wolpe and Cerami 1988; M.Plumb personal communication). It is possible that the 
differences in the AU-rich sequences confer different turnover rates on SCI/MIP-la 
and MIP-ip mRNA at these later times.
It should be borne in mind, however, that the decay of several labile mRNA species 
has been attributed to other poorly-defined sequence components and indeed the 3' 
AU-rich sequence may only be a minor component (Kabnick and Houseman 1988; 
Shyu et al 1989; Han et al 1991a).
These expression patterns are different to those exhibited by the same transcripts in 
RAW264.7 cells in response to LPS where both transcripts are elevated rapidly but 
remain elevated at the peak level even up to 48 hours later (Davatelis et al 1989; 
Orlofsky et al 1991; Widmers et al 1991). In this present study it was found that 
levels of M IP-la and MIP-ip mRNA were still highly elevated in RAW264.7 cells 
twenty-four hours after treatment with LPS (figure 4.2). However, rapid and transient 
expression in response to stimulation of the human equivalent of SCI/MIP-la has 
been reported in both monocytic and T lymphocytic cell lines (Yamamura et al 1989; 
Nakao et al 1990; Schall et al 1992). The same pattern of expression has also been 
reported for human MIP-lp in isolated human monocytes, peripheral blood 
lymphocytes, peripheral blood mononuclear cells and human T and B lymphocytic 
cell lines (Spom et al 1990; Chang and Reinherz 1989; Lipes et al 1988; Schall et al 
(1992).
This pattern of expression is common for many lymphokine genes (Taniguchi 1986, 
Arai et al 1990) and may relate to their role in the response to inflammatory and 
immune stimuli. The confinement of the expression of these genes to discrete bursts 
may be one way of ensuring that they are not expressed at inappropriate times as 
there is a tight coupling between stimulation and response.
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Figure 4.2 Northern analysis of the accumulation of SCI/MIP- 
l a  and MIP-1(3 mRNA in RAW264.7 cells in the presence or 
absence of LPS (2pg/ml).
Total cellular RNA was isolated and blotted in equal am ounts 
(20|ag) onto nylon mem brane. Lane 1, untreated RA W 264.7 cells; 
lane 2, RAW 264.7 cells treated with LPS for 24 hours. Equal 
loading was ensured by ethidium  brom ide staining o f the gel.
4.3 Effect of Actinomvcin D on Expression of SCI/MIP-la and MDMJ3 mRNA. 
Macrophages respond to external stimuli by expressing genes in several different 
time frames (Adams and Hamilton 1984) which may be triggered by several different 
pathways (Vairo and Hamilton 1991). The time course of expression of mRNA for 
SCI/MIP-la and MIP-ip in response to LPS suggested that this response may be a 
part of the early response to stimulation. It has already been stated in chapter 1 that 
rapid accumulation of most cytokines mRNAs is achieved by a burst of 
transcriptional activity, although the induction of some transcripts can be achieved 
completely by posttranscriptional mechanisms such as mRNA stabilisation; for 
example, the induction of GM-CSF mRNA in peritoneal macrophages (Thorens et al 
1987) by a variety of inflammatory stimuli. An understanding of the mechanisms by 
which the induction of these genes is controlled is important for understanding how 
this fits in with the overall coordinated response of the monocyte/ macrophage and its 
response to activation and proliferation stimuli. This, in turn, contributes to our 
understanding of the biology of the macrophage and its activation.
No studies had been carried out at that time on the mechanisms of expression of the 
MIP-1 genes in untransformed primary murine macrophages or in murine 
macrophage cell lines; therefore, simple experiments, using metabolic inhibitors in 
vitro, were designed to attempt to elucidate the molecular mechanism of induction in 
BMDM.
The transcriptional inhibitor actinomycin D was used to test whether or not the 
stimulation of transcription was necessary for the LPS-induced accumulation of 
SCI/MIP-la and/or MIP-lp mRNA. Actinomycin D specifically inhibits RNA 
Polymerase II which is responsible for the synthesis of mRNA by binding to DNA 
and blocking the movement of the polymerase enzyme and hence prevents mRNA 
elongation (Alberts et al 1989; Sambrook et al 1989) It was reasoned, therefore, that
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if addition of actinomycin D to BMDM suppressed the LPS-induced accumulation 
mRNA for either of these genes, this would indicate that stimulation of transcription 
was a necessary regulatory component.
Figure 4.3 shows Northern blot analyses of both SCI/MIP-la and MIP-lp mRNA 
levels at different times after treatment with LPS (2jig/ml) with or without the 
subsequent addition of actinomycin-D (10|ig/ml) one hour after treatment. It can be 
seen that the LPS-mediated rise in the levels of both transcripts is inhibited when 
actinomycin D was added one hour after the LPS, indicating that the stimulation of 
transcription is necessary for the accumulation both mRNAs to take place. As 
expected, the levels of 7S mRNA were unaffected by the treatments.
If lanes 1,2 and 6  of figure 4.3 are compared, it can be seen that the level of both 
mRNAs is reduced to level of controls, from an elevated level, within an hour of the 
addition of actinomycin D. This suggests that the LPS-induced accumulation of both 
SCI/MIP-la and MIP-lp mRNA is dependent on continuous transcription for at least 
the first two hours after LPS stimulation.
Interestingly, the basal level of SCI/MIP-la mRNA is maintained throughout the five 
hours of treatment with actinomycin D while the level of MIP-lp mRNA had 
declined to below basal levels at the end of the experiment. This suggests that 
SCI/MIP-la mRNA is more stable than that of MIP-lp in the presence of 
actinomycin D and LPS.
Accordingly, an experiment was designed, again using actinomycin D, to test whether 
the stabilities of SCI/MIP-la and MIP-ip mRNA are different both before and after 
treatment with LPS.
Firstly, to assess the stability of SCI/MIP-la and MIP-lp mRNA in unstimulated 
BMDM, the levels of both mRNA transcripts (after refeeding of untreated BMDM) 
were monitored over a six hour time period in the presence or absence of actinomycin 
D. It can be seen from lanes 8-14 of figure 4.4 that the level of mRNA for both
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Figure 4.3 Northern analysis of the time course of 
accumulation of SCI/MIP-la and MIP-lp mRNA in BMDM 
treated with LPS (2p.g/ml) in the presence or absence of 
actinomycin D (10qg/ml).
Total cellular RNA was isolated and blotted in equal am ounts 
(20|ig) onto nylon membrane. Lanes 1-5, BM DM  treated with LPS 
for 0, 1, 2, 4 and 6 hours; lanes 6-8, BM DM  treated with LPS for 
2, 4 and 6 hours with the addition o f actinom ycin D after 1 hour. 
Lanes 9-11 o f upper panel are repeats o f lanes 6-8. Equal loading 
was confirm ed by hybridisation with a 7S probe.
SCI/MIP-la and MIP-lp declines to undetectable levels in the presence but not the 
absence of actinomycin D. This suggests that the expression of the basal levels of 
both transcripts is dependent on continuous transcription. It is evident, therefore, that 
the stimulation of transcription is necessary for both the expression of a basal level of 
SCI/MIP-la and MIP-lp mRNA and for the elevation of these levels of upon 
treatment of BMDM with LPS. Interestingly, the ability of actinomycin D to abolish 
expression of both SCI/MIP-la and MIP-ip mRNA within six hours indicates that 
the half-lives of these transcripts would be measured in the range of a few hours, 
which is not inconsistent with the transient patterns of accumulation of these mRNAs 
seen upon stimulation of BMDM with LPS.
One explanation for the differential decay seen in figure 4.3 (and possibly also in 
figure 4.1) is that LPS has a stabilising effect on SCI/MIP-la but not MIP-lp mRNA. 
This possibility was tested by first treating BMDM with LPS and then monitoring the 
decay of mRNA levels after four hours (the peak of mRNA accumulation) in the 
presence or absence of actinomycin D. The rationale behind this approach being that 
the rate of decay after the peak of expression for SCI/MIP-la mRNA might be 
retarded in comparison to that for MIP-lp. The results of one such experiment can be 
seen in figure 4.4.
No difference was detected in the decay of the two molecules at the gross level. In 
figure 4.4 the decay of SCI/MIP-la mRNA levels in the presence of actinomycin D 
(lanes 5, 6  and 7) appears to be retarded; however, this pattern was not borne out by 
repetition; therefore, no evidence for modulation of stabilisation of either of the MIP- 
1 mRNAs was obtained in these experiments.
It is possible that a more detailed analysis of this phenomenon, involving the 
quantitative analysis of several experiments, might reveal subtle differences. 
Unfortunately, only two runs of this experiment yielded interpretable results and 
therefore no such analysis can be carried out.
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Figure 4.4 Northern analysis of the steady-state levels of 
SCI/MIP-la and MIP-lp mRNA in BMDM with or without 
the addition of LPS (2p.g/ml) plus or minus the addition of 
actinomycin D (lOpg/ml).
Total cellular RNA was isolated and blotted in equal amounts onto 
nylon membrane. Lanes 1-4, BMDM treated with LPS for 4, 6 , 8  
and 10 hours. Lanes 5-7, BMDM treated with LPS for 6 , 8  and 10 
hours with addition of actinomycin D after 4 hours. Lanes 8-11, 
BMDM refed with alpha-MEM medium containing 25% DHS for 
4,6,8 and 10 hours; lanes 12-14, BMDM refed with alpha-MEM 
medium plus 25% DHS for 4, 6 , 8  or 10 hours with The addition of 
actinomycin D after 4 hours.
The membrane was hybridised first with a SCI/MIP-la probe, then 
stripped and rehybridised with a MIP-lp probe. Equal loading was 
confirmed by hybridisation with a 7S probe. The lower panel of 
the figure shows hybridisation with both MIP-ip and 7S probes; 
however, the equal hybridisation to the 7S probe can be seen 
clearly.
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It is interesting to note that the presence of actinomycin D did not markedly 
accelerate the decay of either SCI/MIP-la or MIP-lp mRNA 4-8 hours post 
treatment with LPS, which suggests that the contribution of transcription to the 
increased levels of these mRNAs has ceased by these times.
These results therefore suggest that the rate-limiting determinant for the LPS-induced 
increases in both SCI/MIP-la and MIP-lp could be a burst of transcriptional activity 
between zero and around four hours after stimulation, and thereafter the modulation 
of the rate of mRNA turnover, although a role for mRNA stabilisation in the 
induction of either of these mRNAS by LPS has not actually been demonstrated by 
these experiments.
It should be stressed that these data are merely indicative and there are other 
approaches, which were outside the scope of this project might have been more 
informative. For example, the specific time-frame during which transcription of 
SCI/MIP-la and MIP-ip mRNA is stimulated could have been assessed by ’’nuclear 
run-on" analysis or, as indicated above, quantitative analysis of the turnover of both 
mRNAs could have been carried out. Nevertheless, it is interesting to compare these 
results to those reported by Koemer et al (1987) who studied the mechanism of 
elevation of mRNA for the MIP-1 family member JE and the PF4-family member KC 
in murine peritoneal macrophages stimulated with LPS. While the levels of both 
mRNAs were elevated after 30 minutes the kinetics of expression observed thereafter 
were different. The level of KC mRNA peaked at two to four hours and had begun to 
decline by six hours, whereas the accumulation of JE mRNA is stable and stays at a 
constant level after the peak is reached. Using a nuclear "run-on" technique it was 
demonstrated that LPS elevated the transcription of the KC gene within 15 minutes 
with a peak at 1-2 hours and had ceased by six hours. The transcriptional activity of 
the JE gene, on the other hand, was unaffected by treatment with LPS. This would 
indicate that the accumulation of KC mRNA in murine peritoneal macrophages is
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dependent on the stimulation of transcription while the elevation of JE mRNA is most 
likely to be due to a posttranscriptional mechanism such as mRNA stabilisation. It is 
important to realise that the elevation of transiently expressed genes such as these 
may be regulated by different mechanisms in different cell types as Koemer et al 
(1987) and Hall and Stiles (1987) have demonstrated that serum-induced expression 
of JE in fibroblasts is mediated by an increase in the transcriptional activity of the 
gene. This means that any information obtained about the mechanism of 
accumulation of SCI/MIP-la or MIP-1 (3 mRNA in BMDM can not be directly 
extrapolated to other cell types.
No other studies, of the type described above, have been carried out for the murine 
SCI/MIP-la or MIP-1 (3 genes. However, Yamamura et al (1990) have demonstrated 
that actinomycin D abolished the basal human MIP-1 a  (LD78) mRNA levels in the 
human promyelocytic cell line HL60 but not in the HTLV-1-infected human T cell 
line MJ, suggesting that ongoing transcription is necessary for human MIP-1 a  
(LD78) mRNA expression in the former but not the latter cell line.
4.4 Effects of Cvcloheximide on Expression of SCI/MIP-la and MIP-1J3 mRNA.
A common feature of rapidly induced genes (in particular the so-called "immediate 
early" or "early response" genes) is that de novo protein synthesis is not necessary for 
the stimulation of transcription (Rollins and Stiles 1989). The fact that transcription 
can take place in the absence of new protein synthesis allows the induction of 
accumulation of mRNA to take place rapidly after cellular stimulation.
As LPS induces the accumulation of SCI/MIP-la and MIP-lp mRNAs within one 
hour it seemed possible that the transcriptional induction of either or both of these 
genes could share this characteristic of the immediate early genes. Therefore, the 
ability of LPS to induce the accumulation of SCI/MIP-la and MIP-lp mRNA in 
BMDM in the presence of the protein synthesis inhibitor cycloheximide was tested.
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Cycloheximide had slightly different effects on the LPS-mediated induction of 
SCI/MIP-la and MIP-ip mRNA.
In figure 4.5 (lower panel) it can be seen that LPS induces accumulation of MIP-lp 
mRNA after 4 hours to a level which is much greater than that induced by 
cycloheximide alone. The LPS-induced level is not affected by the presence of 
cycloheximide, suggesting that LPS can cause an increase in the level of this 
messenger RNA in the absence of new protein synthesis. The row containing the 
signals produced on hybridisation to MEP-lp mRNA is underexposed as the level of 
increase seen with LPS in this particular experiment is so great as to obscure the other 
lanes on a longer exposure.
The result obtained in these experiments with SCI/MIP-la mRNA were not as 
straight-forward to interpret. In the experiment seen in the upper panel of figure 4.5 it 
can be seen that, in this particular experiment, cycloheximide and LPS induce 
accumulation of SCI/MIP-la mRNA to a level which is approximately equal. 
However, when the two agents are added together, the level of SCI/MIP-la mRNA 
which accumulates after four hours is greater than that seen with each agent alone, 
indicating that the LPS-mediated rise in SCI/MIP-la mRNA is not blocked by 
inhibition of protein synthesis.
These results would again suggest the possibility that the main determinant for the 
rapid induction of both of the MIP-1 mRNAs could be the transient stimulation of 
transcription between zero and approximately four hours. The independence of this 
process from de novo protein synthesis again emphasises that accumulation of both 
SCI/MIP-la and MIP-lp mRNA is part of the early phase of the response of BMDM 
to stimulation.
It is possible, however, that mRNA stabilisation could play some role in determining 
the actual level of the mRNAs and may be responsible for the elevated levels of 
SCI/MIP-la mRNA in relation to unstimulated cells at later time points.
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Figure 4.5 Northern analysis of accumulation of SCI/MIP-la 
and MIP-lp mRNA in BMDM treated with LPS (2jj.g/ml) 
and/or cyclcheximide (10|ig/ml).
Total cellulai RNA was isolated after 4 hours and blotted in equal 
amounts (2 0 |ig) onto nylon membrane.
Upper panel,SCI/MIP-la mRNA. Lane 1, untreated BMDM; lane 
2, BMDM treated with cycloheximide; lane 3, BMDM treated with 
LPS plus cydoheximide; lane 4, BMDM treated with LPS. Equal 
loading was confirmed by hybrdisation to a 7S probe.
Lower panel. MIP-lp mRNA. Lane 1, untreated BMDM; lane 2, 
BMDM treated with LPS; lane 3, BMDM treated with 
cycloheximide; lane 4, BMDM treated with LPS plus 
cycloheximide. Equal loading was confirmed by hybridisation to a 
7S probe.
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Protein synthesis inhibitors, especially cycloheximide, have been shown to cause 
elevation of mRNA levels for several rapidly induced genes (Greenberg et al 1986, 
Subramaniam et al 1989, Mahadevan and Edwards 1991, Collart et al 1986).
Figure 4.6 shows a time course of the expression of MIP-1 a  and M IP-lp mRNAs in 
BMDM after treatment with cycloheximide. It can be seen that the level of SCI/MIP- 
l a  mRNA is elevated at one hour after addition and stays elevated for at least eight 
hours; samples were not taken at any times after this as the cells begin to die after 
prolonged exposure to cycloheximide.
It can also be seen that the level of MIP-1 P mRNA is increased at one hour, but has 
begun to decline by six hours and by eight hours is almost at the level of unstimulated 
controls.
The interpretation of the results of this experiment must be guarded with caution.
The levels of mRNA for several genes such as c-fos, c-myc and actin (Greenberg et al 
1986, Subramanian et al 1989, Mahadevan and Edwards 1991) and TNFa, IL -la  and 
urokinase-plasminogen activator (u-PA) (Collart et al 1986) are increased by 
cycloheximide and other inhibitors of protein synthesis. Conventionally, this has been 
attributed to stabilisation of the mRNA as a consequence of translational arrest (and 
hence be indicative of a role for the modulation of mRNA stability in the control of 
gene expression). Indeed, Wilson and Treisman (1988) have demonstrated that after 
treatment with cycloheximide, the half-life of c-fos mRNA increases from 
approximately thirty minutes to several hours. Hence, elevation of a messenger RNA 
by cycloheximide might be used as evidence for the possibility that modulation of 
mRNA stabilisation might be involved in the control of the expression of that gene. 
However, it has also been demonstrated that the transcription of several genes can be 
affected by cycloheximide; for example Collart et al (1986) have demonstrated that 
cycloheximide increases the rate of transcription of the genes for TNFa, IL -la  and u- 
PA in elicited peritoneal macrophages. In addition to this, Mahadevan and Edwards
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Figure 4.6 Northern analysis of the time course of 
accumulation of SCI/M IP-la and MIP-1(3 mRNA in BMDM 
treated with cycloheximide (1 0 |ig/ml).
Total RNA was isolated from BM DM  0, 1, 2, 4, 6 and 8 hours 
after treatm ent (lanes 1-6) and blotted in equal amounts (20 |ig) 
onto nylon m em brane. Equal loading was confirm ed by 
hybridisation with a 7S probe.
(1991) and Edwards and Mahadevan (1992) have demonstrated that cycloheximide is 
able to act as a nuclear signalling agonist in fibroblasts. Edwards and Mahadevan
(1992) have argued that this process may be making a major contribution to the 
induction of gene expression.
One interpretation of the data from the experiment shown in figure 4.6 could be that 
cycloheximide perhaps induces a transient burst of transcription from the MIP-lp 
gene. This burst, however, ends around four hours after addition of cycloheximide 
and the level of the labile mRNA then declines, whereas the SCI/MIP-la mRNA is 
comparably stable which would account for the unaltered levels of this mRNA 
beyond four hours.
Interestingly, Yamamura et al (1989) reported a transient elevation of hM IP-la 
(LD78) mRNA in the human promyelocytic cell line HL60 after treatment with 
cycloheximide, with levels being elevated as early as one hour and returning to basal 
levels by six hours. The addition of actinomycin D along with cycloheximide 
diminished but did not completely abolish the extent of elevation which suggests that 
both transcription and mRNA stability may be making a contribution.
Accordingly experiments were also performed using actinomycin D in conjunction 
with cycloheximide at early times to test whether transcription was necessary for the 
inductive effect of cycloheximide on SCI/MIP-la and/or MIP-lp levels and at later 
times to test whether the persistence of the elevated levels of SCI/MIP-la could be 
sustained in the absence of transcription. Unfortunately no consistent or interpretable 
results could be obtained in these experiments possibly because the insult sustained 
by the cells in these experiments is too severe.
4.5 Effect of Hydrocortisone on accumulation of SCI/MIP-la and MIP-lp mRNA. 
The induction of many genes which are involved in the inflammatory response, 
including members of the MIP-1 family, have been shown to be down-regulated by
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glucocorticoid hormones. In particular, Kawahara et al (1991) and Poon et al (1991) 
have demonstrated that the induction of the MIP-1 family member JE can be blocked 
by glucocortocoids in fibroblasts and vascular smooth muscle cells, respectively. In 
monocytic cells, Thorens et al (1987) have demonstrated that the accumulation of 
GM-CSF mRNA in mouse peritoneal macrophages in response to various factors is 
prevented by dexamethasone and Hamilton et al (1991) have demonstrated that the 
elevation of u-PA mRNA by rhCSF-1 in BMDM is prevented by dexamethasone.
It seemed likely that the expression of gene | products with such potent biological 
effects as SCI/MIP-la and MIP-ip might be subject to negative, as well as positive, 
regulation. Accordingly, the effect of hydrocortisone on SCI/MIP-la and MIP-lp 
mRNA levels was assessed.
BMDM were placed in serum-free (SF12) medium or serum-containing medium 
(alpha-MEM plus 25% DHS) for four hours in the presence or absence of 
concentrations of hydrocortisone ranging from 1 0 "^ to 10~^M.
It can be seen from figure 4.7 that the levels of both SCI/MIP-la and MIP-1 P mRNA 
are reduced by hydrocortisone at both 10"^ and 10'^M in SF12 medium. In alpha- 
MEM medium, containing 25% DHS, hydrocortisone had no effect on the level of 
SCI/MIP-la mRNA, but did appear to have a modest effect on the levels of MIP-lp 
mRNA. This may reflect a differential sensitivity of SCI/MIP-la and MIP-1 P mRNA 
to hydrocortisone. Interestingly, a basal level of both mRNAs is still seen, even at the 
highest concentration (10"^M) of hydrocortisone (figure 4.7).
The different effect seen in the two media is most likely due the fact that 
hydrocortisone is usually able to oppose rises in levels of mRNA rather than diminish 
basal levels as culturing BMDM in serum-free (SF12) induces accumulation of 
mRNA for both SCI/MIP-la and MIP-ip as will be discussed in chapter 6 . 
Preliminary experiments with other steroids indicated that this effect was specific to 
glucocorticoids as neither testosterone propionate (androgen), 17p-oestradiol
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Figure 4.7 Northern analysis of the effect of hydrocortisone on 
the accumulation of SCI/M IP-la and M IP-lp mRNA in 
BMDM in both SF12 and alpha-MEM media.
Total cellular RNA was isolated after 4 hours and blotted in equal 
am ounts (20|ig) onto nylon membrane.
Lanes 1-6, BM DM  refed with SF12 m edium  plus 0, 10 '^, 10"^,
10“^, 10~9 and 1 0 "^ M  hydrocortisone; lanes 7-12, BM DM  refed
with alpha-M EM  medium plus 0, 10'^, 10"7, 10'^, 10"^ and 10“ 
in1UM hydrocortisone.
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(oestrogen) or retinoic acid (retinoid) at 10~^M had any effect on the accumulation of 
SCI/MIP-la mRNA in BMDM in either serum-free or serum-containing medium 
(data not shown).
As it had already been demonstrated that LPS dramatically increased the levels of 
S CI/MIP-1 a  and MIP-1 p mRNA it seemed likely that theminight be a counteracting / \  
effect of an anti-inflammatory agent on the expression of these genes.
Accordingly, levels of SCI/MIP-la and MIP-lp were assessed in BMDM four hours 
after the addition of either LPS, 10'^M hydrocortisone, or both agents together in 
both SF12 medium and alpha-MEM medium containing 25% DHS. It can be seen 
from figure 4.8 that the LPS-mediated rise in both mRNAs is opposed by 
hydrocortisone in both the serum-free and serum-containing medium; this 
downregulation was found to be between approximately 40 and 60%, for both 
mRNAs, (by laser densitometry) over three experiments, which is similar to the 
downregulation by PGE1 of these mRNAs seen by Martin and Dorf (1991) in the 
J774A.1 macrophage-like cell line.
In addition, the observations made in figure 4.7 are confirmed by these experiments.
From these experiments it can be seen that hydrocortisone opposes rises in SCI/MIP- 
l a  and MIP-ip mRNA above the basal level, which is characteristic of the repressive 
action of glucocorticoid hormones on the expression of cytokine genes. It is 
interesting that most other investigators have demonstrated downregulation of the 
expression of cytokine gene expression using dexamethasone which is approximately 
ten times as potent a glucocorticoid as hydrocortisone (Malan & Gould 1982). This 
means that downregulation of accumulation of mRNA for both SCI/MIP-la and 
MIP-lp can be achieved by the equivalent of 10"^M dexamethasone, which suggests 
that the expression of both of these genes is extremely sensitive to glucocorticoids.
As discussed in chapter 1, hydrocortisone can downregulate gene expression at the 
level of both transcription and mRNA stability. The downregulation of expression of
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Figure 4.8 Northern analysis of the accumulation of SCI/MIP- 
l a  and M IP-ip mRNA in BMDM in SF12 and alpha-MEM 
medium in the presence or absence of LPS (2pg/ml) and/or 
hydrocortisone (10‘^M).
Cells were refed with either SF12 (lanes 1-4) or alpha-M EM  
medium (lanes 5-8). Total cellular RNA was isolated after 4 hours 
and blotted in equal am ounts onto nylon membrane.
Lanes 1 and 5, no additions; lanes 2 and 6, hydrocortisone; lanes 3 
and 7, LPS; lanes 4 and 8, LPS plus hydrocortisone.
SCI/MIP-la and MIP-1 p by hydrocortisone could be mediated at either, or both, of 
these levels.
4.6 Summary of Chapter 4.
The accumulation of mRNA for SCI/MIP-la and MIP-1 P is greatly increased in a 
rapid and transient fashion by stimulation of BMDM with bacterial endotoxin (LPS). 
These inductions can take place in the absence of new protein synthesis and is which 
indicates that upregulation of the expression of these genes is a part of the early 
response of BMDM to stimulation by LPS and allows SCI/MIP-la and MIP-1 P to be 
designated as belonging to the "immediate-early" group of genes.
Early stimulation of transcription is necessary for the accumulation of both SCI/MIP- 
l a  and MIP-lp mRNA in BMDM but it is possible that mRNA stabilisation may also 
play a role in determining the overall level of mRNA induced, although this has not 
actually been demonstrated in this chapter. Cycloheximide on its own is able to 
induce the accumulation SCI/MIP-la and MIP-lp mRNA and the implications of 
this were discussed. In common with many other cytokine genes, accumulation of 
SCI/MIP-la and MIP-lp mRNA can be downregulated by hydrocortisone. The 
features described above are typical of the many cytokine genes whose products are 
involved in mediating inflammation.
The experiments in this chapter also demonstrate that BMDM are a satisfactory in 
vitro system for studying the modulation of expression of both SCI/MIP-la and MIP- 
ip  as mRNA levels for both of these genes can be regulated both positively and 
negatively.
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Chapter 5
Effect of L929CM, rhCSF-1 and rmlFNy on Expression of SCI/M IP-la and 
M IP-lp mRNA in Bone Marrow-Derived Macrophages.
5.1 Introduction.
In chapter 4, the characteristics of the induction of mRNA for SCI/MIP-la and MIP- 
lp  by LPS, which is a potent activator of macrophages (Adams and Hamilton 1984) 
had been investigated. To further investigate the biology of SCI/MIP-la and MIP-lp 
gene expression, and in an attempt to identify candidate regulators of SCI/MIP-la 
and MIP-lp gene expression in vitro, the effects of three other agents, L929CM, 
colony stimulating factor 1 (CSF-1) and interferon-y (EFNy), was investigated.
In the BMDM culture system described in chapter 3, L929CM was used as a source 
of colony stimulating factor 1, the lineage-specific growth factor, which stimulates 
the proliferation, differentiation and survival of cells of the mononuclear phagocyte 
series (Sherr 1991). In BMDM, CSF-1 has been shown to affect the expression of a 
number of genes, as discussed in chapter 1, without causing macrophage activation 
(Phillips and Hamilton 1989, Hamilton et al 1989). Therefore, it was of interest to 
determine whether gene expression could be upregulated by a growth factor as well 
as by a macrophage activating factor as this might give a clearer indication of the 
range of situations in which the induction of expression of these genes might play a 
role. In particular, since bone marrow haemopoiesis has been proposed to be directed 
by interacting networks of cytokines produced by stromal cells it was thought that 
studying the effect of cytokines on the expression of SCI/MIP-la and MIP-lp 
mRNA in BMDM might make a contribution towards understanding the role of these 
molecules in marrow haemopoiesis.
Interferon-y (IFNy) can affect gene expression in a wide variety of cell types (Sen and 
Lengyell 1992) and is believed to play a  role in priming macrophages for antigen
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presentation, as evidenced by its ability to upregulate expression of MHC class II 
molecule genes in both the human (Pestka et al 1987) and the mouse (Yi and 
Willman 1989). It was, therefore, of interest to determine the effect, if any, of IFNy 
on the accumulation of mRNA for the two genes to determine whether expression of 
SCI/MIP-la and/or MIP-ip in the context of the specific response to infection. IFNy 
has also been demonstrated to reversibly oppose the CSF-1-induced proliferation of 
BMDM (Vairo et al 1991, Knight et al 1992).
5.2 Effect of L929CM on Expression of SCI/MIP-la and MIP-1J3 mRNA.
The effects of L929CM and CSF-1 on the expression of both MIP-1 mRNAs was 
investigated for the following reasons:
1) The mRNA for many inducible genes, including MIP-1 family members, as 
discussed in chapter 1, have been shown to be increased in BMDM or related cell 
lines as part of the early response to CSF-1 (Orlofsky and Stanley 1987, Hamilton et 
al 1989, Matsushime et al 1991b, Sherr 1991). Given that the characteristics of 
accumulation of SCI/MIP-la and MIP-lp mRNA in BMDM in response to LPS were 
indicative of this being part of the early response to stimulation, it seemed possible 
that this might also be the case for stimulation by a growth factor. As the ability of 
L929CM to induce proliferation of BMDM had already been established, it was 
reasoned that this might also allow assessment of any relationship between BMDM 
proliferation and expression of SCI/MIP-la and/or MIP-1 P mRNA.
2) Simmons and Lord (1985) had demonstrated that culture, in 20% L929CM, of 
macrophages, sorted on the basis of the expression of the F4/80 antigen, greatly 
increased the production of the Manchester Inhibitor. This increase could have been 
due to either increased production from the cells themselves or to an increase in cell 
number in the culture. It was considered that assessment of the effect of L929CM on 
the expression of SCI/MIP-la mRNA levels over a short-time span in which the
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growth properties of BMDM were well characterised would go some way to 
resolving this issue.
To assess whether L929CM might affect the accumulation of mRNA for SCI/MIP-la 
and MIP-lp in BMDM, and to determine appropriate conditions for this assessment, 
mRNA levels were measured at six and twenty-four hours after reculturing in alpha- 
MEM medium containing 25% DHS or FCS plus or minus 20% L929CM by 
Northern blotting. These time points were chosen in the light of the pattern of 
accumulation of these mRNA transcripts in response to LPS. Hamilton et al (1989) 
had used FCS in their BMDM culture system and therefore the suitability of both 
DHS and FCS for use in the assessment of the effects of L929CM on gene expression 
was assessed. As a control, levels in the treated cultures were compared to those in an 
untreated seven day culture.
In figure 5.1 it can be seen that when BMDM were cultured in alpha-MEM 
containing 25% DHS in the absence of L929CM the level of SCI/MIP-la mRNA is 
reduced to a level which is lower than that of the untreated control culture at both six 
and twenty-four hour hours (lanes 1 and 2). With FCS, a dramatic increase in the 
level of SCI/MIP-la mRNA (approximately 40 to 50 fold as assessed by 
densitometry) at six hours is seen, which appears to be augmented slightly by 
L929CM (lanes 4 and 5). However, this effect is not seen at twenty-fours (lanes 8 and 
9) and indeed, mRNA levels are lower than the control, suggesting that the effect of 
FCS on SCI/MIP-la and MIP-lp mRNA accumulation, like that of LPS, is transient. 
The effect of FCS on the level of SCI/MIP-la mRNA levels is very similar to that 
observed for GM-CSF in murine peritoneal macrophages by Thorens et al (1987).
The effects of these treatments on MIP-lp mRNA levels are essentially identical, 
although the overall extent of hybridisation to MIP-lp is less than that to SCI/MIP- 
la .  This is most likely to be due to the fact that, in the experiment shown in figure 
5.1, the same membrane was first probed for SCI/MIP-la and then stripped before
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Figure 5.1 Northern analysis of the accumulation of SCI/MIP- 
l a  and M IP-lp mRNA in BMDM after refeeding with alpha- 
MEM medium in the presence or absence of various additions.
Total cellular RNA was isolated 6 hours (lanes 2-5) or 24 hours 
(lanes 6-9) after refeeding and blotted in equal am ounts (20pg) 
onto nylon membrane. Lane 1, untreated BM DM; lanes 2 and 6, 
BM DM  refed plus 25% DHS; lanes 3 and 7, BM DM  refed plus 
25% DHS plus 20% L929CM ; lanes 4 and 8, BM DM  refed with 
alpha-M EM  plus 25% FCS; lanes 5 and 9, BM DM  refed with 
alpha-M EM  medium plus 25% FCS plus 20% L929CM . Equal 
loading was ensured by ethidium bromide staining o f the gel. The 
m em brane was probed first for S C I/M IP -la  and then stripped and 
rehybridised for MIP-1 P mRNA.
reprobing for MIP-1 (3. Twenty percent L929CM does appear to have a positive effect 
on the level of both mRNAs as the level seen on refeeding with medium containing 
20% L929CM is greater than that seen in its absence (lanes 2 and 3). This experiment 
provided evidence, therefore, that the levels of SCI/MIP-la and MIP-1 p mRNA in 
BMDM could indeed be affected (positively) by L929CM and it was concluded that 
these effects were worthy of further investigation. An interesting feature of this 
induction was the fact that the upregulation seen in response to 20% L929CM was 
still evident after 24 hours which had not been found with any other mediator and it 
seemed possible that L929CM might be inducing a pattern of expression different 
from that induced by LPS, i.e. a sustained, as opposed to a transient, increase.
The observed increase raised the possibility that L929CM might be affecting the 
accumulation of SCI/MIP-la and MIP-lp mRNA through a different mechanism to 
that of LPS.
An additional consideration was that it was not possible to tell from these 
experiments whether the effect of L929CM was to increase the accumulation of 
SCI/MIP-la and MIP-lp mRNA or merely to prevent the downregulation of mRNA 
levels by DHS. Accordingly, experiments were designed to investigate whether 
L929CM was able to induce the accumulation of SCI/MIP-la and MIP-lp mRNA 
and, if so, the kinetics of this expression.
For these experiments, the cells were "starved" overnight by culturing in alpha-MEM 
medium containing 25% DHS in the absence of any other additions. Starvation 
ensured that the starting levels of SCI/MIP-la and MIP-lp mRNA were as low as 
could be obtained in the culture system, greatly simplifying the analysis of the effects 
of L929CM. In addition to this, overnight starvation, as illustrated in chapter 3, has 
the effect of arresting the proliferation of BMDM which means that the cells would 
respond to the proliferation-inducing effects of L929CM in as uniform a manner as 
could be achieved in the culture system. The level of expression of mRNA for
137
SCI/MIP-la and MIP-lp was then assessed in the starved cultures and at times after 
refeeding with fresh medium plus 20% L929CM (figure 5.2).
Fiure 5.2 shows that the levels of both SCI/MIP-la and MIP-ip mRNAs are 
increased approximately 1 0  to 2 0 -fold (as assessed by laser densitometry) by 
treatment with 20% L929CM. This, in contrast to the observations in the experiment 
described immediately above, is a rapid and transient induction with a peak of 
expression at four hours. Similarly to the LPS-mediated induction (see figure 4.1), the 
levels of mRNA for SCI/MIP-la, but not M IP-lp, are elevated at later times (12 to 
24 hours) in comparison to untreated controls. This experiment was repeated several 
times and the rapid and transient pattern of induction was most commonly seen, 
however sustained elevation of both transcripts, for up to 24 hours, was seen a 
number of times.
Increases in the expression of many inducible genes, including some oncogenes and 
MIP-1 family members have been demonstrated to be increased within one hour of 
stimulation which suggests that the pathways leading to the induction of their 
expression are activated almost immediately on cellular stimulation (as was discussed 
in chapter 1). To investigate whether this was also true of SCI/MIP-la and MIP-lp 
gene expression, BMDM cells were treated as before and levels of mRNA assessed at 
earlier times following refeeding with L929CM.
Figure 5.3 shows the results of an experiment carried out in an identical manner to 
that just described except that the levels of mRNA for both SCI/MIP-la and MIP-lp 
were assessed at times between 20 minutes and six hours after stimulation. It can be 
seen that the level of both mRNAs has begun to increase within one to two hours of 
stimulation which suggests that the induction of expression of both genes with 
L929CM, as with LPS, is extremely rapid and is in the same time frame as that of 
other lymphokine genes expressed as part of the early response to stimulation. This 
pattern was seen in several experiments, although the exact timing of the induction
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Figure 5.2 Northern analysis of accumulation at four hourly 
intervals of SCI/MIP-la and MIP-lp mRNA in BMDM 
treated with 20% L929CM.
Upper Panel, SCI/MIP-la. Lane 1, untreated seven day culture of 
BMDM; lane 2 BMDM starved overnight in alpha-MEM medium 
containing 25% DHS; lanes 3-8, BMDM starved overnight and 
refed with alpha-MEM medium containing 25% DHS plus 20% 
L929CM for 4, 8 , 12, 16, 20 and 24 hours. Total cellular RNA was 
isolated and blotted in equal amounts onto nylon membrane. Equal 
loading was confirmed by hybridisation with a 7S probe.
Lower Panel, MIP-lp. Lane 1, BMDM starved overnight in alpha- 
MEM medium containing 25% DHS; lanes 2-7, BMDM starved 
overnight and refed with alpha-MEM medium containing 25% 
DHS plus 20% L929CM for 4, 8 , 12,16, 20 and 24 hours. Total 
cellular RNA was isolated and blotted in equal amounts onto nylon 
membrane. Equal loading was confirmed by hybridisation with a 
7S probe.
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Figure 5.3 Northern analysis of the time course of 
accumulation of SC I/M IP-la and M IP-lp mRNA in BMDM 
after treatm ent with 20% L929CM.
Total cellu lar RNA was isolated after 0, 0.3, 0.6, 1, 2 and 4 hours 
and blotted in equal am ounts (20 |ig) onto nylon m em brane. Equal 
loading was confirm ed by hybridisation with a 7S probe.
did vary between experiments which is consistent with the observations of Orlofsky 
and Stanley (1987) on the CSF-1-induced accumulation of JE and KC mRNA in the 
BMDM-like BAC1 25F cell line.
It can also be seen in lanes 1 to 5 of figure 5.5 that the action of L929CM in inducing 
the accumulation of both SCI/MIP-la and MIP-lp mRNA in BMDM after 4 hours is 
dose-dependent.
The kinetics of and dose-dependency of L929-induced SCI/MIP-la and MIP-1 P 
expression is very similar to that of the CSF-1-induced expression of u-PA (Hamilton 
et al 1991) and IL -la  (Matsushime et al 1991b) mRNAs in BMDM and suggests that 
the CSF-1 component of L929CM may be making a contribution to this induction.
In common with the expression of these genes is also the fact that the peak of 
expression precedes the onset of DNA synthesis in BMDM as demonstrated in 
chapter 3, figure 3.11.
The coincidence of the stimulation of proliferation and accumulation of mRNA for 
SCI/MIP-la and MIP-lp also raised the possibility that these two processes might be 
linked as has been proposed for the expression of the urokinase-plasminogen 
activator protein and mRNA by macrophages (Hume and Gordon 1984) and 
fibroblasts and keratinocytes (Grimaldi et al 1986), respectively.
A problem with the interpretation of these experiments, however, lies in the 
heterogeneous composition of L929CM. Even though L929CM is a potent source of 
CSF-1 (Stanley and Guilbert 1981) it also contains other components which could 
have an effect on the accumulation of mRNA from inducible genes such as fetal calf 
serum. It is apparent from figure 5.1 (lanes 3 and 4) that 20% fresh FCS could greatly 
upregulate the expression of mRNA for both SCI/MIP-la and MIP-ip in BMDM 
making it possible that the FCS component of L929CM could be making a 
contribution to the upregulation of the MIP-1 mRNAs; however, it is difficult to
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compare the effect of 20% fresh FCS to that of a final concentration of 2% in medium 
in which cells have been cultured.
In addition, although none of the components of this culture system contained 
significant levels of endotoxin (manufacturers' data) it was a concern that this may 
have been introduced during the production of L929CM and hence had an effect on 
the expression of mRNA for SCI/MIP-la and MIP-lp. However, it is unlikely that 
the accumulation of these mRNAs is due to LPS contamination as introducing the 
antibiotic polymixin B, which binds LPS and prevents it interacting with cellular LPS 
receptors (Issekutz 1983), into the culture system had no effect on the level of 
SCI/MIP-la mRNA induced by 20% L929CM (figure 5.4).
As L929CM is a potent source of CSF-1, this cytokine still appeared to be the most 
likely candidate for the inducing agent. There are several ways that this could be 
tested, including the use of neutralising antibodies. However, the most straight 
forward way is to use recombinant CSF-1.
5.3 Effect of rhCSF-1 on the Expression of SCI/MIP-la and MIP-1 jj> mRNA 
The ability of CSF-1 to affect the accumulation of mRNA for SCI/MIP-la and MIP- 
ip  in BMDM was assessed in several experiments using material from two different 
sources (see Chapter 2) and using a range of concentrations from lOU/ml to 
10,000U/ml. The levels of the two transcripts were assessed four hours after 
refeeding with alpha-MEM medium containing 25% DHS with or without the 
addition of recombinant human CSF-1 (rhCSF-1). The potency of these preparations 
was also assessed by their ability to induce thymidine incorporation in BMDM and to 
promote the formation of CFU-M colonies in semi-solid agar cultures of normal 
murine bone marrow. The effect of L929CM was also assessed in all of these 
experiments as a positive control.
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Figure 5.4 Northern analysis of the effect of polymixin B on 
the L929-induced accumulation of SCI/M IP-la mRNA in 
BMDM.
Total cellular RNA was isolated after 4 hours and blotted in equal 
amounts onto nylon membrane. Lane 1, untreated BM DM ; lanes 2 
and 3, BM DM  treated with 20% L929CM ; lanes 4 and 5, BM DM  
treated with 20% L929CM  treated previously with polym ixin B 
(2mg/ml). Equal loading was ensured by ethidium  bromide 
staining o f the gel.
Figure 5.5 shows the results of an experiment in which the ability of rhCSF-1 at 500 
and lOOOU/ml to affect the levels of mRNA for SCI/MIP-la and MIP-lp were 
assessed. The activity of the rhCSF-1 was also assessed, in parallel with L929CM, for 
its ability to induce proliferation of BMDM after 20 hours (figure 5.6) and its ability 
to promote colony formation in normal murine bone marrow (figure 5.7).
Perhaps surprisingly, the rhCSF-1 failed to have a profound effect on the levels of 
either transcript, although in one instance rhCSF-1 caused an apparently 2 to 3-fold 
increase in the levels of both mRNAs (as assessed by laser densitometry, as seen in 
figure 5.5). L929CM, on the other hand, was able to induce accumulation of both of 
these in a dose-dependent manner.
Hamilton et al (1989,1991) had demonstrated that the levels of c-fos, c-myc and 
urokinase-plasminogen activator mRNA could be markedly elevated by as little as 
125 U/ml rhCSF-1, so the inability of the preparation at 500 and 1000 U/ml to have a 
great effect on SCI/MIP-la and MIP-lp mRNA after four hours was surprising.
It was interesting that in these experiments 1000 U/ml rhCSF-1 had an ability to 
induce thymidine incorporation in BMDM which was approximately equal to that of 
5% L929CM. It seemed possible, therefore, that the concentration of rhCSF-1 used 
was too low for changes in gene expression to be detected in this particular system. 
When the potency of this preparation of rhCSF-1 was assessed by its ability to 
promote the formation of normal bone marrow colonies it was found the this was 
modest. According to information supplied by the manufacturer, one unit of rhCSF-1 
should cause the formation of one CFU-M colony under the conditions of the 
experiment. However, it can be seen from figure 5.7 that this particular preparation 
had less than one tenth of the activity ascribed to it.
An alternative source of rhCSF-1 was obtained as a gift from Genetics Institute and 
was used at a concentration of 10,000 U/ml. Unfortunately this concentration had no 
effect on the level of either transcript in a single experiment, while L929CM was
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Figure 5.5 Northern analysis of the effect of recombinant 
human CSF-1 and L929CM on accumulation of SCI/M IP-la 
and M IP-lp mRNA in BMDM.
Total cellular RNA was isolated after 4 hours and blotted in equal 
amounts (20|ig) onto nylon m em brane. Lanes 1-5, BM DM  treated 
with 0, 1 ,5 , 10 and 20% L929CM ; lanes 6 and 7, BM DM  treated 
with 500 and 1000 U/ml recom binant human CSF-1. The 
m em brane was hybridised first for S C I/M IP -la , then was stripped 
and reprobed for M IP -lp . Equal loading was confirm ed by 
hybridisation with a 7S probe.
Figure 5.6 Tritiated thymidine incorporation in BMDM following 
treatment with L929CM or recombinant human CSF-1.
BMDM were starved overnight in alpha-MEM medium containing 
25% DHS in the absence of any other additions. Medium was then 
removed and BMDM refed with alpha-MEM medium containing 25% 
DHS plus the following additions:
1) Nil
2) 20%LCM
3) 10%LCM
4) 5%LCM
5) 500U CSF-1
no additions 
20% L929CM 
10% L929CM 
5% L929CM 
500 U/ml rhCSF-1
Tritiated thymidine incorporation was measured after 20 hours. Data is 
presented as the mean determination of triplicate cultures plus or 
minus one standard deviation.
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Figure 5.7 Effect of L929CM and recombinant human CSF-1 on 
colony formation by normal murine bone marrow.
7 5 .1 0 ^ normal bone marrow cells from B6D2F1 mice were plated in 
lml plates in semi-solid alpha-MEM medium containing 25% DHS 
plus the concentration of L929CM or rhCSF-1 indicated in the figure 
and the cultures incubated for 7 days in the conditions detailed in 
chapter 2. Colonies containing greater than 50 cells were scored and 
data presented as the mean determination of triplicate cultures plus or 
minus one standard deviation.

again effective in a dose-dependent manner (data not shown). The same concentration 
induced proliferation in BMDM equal to that of 5% L929CM (data not shown), 
which again in this experiment had little effect to on the expression of SCI/MIP-la 
and MIP-lp mRNA. This experiment could only be performed once due to scarcity of 
material.
Therefore attempts to demonstrate an effect of rhCSF-1 on the levels of these two 
mRNAs were only marginally successful. This could have been for several reasons:
1 ) the recombinant protein was sticking to the plastic culture dish and therefore was 
prevented from acting on the cells, although this seemed unlikely as all assays were 
performed in the presence of 25% DHS which should be an effective carrier.
2) the constitutive level of SCI/MIP-la and MIP-lp mRNA expressed by the BMDM 
masked any effect which the rhCSF-1 was having on the expression of these genes. 
This seems unlikely as Hamilton et al (1989) were able to demonstrate a change 
above a constitutive level of c-fos in BMDM in response to as little as 125 U/ml 
rhCSF-1.
3) The expression of SCI/MIP-la and MIP-ip mRNA is not affected by rhCSF-1. 
This possibility could have been explored by measuring the levels of a gene known to 
be induced by CSF-1 in BMDM. An attempt was made to measure the levels of c- 
myc in the experiments described above but unfortunately this attemnt was 
unsuccessful due to the inability to radioactively label the DNA probe.
4) The mRNA transcripts for SCI/MIP-la and MIP-lp are induced by rhCSF-1 but in 
a later time-frame from that induced by LPS and L929CM. Unfortunately, 
investigating this possibility would require assessment of expression at multiple time 
points which was not possible due to scarcity of material.
However, the most likely explanation is still that the potency of the rhCSF-1 
preparations used in these experiments were inadequate to affect gene expression. It 
is possible, therefore, that accumulation of SCI/MIP-la and MIP-ip mRNA might be
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induced by different rhCSF-1 preparations. This work was unable to be carried out, 
however, due to constraints of time. It is also possible, in addition to this, that the 
culture conditions used to assess the effects of rhCSF-1 were not optimal; for 
example all of the experiments involving this cytokine were carried out in 25% DHS, 
which is likely to be a rich source of growth factors and biological effector 
molecules. It is possible that the apparent ability of DHS to downregulate the 
accumulation of both SCI/MIP-la and MIP-lp mRNA in BMDM (seen in figure 5.1) 
could mask the inductive effect of cytokines such as rhCSF-1.
The effect of CSF-1 on the expression of the SCI/MIP-la and MIP-ip genes has not 
been reported by any other investigator.
Attempts were also made to investigate the effects of interleukins -1 and - 6  on the 
expression of the two genes. The effect of these cytokines was assessed in two 
separate experiments and no significant difference, either positive or negative, in the 
levels of the two transcripts was detected (data not shown). These cytokines were 
chosen as they have been shown to be positive regulators of haemopoietic stem cell 
proliferation (Ikebuchi et al 1988) and it was thought possible that one of the effects 
of positive stem cell regulators might be to down-regulate the expression of negative 
regulators. Interestingly, however, Martin and Dorf (1991) have also recently 
reported the inability of IL-1 and TNFa to affect the expression of mRNA for 
SCI/MIP— l a  and MIP-ip in the macrophage-like cell line J774A.1.
5.4 Effect of rmlFNy on Expression of SCI/MIP-la and MIP-lg mRNA 
The interferons are proteins which exert multiple biological activities on the immune 
and other systems, primarily by inducing the synthesis of other biologically important 
proteins (Samuel 1991, Sen and Lengyell 1992). Vairo et al (1991) have 
demonstrated reversible inhibition of CSF-1-stimulated proliferation in BMDM by 
IFNy.
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The effect of IFNy on L929-induced proliferation and on the expression of mRNA for 
SCI/MIP-la and MIP-ip in BMDM was therefore assessed as a comparison to 
L929CM and CSF-1.
IFNy (20ng/ml), as expected, as well as LPS (2 fig/ml), was able to block the 
proliferation of BMDM stimulated with 20% L929CM while having no effect on 
thymidine incorporation when used alone, as can be seen from figure 5.8, confirming 
the results of Vairo et al (1991) and Knight et al (1992). The ability of IFNy to block 
BMDM proliferation was blocked by boiling the preparation prior to use, indicating 
that the activity seen in this preparation is not due to contamination due to LPS, 
which is resistant to boiling (data not shown).
From figure 5.9 it can be seen that recombinant murine IFNy (used at 20ng/ml) was 
able to increase expression of mRNA for both SCI/MIP-la and MIP-ip at four hours 
to a level approximately equal to that induced by 20% L929CM. By twenty-four 
hours the levels of mRNA had returned to control levels. This again suggests that the 
induction of accumulation of SCI/MIP-la and MIP-lp mRNA, upon cellular 
stimulation, is transient.
This finding is in agreement with the observations of Martin and Dorf (1991) who 
found that IFNy increased the level of mRNA for JE SCI/MIP-la and MIP-ip in the 
macrophage cell line J774A.1 six hours after treatment.
The fact that rmlFNy could increase the accumulation of mRNA for SCI/MIP-la and 
MIP-lp in BMDM was informative for three reasons:
1) It demonstrates that the accumulation of SCI/MIP-la and MIP-lp mRNA in 
BMDM can be induced by a cytokine as well as a macrophage activating factor 
(LPS).
2) It demonstrates that accumulation of mRNA for SCI/MIP- l a  and MIP-lp can 
take place in the absence of proliferation, providing evidence that the two processes 
can be regulated independently of each other.
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Figure 5.8 Inhibition of L929CM-induced tritiated thymidine 
incorporation in BMDM by LPS (2|ig/ml) and recombinant 
murine IFNy (20ng/ml).
BMDM were starved overnight in alpha-MEM medium containing 
25% DHS in the absence of any other additions. Medium was then 
removed and BMDM refed with alpha-MEM medium containing 25% 
DHS plus the following additions:
1) Nil
2) 20%LCM
3) LPS
4) LPS+LCM
5) IFNg
6 ) IFNg+LCM
No additions 
20% L929CM 
LPS (2|ig/ml)
20% L929CM plus LPS (2pg/ml) 
rmlFNy (20ng/ml)
20% L929CM plus rmlFNy (20ng/ml)
Tritiated thymidine incorporation was measured after 20 hours and 
data presented as the mean of triplicate cultures plus or minus one 
standard deviation.
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Figure 5.9 Northern analysis of the effect of recombinant 
murine IFNy (20ng/ml) and 20% L929CM on the accumulation 
of SCI/M IP-la and M IP-ip mRNA in BMDM.
Total cellular RNA was isolated after 4 hours (lanes 1-4) or 24 
hours (lanes 5-8) and transferred in equal amounts (10pg) onto 
nylon m em brane. Lanes 1 and 5, untreated BM DM ; lanes 2 and 6, 
BM DM  treated with 20% L929CM ; lanes 3 and 7, BM DM  treated 
with IFNy, lanes 4 and 8, BM DM  treated with 20% L929CM  plus 
IFNy. The m em brane was probed first for S C I/M IP -la , then 
stripped and reprobed for M IP -lp . Equal loading was confirm ed 
by hybridisation with a 7S probe.
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3) It raises the possibility that expression of SCI/MIP-la and MIP-lp may be 
involved in the specific immune response as well as in the non-specific response as 
evidenced by the effect of LPS.
5.7 Summary of Chapter 5
The accumulation of mRNA for SCI/MIP-la and MIP-1 (3 in BMDM by L929CM, 
recombinant human (rh) CSF-1 and recombinant murine (rm) IFNy was assessed as 
part of a study to investigate candidate regulators of the expression of the SCI/MIP- 
l a  and MIP-lp genes. The effects of two different sera, donor horse (DHS) and fetal 
calf (FCS), were also assessed.
Refeeding cells with medium containing 25% FCS lead to a profound, although 
transient increase in the levels of both mRNAs above the level in untreated control 
cultures. Replacing the FCS with DHS, on the other hand, lead to a marked decrease. 
Twenty percent L929CM induced accumulation of both mRNA transcripts 
approximately 10 to 20-fold, in a rapid and transient manner. Increases in the levels 
of both transcripts could be detected by one hour after stimulation. These patterns of 
expression are extremely similar to that seen with LPS, further emphasising that 
accumulation of mRNA for SCI/MIP-la and MIP-lp is a component of the early 
response to stimulation of BMDM. With L929CM, accumulation of SCI/MIP-la and 
MIP-lp mRNA was dose-dependent when measured 4 hours after treatment and 
preceded the onset of DNA synthesis. This may suggest that the signal transduction 
pathways and/or genetic programmes which control the induction of accumulation of 
SCI/MIP-la and MIP-lp mRNA and the proliferation of BMDM may share elements 
in common.
Recombinant human CSF-1 had only a slight effect, if any, on the expression of the 
mRNAs, although this most likely relates to the activity of the preparations used as 
evidenced by the assays for activity performed in parallel with the gene expression
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experiments; however, the culture conditions used may play a part. Further 
experiments are required if this issue is to be pursued.
Recombinant murine IFNy, which opposed the L929CM-induced proliferation of 
BMDM, also increased accumulation of mRNA for both SCI/MIP-la and MIP-ip 
after four hours, again in a transient manner. This result demonstrates that SCI/MIP- 
l a  and MIP-lp mRNA accumulation can be induced by a cytokine and also that this 
induction and BMDM proliferation can be regulated independently.
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Chapter 6.
Accumulation of mRNA for SCI/MIP-la and MIP-ip in Bone Marrow-Derived 
Macrophages in Serum-Free Medium.
6.1 Introduction
The investigation of changes in the accumulation of SCI/MIP-la and MIP-lp mRNA 
induced by cytokines in alpha-MEM medium containing 25% DHS (in chapter 5) had 
yielded some useful data. However, the minimal efficacy of recombinant human 
CSF-1, especially in inducing BMDM DNA synthesis, suggested that the culture 
conditions employed might not be optimal for assessing the effects of recombinant 
material on the accumulation of SCI/MIP-la and MIP-lp mRNA in BMDM. In 
particular, the apparent ability of DHS to affect the accumulation of both SCI/MIP- 
l a  and MIP-lp mRNA suggested that inclusion of this in the culture system might be 
masking the effects of recombinant proteins such as CSF-1.
In addition, experiments with the SF12 serum-free medium (in chapter 3) had 
suggested that the survival of BMDM could be enhanced in this medium in 
comparison to alpha-MEM.
In an attempt to determine whether modulation of the expression of SCI/MIP-la and 
MIP-lp genes might be more effectively studied under different, and more defined, 
culture conditions and to assess the effects on SCI/MIP-la and MIP-ip gene 
expression of different components of the culture conditions used in chapters 3 ,4  and 
5, the accumulation of SCI/MIP-la and MIP-lp mRNA was assessed on culturing 
BMDM in SF12 medium in the presence and absence of DHS, L929CM and 
hydrocortisone. SF12 medium was used in preference to reducing the level of DHS in 
alpha-MEM as SF12 has been specially formulated for the culture of primary 
haemopoietic cells.
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6.2 Accumulation of SCI/MIP-la and MIP-1J3 mRNA in Bone Marrow-Derived 
Macrophages in SF12 Medium.
As a pilot experiment, SCI/MIP-la mRNA accumulation was assessed before and 
after culturing in SF12 medium in the presence or absence of either 20% DHS or 20% 
L929CM. Levels were measured at one, three and six as well as twenty-four hours, as 
if accumulation of SCI/MIP-la mRNA was going to be affected by this treatment it 
was likely that this would happen within a few hours.
It can be seen from figure 6.1 that the relative level of SCI/MIP-la mRNA in BMDM 
after 24 hours in serum-free medium is approximately the same as that seen in the 
unstimulated cells in serum-containing medium (figure 6 .1  upper panel, lanes 1 and 
6 ). However, the level of SCI/MIP-la mRNA is increased relative to control levels at 
three and six hours after refeeding, with the highest level observed after 6  hours 
(figure 6.1 upper panel, lanes 4 and 5). The addition of donor horse serum (DHS) 
appears to block this induction, suggesting that DHS is a downregulator of SCI/MIP- 
l a  (and hence possibly MIP-lp) mRNA accumulation. In this particular experiment, 
addition of L929CM at the same time as the medium change appears to augment the 
induction of SCI/MIP-la mRNA but this was found to vary between experiments.
It was decided that, in order to further assess the suitability of SF12 medium for 
investigating the expression of SCI/MIP-la and MIP-ip mRNA, this induction 
would be further investigated.
Figure 6.2 shows the effect of refeeding with SF12 alone on levels of both SCI/MIP- 
l a  and MIP-lp mRNA in greater detail. It can be seen that the accumulation of both 
transcripts is rapid and transient with the peak of accumulation occurring at around 
four hours. The similarity between this pattern and that seen after stimulation with 
LPS or L929CM is obvious; this pattern again indicates that accumulation of
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Figure 6.1 Northern analysis of the accumulation of SCI/MIP- 
l a  mRNA in BMDM on refeeding with SF12 medium.
Total cellular RNA was isolated at various times after refeeding 
with SF12 m edium  plus or minus 20% L929CM  and/or DHS 
(25% ) and blotted in equal amounts (20pg) onto nylon m em brane.
U pper panel: Lane 1, RNA ladder; lane 2, untreated BM DM ; lane 
3, BM DM  refed with SF12 containing 25% DHS plus 20% 
L929CM  for 24 hours; lanes 4-7, BMDM refed with SF12 m edium  
for 1, 3, 6 and 24 hours; lanes 8-11, BM DM  refed with SF12 
m edium  plus 25% DHS for 1, 3, 6 and 24 hours; lane 12, untreated 
J774.2 cells. Equal loading was ensured by hybridisation to a 7S 
probe.
Low er panel: Lane 1, RNA ladder; lanes 2-5, BM DM  refed with 
SF12 containing 20% L929CM , lane 6, untreated J774.2 cells. 
Equal loading was confirm ed by hybridisation to a 7S probe.
SCI/MIP-la and MIP-ip mRNA is an early response to stimulation; in this case 
stimulation consists of changing the medium.
The effect of DHS on the accumulation of SCI/MIP-la and MIP-lp mRNA was of 
interest as it was reasoned that investigating the effects of DHS on accumulation of 
mRNA for SCI/MIP-la and MIP-ip in SF12 medium might contribute to 
understanding the role played in this respect by DHS in alpha-MEM medium and 
hence enhance the interpretation of the results of chapter 5.
The effect of L929CM on MIP-1 mRNA accumulation in SF12 medium was also 
investigated to allow direct comparison between SF12 and alpha-MEM cultures. 
Accordingly, the levels of SCI/MIP-la and MIP-lp mRNA were assessed in BMDM 
four hours after culturing in SF12 medium with the addition of various concentrations 
of DHS in the presence or absence of 20% L929CM. The four hour time point was 
chosen as this represented the peak of accumulation of both SCI/MIP-la and MIP-1 P 
mRNA transcripts on refeeding with SF12 medium, as illustrated in figure 6.2.
Figure 6.3 shows the results of a representative of one of two experiments. It can be 
seen that DHS reduces the level of mRNA for both SCI/MIP-la and MIP-1 P mRNA 
after four hours in a dose-dependent manner. In this experiment, the presence of 20% 
L929CM appears to have a positive effect on the levels of both transcripts, however, 
this effect was not seen in all of these experiments; as stated above, this inconsistency 
in the effect of L929CM was a persistent feature of experiments carried out in SF12 
medium.
To assess the specificity of the effect of DHS on the induction in SF12 medium and 
to assess the suitability of using FCS in this system, the effect of various 
concentrations of FCS on the accumulation of SCI/MIP-la mRNA on refeeding 
BMDM with SF12 medium was assessed. It was found that FCS was unable to cause 
the same down-regulation in the level of SCI/MIP-la mRNA as DHS even when 
used at 20% of the total volume of the medium (figure 6.4), mirroring the differential
149
:: K iff§4 J I
mip-1 a
7S
mip-1 b 
7S
0  2 4  6 8 10 12
hours post SF refeed
Figure 6.2 Northern analysis of the time course of accumulation 
of SCI/M IP-la and M IP-lp mRNA in BMDM refed with SF12 
medium.
Total cellular RNA was isolated from BMDM 0, 2, 4, 6, 8 and 10 
hours after refeeding with SF12 medium and blotted in equal am ounts 
(20|ig) onto nylon membrane. Equal loading was confirm ed by 
hybridisation with a 7S probe.
Figure 6.3 Northern analysis of accumulation of SCI/MIP-la 
and MIP-ip mRNA in BMDM after refeeding with SF12 
medium in the presence and absence of various concentrations 
of DHS plus or minus 20% L929CM.
Upper panel, SCI/MIP-la mRNA. Lane 1, untreated BMDM; 
lanes 2-6, BMDM refed with SF12 medium in the presence of 0, 5, 
10, 15 and 20% DHS; lanes 7-11, BMDM refed with SF12 
medium containing 20% L929CM in the presence of 0, 5,10, 15 
and 20% DHS; lane 12, untreated STO cells; lane 13, untreated 
J774.2 cells. Equal loading was confirmed by hybridisation with a 
7S probe.
Lower panel, MIP-lp mRNA. Lane 1, untreated BMDM; lanes 2- 
6 , BMDM refed with SF12 medium in the presence of 0, 5, 10, 15 
and 20% DHS; lanes 7-11, BMDM refed with SF12 medium 
containing 20% L929CM in the presence of 5, 10, 15, 20 and 0% 
DHS. Equal loading was ensured by ethidium bromide staining of 
the gel.
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Figure 6.4 Northern analysis of the accumulation of SCI/MIP- 
l a  mRNA in BMDM in the presence or absence of various 
concentrations of FCS.
Total cellu lar RNA was isolated after 4 hours and blotted in equal 
am ounts onto nylon m em brane. Lane 1, untreated  BM D M ; lanes 2- 
6, BM D M  refed with SF12 m edium  in the presence o f  0, 5, 10, 15 
and 20%  FCS; lanes 7-11, BM D M  refed w ith SF12 m edium  
containing 20%  L929C M  in the presence o f  0, 5, 10, 15 and 20%  
FCS.
effects of the two sera on the accumulation of SCI/MIP-la and MIP-1 P mRNA in 
alpha-MEM medium.
The ability of DHS to oppose the accumulation of SCI/MIP-la and MIP-lp mRNA 
was further investigated by comparing this with the effect of hydrocortisone, which 
had been shown to have a similar effect (as discussed in chapter 4). Again the four 
hour time point was chosen to assess the effects of these agents. It can be seen from 
figure 6.5 that both DHS and hydrocortisone are able to reduce the levels of both 
SCI/MIP-la and MIP-ip mRNA.
When the combined effects of DHS and hydrocortisone on the levels of SCI/MIP-la 
and MIP-lp in serum-free medium were assessed (figure 4.4) it was found that these 
were additive and that the two agents in combination reduced the level of both 
transcripts to approximately control levels. However, even when both of the 
repressive factors were combined a basal level of both SCI/MIP-la and MIP-lp 
mRNA could still be detected. This makes it possible that both DHS and 
hydrocortisone exert their effects on the level of mRNA for both SCI/MIP-la and 
MIP-1 P at the level of mRNA stability rather than transcription as it had already been 
demonstrated (in chapter 4, figure 4.4) that the basal levels of these mRNA 
transcripts expressed in resting BMDM was sensitive to actinomycin D, from which it 
was inferred that the expression of the basal levels was dependent on ongoing 
transcription. If either or both of the above-mentioned agents had been negatively 
affecting transcription of these genes it is unlikely that a basal level of transcript 
could have been detectable when both agents were used in combination, considering 
the profound effects of both agents in downregulating the levels of both SCI/MIP-la 
and MIP-1 P mRNA. This assumes, of course, that the mechanisms underlying the 
expression of a basal level of SCI/MIP-la and MIP-ip mRNA are the same in SF12 
as in alpha-MEM medium.
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Figure 6.5 Northern analysis of the accumulation of SCI/MIP- 
l a  and MIP-lp mRNA in BMDM in SF12 medium in the 
presence or absence of DHS (25%) and/or hydrocortisone.
Total cellular RNA was isolated after four hours and blotted in 
equal amounts (20|ig) onto nylon membrane. Lane 1, BMDM 
refed with SF12 medium; lane 2, BMDM refed with SF12 medium 
plus lO'^M hydrocortisone; lanes 3 and 5, BMDM refed with 
SF12 medium plus 25% DHS plus HT^M hydrocortisone; lanes 4 
and 6 , BMDM refed with SF12 medium plus 25% DHS plus 10" 
^M hydrocortisone; lane 7, BMDM refed with SF12 plus 25% 
DHS; lane 8 , BMDM refed with SF12 medium plus 20%
L929CM; lane 9, BMDM refed with SF12 medium plus 20% 
L929CM plus 10'^M hydrocortisone; lane 10, BMDM refed with 
SF12 medium plus 25% DHS plus 20% L929CM; lane 11, BMDM 
refed with SF12 medium plus 25% DHS plus 20% L929CM plus 
10'^M hydrocortisone; lane 12, untreated BMDM. Equal loading 
was confirmed by ethidium bromide staining of the gel.
DH
S
In this experiment L929CM does not appear to have any effect, apart from the fact 
that it seems to have reduced the accumulation of MIP-1 (3 mRNA upon refeeding 
with SF12 medium, (compare lanes 8  and 1). This is in contrast to the effects seen 
with L929CM in alpha-MEM medium containing 25% DHS (as demonstrated in 
chapter 5) and also to the effect seen in SF12 medium in figures 6.1 and 6.3).
The transient accumulation of SCI/MIP-la and MIP-lp mRNA in BMDM on culture 
in serum-free medium was unexpected as this medium contains no growth factors, 
mitogens or hormones other than insulin (which is supplied by the serum-free 
supplement). It is possible that the rise was due to the effects of non-specific cellular 
stress but this was thought to be unlikely for several reasons. Firstly, it had already 
been demonstrated in chapter 3 (figure 3.10) that the survival of BMDM in serum- 
ffee medium is not inferior to that seen with the growth medium (alpha MEM 
containing 20% L929CM), indeed it was apparently enhanced on addition of either 
L929CM and/or DHS to SF12 medium. Secondly, the induction is transient, which 
implies control at both induction and in termination of expression. It is unlikely that 
an increase due to non-specific effects would display such characteristics. The fact 
that hydrocortisone downregulated the expression of both transcripts in SF12 medium 
both in the presence and the absence of 25% DHS also suggested that the gene 
expression machinery of the cell was intact, again arguing against a non-specific 
inductive effect of culturing in SF12 medium. In addition to this, the elevation of both 
the mRNA transcripts studied is specifically down-regulated by one type of serum but 
not another, which argues against the possibility that the down-regulation seen with 
DHS is not due to an increase in cell viability due to non-specific trophic effects. This 
fact also argues that the induction in serum-free medium was not due to non-specific 
effects of the absence of serum such as changes in pH or osmolarity. Nevertheless, 
the pH and osmolarity of SF12 medium was checked and found to be within the 
normal range (data not shown). Furthermore, the level of 7S RNA is not affected by
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this treatment which argues against a non-specific effect on general RNA 
metabolism. It may have been instructive, however, to follow changes of the mRNA 
for another lymphokine gene in the same cells to gauge whether this effect was 
specific to the MIP-1 transcripts or was general for other inducible genes.
6.3 Summary of Chapter 6 .
The expression of SCI/MIP-la and MIP-1 P mRNA in BMDM on culturing in a 
specially formulated serum-free medium (SF12) was assessed. In SF12 medium 
alone, it was found that the level of both SCI/MIP-la and MIP-lp mRNA was 
increased in a rapid and transient manner, suggestive of this being part of the early 
response to stimulation, in a similar way to that seen by treatment of the BMDM with 
either LPS, L929CM or FCS.
Both DHS and hydrocortisone downregulated the level of SCI/MIP-la and MIP-lp 
mRNA in BMDM in SF12 medium. The effects of these two agents was additive; 
therefore the accumulation of SCI/MIP-la and MIP-1 P mRNA accumulation in 
BMDM in SF12 medium was demonstrated to be able to be both induced and down- 
regulated. However, the effects of L929CM on the accumulation of these transcripts 
was highly variable between experiments which suggested that this culture system 
was unsuitable for studying the effects of growth factors on accumulation of 
SCI/MIP-la and MIP-lp mRNA.
The marked ability of DHS to downregulate the accumulation of both SCI/MIP-la 
and MIP-lp mRNA may mean that the effects of some inducing agents might be 
masked when DHS is included in the culture system, especially if the induction is 
modest; this suggests that DHS may not be the most suitable serum for use in the 
study of SCI/MIP-la and MIP-lp gene expression.
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Taken together, the data presented in this chapter indicate that SF12 is not a suitable 
culture medium for the assessment of candidate cytokine regulators of SCI/MIP-la 
and MIP-lp gene expression.
However, although the experiments detailed immediately above and in chapter 5 
describe the use of an experimental system for assessing the effects of various agents 
on the accumulation of SCI/MIP-la and MIP-1 P mRNA, the data are sufficient to 
allow conclusions to be drawn about other aspects of the expression of SCI/MIP-la 
and MIP-lp mRNA in BMDM especially with respect to its relationship to cellular 
proliferation.
It has often been speculated that the induction of expression of many cytokine genes 
in the process of macrophage and T lymphocyte activation or proliferation is directly 
coupled to the mitogenic response and subsequent DNA synthesis; for example Hume 
and Gordon (1984) and Grimaldi et al (1986) in the case of u-PA expression in 
macrophages and keratinocytes and fibroblasts, respectively. Siderovski et al (1990) 
have argued for a direct link between the induction of accumulation of mRNA for 
human MIP-1 a  (GOS 19-1) in activated human T peripheral blood mononuclear cells 
and GO to G1 transition of the cell cycle. This is a particularly attractive hypothesis 
for the expression of cytokine genes given that they are generally expressed within a 
similar time frame after stimulation as proto-oncogenes believed to be involved in the 
initial commitment to proliferation. These two types of genes often have 5' regulatory 
elements in common such as consensus sequences for the binding of the 
transcriptional regulator AP-1 and elements shown to be involved in the 
transcriptional response to serum and oestrogen (for review see Hall and Stiles 1989) 
which suggests that it is likely that their expression is controlled by similar genetic 
programmes.
Plumb et al (1991) have also postulated that such a coupling, in the case of the 
expression of SCI/MIP-la, could be directly relevant to its role as an inhibitor of
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haemopoietic stem cells. They postulate that production of SCI/MIP-la from 
proliferating cells at the mature end of the monocyte/macrophage lineage could 
constitute a feedback signal to proliferating stem cells which is independent of the 
resident bone marrow macrophage population. The fact that the induction of 
accumulation of SCI/MIP-la and MIP-lp mRNA has been shown in this study to 
have properties characteristic of "immediate early" genes strengthens this hypothesis. 
If the thymidine incorporation and mRNA expression data of chapters 3 and 5 and the 
results of this chapter are compared it is possible to comment on this idea with 
respect to the expression mRNA for SCI/MIP-la and MIP-lp in BMDM.
Figure 6 . 6  shows a summary table of the effects of different culture conditions on 
both the proliferation of BMDM and their expression of mRNA for SCI/MIP-la and 
MIP-lp.
An increase in the expression of SCI/MEP-la and MIP-lp mRNA is coincident with 
the induction of proliferation when BMDM are cultured in the presence of 20% 
L929CM in alpha MEM medium containing either DHS or FCS, which suggests a 
coupling between the two processes. However, the rest of the data demonstrates that 
these two processes can be regulated independently of each other. For example, the 
level of both transcripts can be increased in the absence of subsequent proliferation 
on culturing BMDM in SF12 medium alone or in alpha MEM medium containing 
25% FCS in the absence of L929CM. It also seems to be possible to have a reduction 
in the level of both SCI/MIP-la and MIP-lp mRNA in BMDM which will 
subsequently proliferate as BMDM cultured in the presence of SF12 plus 20% 
L929CM, which do not proliferate, express a higher level of both SCI/MIP-la and 
MIP-lp mRNA than those cultured in SF12 with both 20% L929CM and 20% DHS 
which have been demonstrated to be proliferating rapidly after twenty hours. 
Therefore, although coincident expression of SCI/MIP-la and MIP-lp can be 
induced by one set of conditions, the coupling between these two processes is not
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Figure 6.6 The accumulation of SCI/MIP-la and MIP-ip 
mRNA versus proliferation (DNA synthesis) in bone marrow- 
derived macrophages.
This figure summarises several sets of experiments with regards to 
both the accumulation of SCI/MIP-la and MIP-lp mRNA and the 
induction of DNA synthesis in BMDM in several different culture 
conditions.
Induction of proliferation (DNA synthesis) is denoted by (+), while 
its absence is denoted by (-).
Relative levels of the accumulation of SCI/MIP-la and MIP-lp 
mRNA (arbitrary units) are denoted by the number of crosses (+).
absolute. Hence, it would then follow that the programmes regulating BMDM 
proliferation and the expression of SCI/MIP-la and MIP-lp are may be overlapping 
but are not identical.
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Chapter 7
Expression of SCI/MIP-la mRNA in Murine Bone Marrow.
7.1 Introduction.
In chapters 3 to 6 , the use of a system which allows the expression of mRNA for both 
SCI/MIP-la and MIP-lp in primary murine macrophages to be studied was 
described. However, as with most cytokines, the role which this expression plays in 
marrow homeostasis, if any, is unclear, although observations by several 
investigators, as discussed in chapter 1 have strongly suggested the ability of 
SCI/MIP-la and/or the Manchester Inhibitor to act as a physiological regulator of 
CFU-S proliferation in vivo.
Initial experiments in this study (chapter 3, figure 3.13) had shown that mRNA for 
SCI/MIP-la could be readily detected by Northern blotting, demonstrating 
expression of the gene in normal, unperturbed marrow. It was reasoned that it might 
be possible to exploit this situation to study changes in the level of expression of 
SCI/MIP-la in the bone marrow in relation to changes in the cycling of stem cells. If 
so, it might be possible to generate evidence for or against a role for SCI/MIP-la 
gene expression in stem cell proliferation regulation in vivo and also set up a model 
which would allow for further analysis of the mechanisms and signals underlying this 
expression in vivo. Two model systems utilising drugs with well characterized effects 
on the haemopoietic system were used for this purpose.
5-fluorouracil (5-FU) is an agent which kills proliferating cells through its ability to 
inhibitjthymidylate synthetase activity and, hence, DNA synthesis. 5-FU may also 
affect some non-proliferating cells as it can affect the metabolism of RNA (Parker 
and Cheung 1991).
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This drug has been shown to have profound effects in both the short- and the long­
term on the haemopoietic compartment. Marrow cellularity is reduced by between 80 
and 95% by four days after a single injection of 5-FU and has regenerated to 
approximately normal levels by days twelve to fourteen. A transient overshoot of cell 
number is often seen at this time (Hodgson and Bradley 1979; Lemer and Harrison 
1990; Harrison and Lemer 1991; Rich 1991).
Lorimore et al (1990) observed that both the CFU-S and CFU-A compartments are 
extremely sensitive to a single injection of 5-FU with all three compartments being 
reduced by approximately 98% within twenty-four hours of a single injection and that 
these primitive cells display characteristic recovery patterns. CFU-S recover from the 
drug-induced nadir to approximately control levels at day 7-8. This is followed by an 
overshoot in CFU-S numbers which reaches a peak of four-fold over control by day 
15. CFU-S numbers have returned to control levels by day 18. Lorimore et al (1990) 
also observed that CFU-A exhibit a biphasic pattern of recovery with numbers 
returning to 2.5 times control by day 8 , decline over the next five days then reach 
another peak at twice control values at day 15 before returning to control values by 
18.
Pluripotential Haemopoietic Stem Cells (PHSC), as defined by the repopulation 
studies of Harrison et al (1980), on the other hand, are resistant to a single injection of 
5FU (Lemer and Harrison 1990). However, they are sensitive to a second injection, 
the effect of which is dependent on its time after the first injection. From these studies 
it can be concluded that the PHSC cycle rapidly during the initial recovery phase with 
the greatest proliferation at days 3-5. Proliferation has returned to control levels by 
day 8  (Harrison and Lemer 1991).
5-fluorouracil has also been demonstrated to have characteristic effects on lineage- 
committed cells. Vetvicka et al (1986) have demonstrated that B lineage cells in the
157
marrow are extremely sensitive to 5-FU with a profound depletion in their numbers 
by 24 hours which do not return to control levels for 4-5 weeks.
The effects of 5-FU on the erythropoietic compartment have also been documented 
(Rich 1991). A single injection severely reduces all of the mature eythroid and in 
vitro erythropoietic progenitors. A transient overshoot of the BFU-E and CFU-E 
populations on days 6  and 7 leads to a profound reticulocytosis after day 9. 
Phenylhydrazine (PHZ) is another drug with well documented effects on 
haemopoiesis, causing a severe anaemia through erythrolysis (Rencricca et al 1970). 
Rencricca et al (1970) demonstrated that CFU-S migrate from the marrow to the 
spleen five days after initiation of a course of phenylhydrazine. The CFU-S 
remaining in the marrow enter cell cycle on day 7, presumably to self-renew in order 
to restore marrow CFU-S numbers to a full complement. The proliferation of CFU-S 
returns to normal by day 9. A slight overshoot of CFU-S numbers is observed 
between days twelve and sixteen after drug treatment.
Interestingly, Lord and Wright (1982) had demonstrated that CFU-S inhibitory 
activity (Manchester Inhibitor) could not be detected in marrow from mice seven 
days after the beginning of a course of phenylhydrazine but could be readily detected 
on day nine. This is strong evidence for the Manchester Inhibitor playing a role in the 
control of CFU-S proliferation.
As mRNA for SCI/MIP-la could be detected in normal untreated bone marrow it 
was reasoned that any alterations in the level of expression of this transcript which 
were associated with disruption of the haemopoietic system would be detectable by 
Northern blotting and that it might be possible to relate these to changes in stem cell 
physiology.
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7.2 Expression of SCI/MIP-la mRNA in Post 5-FU Bone Marrow.
The effects of a single injection of 5-fluorouracil on the level of SCI/MIP-la mRNA 
expressed in the marrow of female B6D2F1 mice was assessed by Northern blotting 
at various times after treatment.
To ensure that 5-FU was having an effect on the marrow and to monitor changes in 
stem cell cycling, both marrow cellularity and the cycle status of CFU-A were 
followed during the course of the experiment. These data are presented in figure 7.1. 
It can be seen that on day 8  following a single injection of 5-FU, the numbers of cells 
per femur were between 10 and 20% of normal controls counted on the same day. By 
day 24 numbers had returned to normal. A similar pattern was observed in two other 
experiments. These figures were in general agreement with those of Lemer and 
Harrison (1990) and other reports in the literature.
The cycling status of CFU-A in the marrow at times after 5-FU was assessed by 
cytosine arabinoside suicide assay. From figure 7.1 it can be seen that at day 8  post 5- 
FU approximately 60% of CFU-A are proliferating. By day 12, cycling has returned 
to control values. It should be noted that these are the results of a single experiment 
and that several repetitions would be required to constitute a thorough investigation 
of CFU-A proliferation in response to 5-FU. Nevertheless, these values do agree with 
results published for CFU-S (Shibagaki et al 1986) and recently for CFU-A (Dunlop 
et al 1992).
When the expression of SCI/MIP-la mRNA in post 5-FU bone marrow was 
evaluated an unexpected pattern of expression was obtained. It can be seen from 
figure 7.2 (panel B) that at days 8  and 11 post 5 FU the marrow expresses two readily 
detectable transcripts; this level is approximately equal to that of the untreated 
control. However, on days 18,20 and 22 the intensity of these two bands increases. 
By day 28 the intensity of hybridisation has declined, but is still at an elevated level.
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Figure 7.1 Bone marrow cellularity and CFU-A cycling 
following treatment of B6D2F1 mice with 5-fluorouracil 
(150mg/kg).
Bone marrow cells were counted electronically. Data is presented 
as the mean count from three femora from experimental animals 
expressed as a percentage of the mean count from three femora 
from control animals counted on the same day.
Percentage of CFU-A in cycle was determined by cytosine 
arabinoside "suicide" assay as described in chapter 2 .
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Figure 7.2 Northern analysis of the accumulation of SCI/MIP- 
l a  mRNA in total murine bone marrow following treatment of 
animals with 5-FU (150mg/kg).
Panel A: Total cellular RNA was isolated and blotted in equal 
amounts (5|ig) onto nylon m em brane 0, 8, 12, 16, 20, 22, 24, 26 
and 28 days after 5-FU treatm ent (lanes 1-9). Lane 10, 10|!g total 
RNA from untreated J774.2 cells. Equal loading was ensured by 
ethidium bromide staining o f the gel.
Panel B: Total cellular RNA was isolated and blotted in equal 
amounts (5 |ig) onto nylon m em brane 0, 8, 11, 13, 15, 18, 20, 22 
and 28 days following 5-FU treatm ent. Equal loading was ensured 
by ethidium bromide staining o f the gel.
A similar, though less marked pattern of accumulation is seen in panel A of figure 7.2 
which represents a separate experiment.
In panel A an additional higher molecular weight band is also seen, although this 
appears to be artefactual and produced by non-specific hybridisation, suggested by 
the fact that this band is also seen in the positive control. The loading of RNA on the 
formaldehyde gel was approximately equal and could not account for the differences 
in intensity of hybridisation, so the increase in the amount of RNA hybridising to the 
SCI/MIP-la probe appears to be a genuine effect. A similar pattern of expression was 
found in one other experiment. It is unlikely that the additional band, seen at the same 
level as that of SCI/MIP-la mRNA arose as a result of non-specific hybridisation, 
which, as mentioned in chapter 3, is a common problem with riboprobes, for two 
reasons:
1) If the additional band was seen as a result of non-specific hybridisation, the band 
would be present in the lane containing the positive control, but this was not the case.
2) The RNA samples in both of the experiments illustrated in figure 7.2 were 
reblotted and hybridised with separate probes three times and one of these occasions 
were washed at 70 rather than 65°C, to reduce the possibility of non-specific binding 
and still gave the same pattern of hybridisation.
Two aspects of this expression pattern, were of potential interest as regards possible 
roles of SCI/MIP-la in haemopoietic stem cell regulation.
Firstly, the timing of the increase in the level of expression of SCI/MIP-la at later 
times may indicate a role for SCI/MIP-la in inducing or maintaining quiescence of 
the CFU-S/CFU-A compartment of the marrow as the upregulation corresponds 
roughly with the descent from the peak of post 5-FU-induced cycling.
The double band was also of great interest as the soluble and matrix-associated forms 
of LIF identified by Rathjen et al (1990) are translated from two mRNA transcripts 
which are generated by alternative promoter usage. It seemed possible, therefore, that
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the Northern blotting analysis of post 5-FU bone marrow could have been detecting 
mRNA encoding two distinct forms of the SCI/MIP-la protein.
Alternatively, the additional band may have represented a slowly-spliced precursor of 
the mature SCI/MIP-la mRNA, which raised the possibility that mRNA processing 
might be a point of control, or at least a rate-limiting step, in the production of 
SCI/MIP-la in the marrow.
It was, therefore, decided that the nature of the additional transcript observed in the 
initial experiments was worth pursuing because of the potentially important 
ramifications for our understanding of the biology of SCI/MIP-la.
An attempt was made to determine whether the upper band might contain intronic 
sequence which would indicate that this was a precursor of SCI/MIP-la mRNA.
The approach taken was to generate, as a polymerase chain reaction product, a probe 
specific for the first intron of the SCI/MIP-la gene. It was reasoned that if spliced 
intermediates were represented in the extra bands expressed post 5-FU, then their 
presence would be detected by hybridising with a DNA probe against an intron 
sequence as introns do not constitute a part of the mature messenger RNA. The first 
intron was chosen because comparison of the relative sizes of the two SCI/MIP-la- 
specific bands indicated that the difference in size was in approximately the same 
range as the length of this intron.
The radioactive intron 1 probe was hybridised against total cellular RNA from 
unfractionated post 5-FU bone marrow. Unfortunately, the signal to noise ratio in this 
experiment was too low for any discrete hybridisation bands to be detected and no 
useful information was generated by this experiment. In hindsight a much more 
efficient probe could have been generated by cloning the intron 1 sequence into a 
riboprobe vector. In addition, this experiment had a basic design fault in that a 
negative result was uninterpretable. As using the technique described above proved 
unfruitful, the problem was approached from a different angle.
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The poly A-positive (poly (A+) fraction of cellular RNA contains, in addition to the 
mature messenger RNA molecules, the intermediate nuclear processing forms of 
genes transcribed by RNA polymerase n. However, it does not contain any of the 
structural or ribosomal RNA molecules. It was reasoned that hybridisation of the 
SCI/MIP-la riboprobe to poly (A+) RNA from post 5-FU mice would only lead to 
the detection of RNA molecules associated with the production of mature RNA 
coding for the SCI/MIP-la protein.
Total cellular RNA was extracted from the femoral bone marrow of mice at various 
times after treatment with 5-FU and the poly (A)+ fraction of these samples isolated. 
When the level of SCI/MIP-la mRNA was assessed by Northern blotting analysis, a 
similar but non-identical pattern of hybridisation was seen (figure 7.3).
A single transcript was expressed in normal, untreated marrow (as before) and the 
level of expression increased dramatically (at least 2 0 -fold as assessed by laser 
densitometry) at day 1 2 , had begun to decline by day 2 0  and had disappeared by day 
24. The double band pattern of hybridisation seen at later times after 5-FU with total 
RNA was not evident in this experiment which suggests that these transcripts are not 
involved in the production of the mature SCI/MIP-la mRNA.
Nevertheless, the rise in the level of SCI/MIP-la mRNA around day 12 post 5-FU is 
borne out by using poly (A)+ RNA which demonstrates that this is a genuine effect. It 
is important to note, however, that the timing of the rise of SCI/MIP-la mRNA is 
extremely variable between experiments which should be borne in mind when 
interpreting the data.
This data suggests several possibilities. Firstly, it could be argued that there is a 
connection between the late rise in SCI/MIP-la mRNA and the return of the CFU- 
A/CFU-S compartment to the quiescent state. In this case, upregulation of expression 
of SCI/MIP-la mRNA might be associated either with inducing or maintaining a 
quiescent state in the myeloid stem cells. The variation in the timing of the
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Figure 7.3 Northern analysis of the accumulation of SCI/MIP- 
l a  mRNA in the poly(A)+ fraction of RNA from total murine 
bone marrow after treatment of animals with 5-FU 
(150mg/kg).
Total cellular RNA was isolated and blotted in eaual amounts 
( l |ig )  onto nylon m em brane 0, 8, 12, 16 and 24 days after 
injection. Equal amounts o f RNA were loaded according to 
spectrophotom etric m easurement.
upregulation of SCI/MIP-la mRNA makes it unlikely that this is a critical event for 
inducing quiescence.
It is, however, possible to envisage that a strong inhibitory signal is necessary to 
overcome the extremely powerful proliferative signals which must be part of the 
regeneration process; therefore the data is not inconsistent with a role for SCI/MIP- 
l a  in the maintenance of myeloid stem cell quiescence.
On the other hand, it may be more useful to think of the increase in expression as part 
of macrophage-bome wound and/or tissue remodelling response to the profound 
changes in marrow architecture which must accompany the action of 5-FU and the 
response which it elicits.
It should also be borne in mind that 5-FU has been demonstrated to have profound 
effects on RNA metabolism (Parker and Cheung 1991).
The nature of the additional RNA band hybridising to the SCI/MIP-la-specific probe 
is unclear. The data indicate that it is not a precursor or mature mRNA but is 
probably not seen as a result of non-specific hybridisation. One possibility is that it is 
an unusual metabolite of SCI/MIP-la mRNA which is induced by the drug treatment. 
Wilkenson and Pitot (1973) have demonstrated that incubation of cells with 5-FU 
inhibits the maturation of the 45S ribosomal RNA (rRNA) precursor to the 18 and 
28S molecules. Will and Dolnick (1987) have shown that 5-FU causes an increase in 
the level of an unspliced precursor of the dihydrofolate reductase (DHFR) mRNA. In 
addition, Dolnick and Pink (1983) have shown that treatment of KB cells can increase 
the accumulation of the mature DHFR mRNA transcript by 3-fold. Therefore, it can 
be seen that both the metabolism and the accumulation of mRNA can be affected by 
5-fluorouracil. However, it seems unlikely that interference with the metabolism of 
SCI/MIP-la mRNA could account for the pattern of expression seen in regenerating 
marrow two weeks after injection of 5-FU as clearance of 5-FU (via the liver) is an
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extremely rapid process, and happens within a few days at the most (Parker and 
Cheung 1991).
7.3 Expression of SCI/MIP-la mRNA in Post-Phenvlhvdrazine Bone Marrow.
A salient feature of the 5-FU model is that marrow regeneration is dependent on 
increased CFU-S proliferation which means that these two processes can not be 
studied separately in this model. In an attempt to differentiate between the these two 
possibilities, the expression of SCI/MIP-la mRNA in bone marrow at various times 
after mice had been treated with phenylhydrazine (PHZ) was assessed. For this study, 
the advantage with using PHZ to alter CFU-S proliferation is that this can be 
achieved without a profound change in marrow cellularity which means that any 
changes in gene expression in the marrow as a result of tissue remodelling will be 
kept to a minimum. In addition to this, any changes in the level of SCI/MIP-la 
mRNA observed during the course of the experiment could be related to the 
observations of Lord and Wright (1982) on changes in the level of the Manchester 
Inhibitor, as discussed above.
Phenylhydrazine was administered according to the method of Rencricca et al (1970). 
Spleen weight and marrow cellularity were followed throughout the course of 
treatment to ensure that the drug was acting. In the expected manner, Marrow 
cellularity was not greatly affected by the treatment (figure 7.4) as previously 
observed by Rencricca et al (1970). The average wet splenic weight was increased by 
approximately 500% over control values on days seven and nine after treatment with 
drug but had returned to control values by day 10 (figure 7.5). It should be noted that 
wet spleen weight is not a direct measure of spleen cellularity as the spleen 
vasculature and its associated blood will be making a contribution to the overall 
weight. Nevertheless, the data in figure 7.5 is indicative that the phenylhydrazine 
treatment is inducing the "emergency" haemopoiesis which is a characteristic reaction
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Figure 7.4 Bone marrow cellularity in murine femora following 
treatment with phenylhydrazine (60mg/kg).
Bone marrow cells were counted electronically and data presented as 
the mean determination from three femora.
Figure 7.5 Mouse splenic weight following treatment with 
phenylhydrazine (60mg/kg).
Splenic weight was measured using an electronic balance. Data is 
presented as the mean weight of 4 spleens plus or minus one standard 
deviation.
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to the anaemia induced by the drug. A deepening in the red colour of the spleens at 
times following drug administration was also indicative of splenic erythropoiesis. 
Attempts were also made to measure the proportion of CFU-A in cell cycle at 
different times after phenylhydrazine, in the same manner as for post 5-FU marrow. 
Unfortunately, these experiments did not yield any interpretable results.
The expression of SCI/MIP-la mRNA in post-PHZ marrow was first assessed by 
Northern analysis of total RNA samples prepared from femoral marrow of mice at 
various times after treatment. It can be seen from figure 7.6 that no changes in the 
expression of SCI/MIP-la mRNA could be detected, indeed no message could be 
detected even in samples from untreated mice. A band corresponding to the correct 
size could, however, be detected in total RNA prepared from the macrophage cell line 
J774.1 and each lane was shown to contain approximately equal amounts of RNA by 
hybridisation to a probe for the 7S RNA which demonstrates that the hybridisation 
and transfer of the RNA was efficient. This experiment was repeated twice and the 
samples from each experiment reblotted and hybridised twice with identical results. 
Even on exposure of the filters for periods up to 4 weeks no bands hybridising to any 
lanes other than that containing the positive control sample could be detected. This 
was a surprising finding as SCI/MIP-la mRNA had been readily detectable in 
normal, murine bone marrow in previous experiments (chapter 1, figure 3.13). There 
had been no change in the experimental conditions or method which suggests that the 
difference lay in the experimental animals.
It has been previously documented (Metcalf 1984) that bone marrow colony 
stimulating activity in murine serum disappears on housing mice in strict pathogen- 
free conditions. A change in the living-conditions of the strain of mice used 
throughout this study could be one explanation for the change in ability to detect 
SCI/MIP-la mRNA given that it is expected that the gene product plays a role in the
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Figure 7.6 Northern analysis of time course of accumulation of 
SCI/M IP-la mRNA in total murine bone marrow after 
treatment of animals with phenylhydrazine (60mg/kg).
Total cellular RNA was isolated and blotted in equal am ounts 
(10|ag) onto nylon m em brane. Lane 1, RNA ladder; lanes 2-6, total 
cellular RNA isolated from total murine bone m arrow 0, 3, 5, 7 
and 10 days after phenylhydrazine; lane 7, untreated STO  cells; 
lane 8, untreated J774.2 cells. Equal loading was confirm ed by 
hybridisation with a 7S probe.
immune response. However, there was no obvious reason to suspect that this might be 
the case for the mice used in this study.
It should also be noted that on administration of bacterial endotoxin to mice, Troutt 
and Lee (1989) observed induction of accumulation of mRNA for IL -la  and IL- 6  in 
lung and heart but failed to observe accumulation of any of a number of haemopoietic 
growth factor mRNAs in bone marrow, so bacterial infection may not necessarily be 
associated with changes in the expression of cytokine mRNAs in the marrow.
The inability to detect SCI/MIP-la mRNA by Northern blotting of total RNA did not 
necessarily mean that the gene was not being expressed at all as it was possible that 
the message was still present in bone marrow but at a level too low for detection 
using this technique; thus any changes in the level of SCI/MIP-la mRNA would 
remain undetected.
In order to overcome this problem, more sensitive methods for detecting mRNA were 
employed.
Firstly, the poly(A)+ fraction of total RNA from post-PHZ marrow was isolated and 
subjected to Northern blotting analysis; this allows a greater amount of RNA to be 
analysed at one time. As approximately 1-5% of total RNA is poly(A)+ (Sambrook et 
al 1989), this means that the representation of specific messenger RNAs in these 
samples should be greatly increased. Unfortunately no expression could be detected 
using this method (data not shown).
Next, the polymerase chain reaction (PCR) was employed to detect expression of 
SCI/MIP-la mRNA in post-PHZ marrow. Marrow samples were extracted by the 
author and PCR reactions and Southern blotting and hybridisations of the products 
was performed by Dr.E. Barone of the Beatson Institute.
Preliminary experiments indicated that the level of SCI/MIP-la mRNA in the 
marrow is reduced on day seven of the treatment regime (data not shown) when CFU- 
S should be proliferating rapidly, compared to controls and day five and day nine
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marrow, in which CFU-S are only proliferating minimally. This is strong 
circumstantial evidence of an involvement of SCI/MIP-la in the control of bone 
marrow CFU-S proliferation and mirrors the changes in the levels of the Manchester 
Inhibitor observed by Lord and Wright (1982).
7.4 Summary of Chapter 7.
The level of mRNA for SCI/MIP-la in the femoral bone marrow of female B6D2F1 
mice was investigated before and after treatment with two drugs which have profound 
effects on the haemopoietic system.
The level of SCI/MIP-la mRNA is greatly increased above control levels at variable 
times between twelve and approximately twenty-four days after treatment with a 
single injection of the marrow ablative agent 5-fluorouracil and later declines to 
normal levels. The marrow cellularity and proliferative status of marrow CFU-A were 
also followed over the same treatment period. Femoral marrow cellularity was 
decreased by 80-90% on day eight after treatment and had returned to almost control 
values after twelve days. Reflecting this regenerative process, approximately 60% of 
femoral marrow CFU-A were found to be in cycle on day 8  but had returned to 
control (quiescent) levels by day 1 2 .
The fact that the upregulation of SCI/MIP-la mRNA levels in femoral marrow 
corresponds approximately with the return of the CFU-A compartment to its normal, 
minimally proliferative, status suggests the possibility of an association between the 
two events. However, this is only one explanation for the observed phenomenon; it is 
equally as likely that the upregulation in the levels of this transcript could be 
associated with the extensive tissue remodelling which must accompany 
haemopoietic regeneration.
In an attempt to differentiate between these two possibilities, the level of SCI/MIP-la 
mRNA was assessed in femoral marrow before and after treatment with the
167
erythrolytic agent phenylhydrazine. This agent also has a well-documented effect on 
the proliferation of marrow CFU-S without greatly affecting marrow cellularity; 
hence extensive marrow regeneration is not a feature of the recovery from treatment 
with this agent. Unfortunately, SCI/MIP-la mRNA could not be detected in any of 
these experiments by Northern blotting but polymerase chain reaction (PCR) proved 
to be a sensitive enough technique to detect the presence of SCI/MIP-la mRNA in 
experimental samples.
PCR analysis detected a lower level of mRNA for SCI/MIP-la in post-PHZ marrow 
than controls at a time when CFU-S should be proliferating rapidly but levels were 
restored at times when CFU-S cycling has ceased.
The data presented in this chapter is not inconsistent with changes in SCI/MIP-la 
gene expression playing a role in the control of CFU-A/CFU-S proliferation.
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Chapter 8  
Discussion.
8.1 Introduction.
This chapter will be divided into two main sections. Firstly, the expression of 
SCI/MIP-la and MIP-ip mRNA and the possible underlying mechanisms, 
will be discussed and then the implications of this data for understanding the 
role of SCI/MIP-la and MIP-ip in haemopoietic regulation and other 
processes will be considered.
8.2 Expression of SCI/MIP-la  and MIP-lj^ in Bone Marrow-Derived 
Macrophages.
8.2.1 The use of bone marrow-derived macrophages.
Like all in vitro experimental systems, using BMDM as a surrogate for in vivo 
bone marrow macrophages is a compromise. However, using BMDM has 
definite advantages over the more conventional use of macrophage-like cell
i
lines. The first and most obvious advantage / is that these are an easily obtainable 
essentially homogeneous, primary population and therefore should represent a 
better approximation to "normal" macrophages than cell lines. The difference 
in the length of the period of accumulation of SCI/MIP-la and MIP-lp 
mRNA in BMDM and in the RAW264.7 cells described in chapter 4 (figures
4.1 and 4.2) of this thesis is one example of how the expression of these genes 
might be qualitatively different in primary and transformed cells. The 
apparent dysregulation of expression of the human M IP-la gene in fresh 
leukemic samples and leukemic cell lines (Yamamura et al 1989, Nakao et al 
1990) is another. The BMDM population also has characteristic proliferative
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properties (figures 3.7 to 3.10) and this allows the expression of genes by 
BMDM to be related to DNA synthesis.
In addition, previous investigators (Wright and Lorimore 1987, Pojda et al
1988) have used macrophages cultured from marrow as sources of the 
Manchester Inhibitor, allowing a degree of continuity between this study and 
previous work on the production of negative regulators of CFU-S proliferation 
by macrophages.
An obvious disadvantage with using macrophages derived in vitro from 
monocytic progenitors, is that they have not been exposed to exactly the same 
environment as the macrophages of the marrow stroma. The BMDM 
population has growth properties which are very similar to isolated human 
monocytes (Tushinski and Stanley 1985, Hamilton et al 1988, Cheung and 
Hamilton 1992), which suggests that this population may be more 
representative of blood-borne monocytes than macrophages of the bone 
marrow stroma. The minimal mitotic activity of the resident macrophages of 
the marrow (Crocker et al 1988) might be cited to support this point.
However, this argument may not carry as much weight as first anticipated.
The Manchester Inhibitor-producing population sorted directly from normal 
marrow by Simmons and Lord (1985) on the basis of the expression of the 
F4/80 antigen, which is present on resident macrophages in the marrow 
stroma, proliferate readily. The BMDM population used in this study has very 
similar growth properties to this sorted population (as was demonstrated in 
chapter 3, figure 3.7) which indicates the suitability of using BMDM for 
studying the expression of SCI/MIP-la and MIP-lp in the context of 
haemopoietic regulation.
Adams and Hamilton (1984) have argued that the resident phenotype is 
conferred on macrophages only in the context of the tissue and may be
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reversible. It follows, then, that resident macrophages may actually be 
monocytes upon which a particular phenotype has been conferred by 
geographical location; hence, this would mean that even if a pure population 
of resident marrow macrophages could be sorted directly from bone marrow, 
they would be likely to behave like isolated monocytes in culture, so there 
may, in fact, be no added advantage to be had by studying gene expression in 
a sorted population.
8.2.2 Characteristics of accumulation of SCI/MIP-la and MIP-lj^ mRNA in 
BMDM.
The characteristics of expression of mRNA for SCI/MIP-la and MIP-ip in 
BMDM are extremely similar. The experiments presented in chapter 4 
demonstrated that both the SCI/MIP-la and MIP-lp genes behave like typical 
cytokine genes in that they display the rapid and transient, protein synthesis- 
independent induction of "immediate early"-type genes (figures 4.1 and 4.5). 
Early stimulation of transcription was also demonstrated to be necessary for 
the induction of accumulation of both SCI/MIP-la and MIP-lp mRNA by 
LPS (figures 4.3 and 4.4) indicating that the rapid induction of transcription is 
likely to be the primary control point for the expression of these genes. In 
addition, the accumulation of both SCI/MIP-1 a  and MIP-1 p mRNA is 
downregulated by the glucocorticoid hormone hydrocortisone (figures 4.4.7 
and 4.8), which is again typical of genes whose products have a role to play in 
the inflammatory response and demonstrates that the expression of both of 
these genes can be efficiently downregulated as well as induced.
These characteristics are perhaps not surprising considering that SCI/MIP-la 
and MIP-lp are members of a cytokine family, although it was important that 
this be established in primary cells as it should be noted that not all of the
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MIP-1 family cytokines display these characteristics of expression (Schall et 
al 1988,1992, Orlofsky et al 1991).
The rapid and transient nature of the induction, which was seen with all cases 
of the induction of both SCI/MIP-la and MIP-1 (5 mRNA in BMDM in this 
study, allows a close coupling between stimulus and response. Given the 
ability of these molecules to alter cell behaviour at very low concentrations 
and in view of the possible role of over-production of SCI/MIP-la and MIP- 
lp  in diseases involving chronic inflammation (Wilcox et al 1990, Schall 
1991, Graves et al 1989) and myelosuppression (LPragnell personal 
communication), this "quantal" pattern of expression is likely to be an 
extremely important aspect of the biology of these molecules.
A basal level of mRNA for both molecules is detected in unstimulated 
BMDM which appears to be dependent on ongoing gene transcription, as 
evidenced by the ability of actinomycin D to abolish the basal level of both 
mRNAs (figure 4.4). This basal level was observed, in several different 
experiments, to be refractile to agents which are potent downregulators of 
SCI/MIP-la and MIP-1 P mRNA induction (figures 6.3 and 6.5), which makes 
it possible that the mechanisms underlying the regulation of expression of the 
basal and induced levels of SCI/MIP-la and MIP-lp mRNA are different.
The two mRNAs appear to be co-induced in all the situations examined in this 
study.
Widmer et al (1991) have identified elements in the 5' regulatory region of the 
SCI/MIP-la gene which are conserved in a number of inducible lymphokine 
genes. For example, the promoter region contains two decanucleotide 
elements, CLE1 and CLE2, which are conserved in the promoters of several 
lymphokine genes, including IL-2, IL-3, GM-CSF and G-CSF (Arai et al 
1990). Recent work by M.Grove (personal communication) has indicated that
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the 5' regulatory sequences of the SCI/MIP-la gene bind proteins related to 
the inducible transcriptional activators NFkB and AP-1 upon LPS stimulation 
of the macrophage cell line RAW264.7, again emphasising the designation of 
these genes as belonging to the set induced as part of the early response to 
stimulation and indicating the rapidity of transcriptional activation of both of 
these genes.
Although stimulation of transcription is necessary for the induction of 
accumulation of both of these mRNAs it is possible that stabilisation of the 
mRNA product plays a significant role in determining the exact level of 
mRNA induced as seen for the induction of mRNA for erythropoietin 
(Goldberg et al 1991) and TNFa (Beutler and Cerami 1988). Further studies 
will be needed to determine whether stabilisation of SCI/MIP-la and MIP-lp 
mRNA plays such a role.
The genomic sequence of the MIP-lp gene has recently been obtained 
(M.Plumb personal communication). Interestingly, the promoter sequence 
contains no significant homology with that of SCI/MIP-la, which makes it 
likely that the expression of these genes is controlled by very different 
mechanisms. This is perhaps surprising, given that the two genes may have 
evolved through duplication and subsequent divergence of a common 
ancestral sequence (Wolpe and Cerami 1989, Schall 1991) and the observed 
coinduction of SCI/MIP-la and MIP-1 P mRNA seen in this study. This also 
raises the possibility of differential regulation of the two genes in situations 
other than those employed in this study.
Interestingly, Schuler et al (personal communication) have observed 
accumulation of mRNA for SCI/MIP-la, but not MIP-1 P, on in vitro culture 
of purified epidermal Langerhan's cells.
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Differential control of expression of the two genes is an important question in 
understanding the biology of both SCVMEP-la and MIP-ip, given that the 
biological properties of the two molecules are overlapping but not identical 
and the possible interactive effects of the two molecules. Further studies on 
the incidence, and the underlying mechanisms, of SCI/MIP-la and MIP-1 P 
expression in a wide variety of circumstances will allow this question to be 
answered.
The relationship between the accumulation of SCI/MIP-la and MIP-lp 
mRNA and the proliferation of BMDM has been discussed in detail in the 
summary of chapter 6 . It was demonstrated (and summarised in figure 6 .6 ) 
that while accumulation of both MIP-1 mRNAs can be concomitant with the 
stimulation of proliferation, the two processes can be regulated independently. 
This indicates that while the signals and mechanisms directing the two 
processes may be overlapping, they are not identical. These results are 
consistent with the work of Vairo et al (1990) who demonstrated that the 
proliferation of BMDM could be inhibited independently of a variety of early 
responses including immediate-early gene expression.
Another important issue concerning the expression of SCI/MIP-la and MIP- 
ip  in BMDM is whether changes in mRNA levels are reflected in the 
production of protein by these cells. In chapter 1 of this study (figure 3.16) it 
was demonstrated that upon stimulation with LPS, BMDM can secrete 
sufficient levels of SCI/MIP-la protein to be detected by Western blotting. 
The inability to detect SCI/MIP-la protein in media conditioned by 
unstimulated BMDM by Western blot may suggest that no protein is produced 
in the absence of a specific stimulus. However, it is possible that protein is 
produced by these cells but at a level below the sensitivity of the technique 
used. As demonstrated recently by Kittler et al (1992) such low levels of
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cytokines may still be biologically relevant. Studies with more sensitive 
protein-detection techniques, such as an ELISA assay specific for SCI/MIP- 
l a  may allow this question to be answered. It should be noted, however, as 
discussed in chapter 1, that uncoupling between the synthesis of mRNA and 
its translation into protein, in some circumstances, has been demonstrated for 
several cytokines including, recently, human MIP-1 a  and MIP-1 P (Schall et 
al 1992).
Martin and Dorf (1991) have reported that the accumulation of mRNA for IL-
6  and TNFa induced by IFNyin the J774A.1 cell line is not accompanied by
an increase in levels of protein secreted. It is conceivable that the IFNy- 
%
mediated increase in SCI/MIP-la and MIP-lp mRNA levels in BMDM has 
similar characteristics. It may be that a second signal (such as LPS) or more 
intense stimulation is required to induce translation and/or secretion of the 
cytokine. The question of whether macrophages have the ability to store 
SCI/MIP-la and MIP-lp mRNA in an untranslated form or protein in lieu of 
subsequent secretion is obviously important for a full appreciation of the 
expression of these molecules and is worthy of investigation. This possibility 
also means that caution should be employed when inferring biological activity 
from mRNA expression data. Further studies with antisera which specifically 
recognise SCI/MIP-la and MIP-lp, which are now available, will enable this 
issue to be addressed.
8.3 Expression of SCI/MIP-la mRNA in Murine Bone Marrow.
A low level of mRNA for SCI/MIP-la was detectable in normal, untreated, 
unfractionated marrow by Northern blotting (chapter 3, figure 3.13).
The inability of other investigators to detect mRNA for other cytokines and 
CSFs in the marrow from normal and LPS-treated mice (Troutt and Lee
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1989), and of Fahey et al (1990) to detect expression of SCI/MIP-la and 
MIP-1 P mRNA in murine peripheral blood leukocytes, even when using 
techniques more sensitive than Northern blotting is strongly suggestive of a 
role for SCI/MIP-la in the marrow.
When the ability to detect mRNA for SCI/MIP-la in cell lines representing 
several cell lineages, including fibroblasts, erythroid cells and lymphocytes, 
was tested, it was found that SCI/MIP-la mRNA could only be detected in 
monocytic cells and in a transformed T cell line (chapter 3, figure 3.14).
Given that a basal level of SCI/MIP-la mRNA is expressed in BMDM and 
since cells of the T lymphocyte and mast lineage are extremely rare in the 
marrow (Kincaide et al 1990, Gordon et al 1990) and have to be activated by 
specific immune stimuli to express SCI/MIP-la and/or MIP-1 P mRNA (Burd 
et al 1989, Brown et al 1989), it is likely that cells of the 
monocyte/macrophage lineage are the main producers of SCI/MIP-la mRNA 
in the marrow. The fact that the Manchester Inhibitor can be prepared merely 
by washing unfractionated murine bone marrow suggests that this mRNA 
level is reflected in the production of protein.
The level of SCI/MIP-la mRNA detectable in unfractionated murine bone 
marrow increases dramatically in the recovery period following marrow 
ablation by treatment of mice with the cytotoxic agent 5-fluorouracil (5-FU) 
(figures 7.2 and 7.3). It is unlikely that this increase is a direct consequence of 
the effects of 5-FU on RNA metabolism as discussed in chapter 7. The 
possible biological significance of this increase will be dealt with in the next 
section.
One striking feature of the expression of SCI/MIP-la in total cellular RNA 
extracted from post-5-FU bone marrow was the appearance of two bands 
specifically hybridising to the SCI/MIP-la probe (figure 7.2). The additional
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band suggested that an alternative form of the molecule might be expressed in 
murine bone marrow. However, analysis of poly(A)+ RNA from post-5FU 
marrow (figure 7.3) suggested that the additional band is not polyadenylated 
and hence it is unlikely, but not impossible, that it is representative of a 
messenger RNA. However, the stringency of hybridisation employed in these 
experiments still makes it unlikely that the additional band is an artefact. 
Further experiments will aid the understanding of this potentially interesting 
aspect of the molecular biology of marrow regeneration.
8.4 The Possible Roles of the Control of Gene Expression in the Biology of 
SCI/MIP-la and MIP-lg.
8.4.1 Inflammatory Situations.
Upon injury or infection, organisms initiate synthesis of a complex set of 
mediators which lead to the induction of inflammation at both a local tissue 
and a systemic level (Stadnyck and Gauldie 1991).
Nearly all inflammatory responses to host invasion involve the activation of 
tissue macrophages and infiltrating blood monocytes (Titus et al 1991). The 
ability of macrophages and monocytes to recognise and respond to the 
presence of bacteria, viruses and parasites by the rapid synthesis of cytokines 
l a  and IL-6 , which play major roles in inducing and sustaining an acute phase
inflammatory response, , makes it likely that
macrophage activation plays a pivotal role in this process.
TNFa, IL -la  and IL- 6  have overlapping but non-identical activities in 
mediating the inflammatory response which include the induction of fever, the 
elicitation of specific acute phase response proteins from hepatocytes and the 
differentiation and/or activation and augmentation of the effector functions of 
T cells, B cells and/or macrophages. These cytokines can also induce the local
such as TNFot,
177
synthesis of other cytokines from tissue fibroblasts and endothelial cells. In 
addition, TNFa and EL-la can induce the synthesis of each other and IL-6 . 
The concentration of cortisol (hydrocortisone) in the circulation is greatly 
increased as part of this process and may be important as a general 
downregulatory signal (Stadnyck and Gauldie 1991).
An early response-type expression pattern would be expected of the genes for 
proteins with such properties and indeed this pattern of expression is exhibited 
in macrophages by these three genes (Dinarello 1991, Beutler and Cerami 
1988).
Evidence is accumulating which associates the MIP-1 proteins with 
inflammatory situations (Fahey et al 1990) and indicating the ability of these 
proteins to induce leukocyte mobilisation (Wolpe and Cerami 1989, Schall 
1991, Saukonnen et al 1991, Fahey et al 1992) and fever (Davatelis et al 1989, 
Minano et al 1990) as discussed in chapter 1.
Since it has been demonstrated in this study that the accumulation of 
SCI/MIP-la and MIP-lp mRNA (figures 4.1 to 4.6), and secretion of 
SCI/MIP-la protein (figure 3.16) are induced as part of the early macrophage 
response to challenge by the bacterial cell wall product lipopolysaccharide 
(LPS), it is possible that SCI/MIP-la (and MIP-1 P) might also play an 
important role in the initiation of the acute phase response. The ability of 
SCI/MIP-la to induce the synthesis of TNFa, IL -la  and IL- 6  (Fahey et al 
1992) and the inability of TNFa or IL -la  to induce accumulation of 
SCI/MIP-la mRNA (Martin and Dorf 1991 and this study, chapter 5) 
suggests that secretion of SCI/MIP-la could be a part of the primary wave of 
cytokine production associated with acute inflammatory defence. It should be 
borne in mind, however, that accumulation of SCI/MIP-la and MIP-lp 
mRNA in BMDM can be induced by IFNy (figure 5.9), so it is possible that
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SCI/MIP-la production from macrophages may be induced from 
macrophages at several points during the acute response.
Fahey et al (1990) failed to detect mRNA for SCI/MIP-la and MIP-1 (3 in 
murine peripheral blood leukocytes implying that these proteins do not play a 
role in the circulation in the absence of a challenge to the organism. The 
ability of IFNy, which primes macrophages for antigen presentation (Roitt et 
al 1985) to induce accumulation of both SCI/MIP-la and MIP-lp mRNA 
observed in this study in BMDM (chapter 5) and in the J774.1 cell line by 
Martin and Dorf (1991) may suggest a role for the expression of these genes 
in the specific, as well as the non-specific, immune response.
A major difference in the biology of SCI/MIP-la and that of TNFa, IL -la  
and IL- 6  is that expression of SCI/MIP-la appears to be restricted to 
haemopoietic cells whereas the other genes are expressed in a wide variety of 
cell types (Dinarello 1991, Beutler and Cerami 1988). This may suggest a 
divergence in the roles of SCI/MIP-la and TNFa, EL-la and IL- 6  in the 
secondary part of the acute response.
The heparin-binding properties of SCI/MIP-la and MIP-1 P makes it likely 
that these molecules will be sequestered in the immediate vicinity of the 
producer cells. The confinement of the expression of these genes to 
macrophages, and other haemopoietic cells, may be a way of ensuring that 
SCI/MIP-la and MIP-1 P proteins are only deposited at sites of active 
inflammation.
The role played by MIP-lp in inflammation is not clear at the moment. 
Recombinant MIP-lp has been shown to be ineffective in a variety of systems 
in which SCI/MIP-la has a potent activity (Graham et al 1990, Saukonnen et 
al 1991, Broxmeyer et al 1990). The only activity ascribed to MIP-lp,
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independent of its association with SCI/MIP-la, is that of a specific inhibitor 
of the action of SCI/MIP-la (Broxmeyer et al 1991, Fahey et al 1992).
It is now becoming clear that the activities of many cytokines can be 
controlled post-secretion by mechanisms including specific antagonists of 
cytokine receptors (for review see Dinarello 1991). Specific inhibition of 
SCI/MIP-la activity by MIP-1 (3 may be one way of controlling its activity. 
The coordinate expression of mRNA for both genes in BMDM seen 
throughout this study indicates that SCI/MIP-la and MIP-lp would be 
secreted by BMDM simultaneously. For MIP-1 P to be effective as an 
antagonist it has to be present in excess of SCI/MIP-la; regulation of the 
relative levels of production of these two molecules, perhaps at the level of 
gene expression, could be one way of controlling this interaction.
The ability of hydrocortisone to downregulate the expression of both 
SCI/MIP-la and MIP-lp mRNA (as demonstrated in chapter 4, figures 4.7 
and 4.8) in addition to that of TNFa, IL -la  and IL- 6  (Dinarello 1991, Beutler 
and Cerami 1988) may represent a "main switch" mechanism for down- 
regulating the acute phase response. It seems that expression of SCI/MIP-la 
and MIP-1 p can be downregulated by immunosuppressants acting both 
locally, in the case of prostaglandin E l (Martin and Dorf 1991) and 
systemically. When this is considered along with the transient nature of 
accumulation, it seems clear that the ability for an organism to downregulate 
the expression of these gene is likely to be just as important as the ability to 
induce expression.
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8.4.2 Haemopoietic Regulation.
Steadv-State Haemopoiesis.
Assuming, and there is no definite reason not to, that the expression of 
SCI/MIP-la in BMDM in vitro and in macrophages in the mairow display the 
same characteristics it is pertinent to ask how this might relate to the possible 
role of SCI/MIP-la in steady-state haemopoiesis.
It is possible that the low level of SCI/MIP-la mRNA seen in unstimulated 
BMDM is translated into protein and that the production of SCI/MIP-la 
mRNA by unstimulated macrophages in the marrow is sufficient for the level 
of SCI/MIP-la mRNA detected in normal, unstimulated bone marrow. 
Therefore, it might be possible to propose a role for a constant level of 
SCVMIP-la in maintaining myeloid stem cells in the marrow in a state of 
minimal proliferation.
This might be achieved by a continuous production and destruction of the 
molecule in the marrow which would allow for rapid modulation of levels to 
control the rate of myeloid stem cell proliferation. The changes in the level of 
SCI/MIP-la mRNA in post-phenylhydrazine marrow detectable by PCR, as 
discussed in chapter 7, might indicate such an association between SCI/MIP- 
l a  mRNA expression and CFU-A proliferation. However, this data is very 
preliminary and should be considered in this light.
On the other hand, the proliferative status might be regulated by the relative 
level of positive to negative regulators and SCVMIP-la may only be 
produced at a constant level. Such an arrangement removes the need for 
modulation of the levels of SCVMIP-la production in normal marrow as stem 
cell proliferation could be regulated by changes in the levels of positive 
regulators.
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It is pertinent to ask what factors might regulate the production of the 
SCVMIP-la and MIP-lp in the marrow stroma.
It was demonstrated in chapter 5 that the expression of mRNA for both 
SCVMIP-la and MIP-lp mRNA can be upregulated by the cytokine IFNy. A 
role for cytokine stimulation of SCVMIP-la and MIP-lp expression in the 
inflammatory response has already been argued; it is also possible that stromal 
cell-derived cytokines may trigger the expression of SCI/MIP-la mRNA.
This might be a feasible basis for the negative regulation of primitive cell 
proliferation by SCI/MIP-la in that both a negative stem cell regulator and a 
stimulatory growth factor would be present at the same location in the marrow 
at the same time; as the marrow is an extremely active tissue in terms of 
cellular kinetics this is highly likely to be the case. The specificity of the 
negative regulatory activity of SCI/MIP-la for primitive cells, would ensure 
that only the division of primitive cells would be inhibited while the 
proliferation of the more mature progenitors would be augmented. This could 
represent the "normal" situation in unstressed marrow.
The expression of both SCVMIP-la and MIP-ip mRNA has been 
demonstrated, in this study (chapter 5, figure 5.1) to be induced by (fetal calf) 
serum and on refeeding with SF12 medium (chapter 6 , figures 6.1 to 6.4).
This may be seen as a tissue culture artefact and merely a function of cellular 
refeeding. However, Caldwell et al (1991) have calculated that the rate of 
delivery of plasma proteins and nutrients to bone marrow is far higher in vivo 
than in, for example, long-term bone marrow culture given a medium change 
once weekly. It may be, therefore, that nutrient delivery is a relevant 
experimental parameter when considering conditions affecting the production 
of a molecule in the marrow. It might be argued, then, that the production of
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SCI/MIP-la in the marrow could be maintained simply by the trafficking of 
blood components.
In the model of the control of proliferation of CFU-S cells by the Manchester 
Inhibitor and Stimulator, discussed in chapter 1, an essential component is the 
ability of Stimulator to block production of the Inhibitor by stromal 
macrophages. This could be tested at the level of gene expression by assessing 
the ability of Stimulator to downregulate the expression of SCI/MIP-la 
mRNA by BMDM. This work would also be enhanced by the molecular 
characterisation of the Stimulator. However, whatever the outcome of such 
studies, it is clear from the work presented in this thesis that the model 
proposed by Wright and Lord (1982) and Lord (1988) is incomplete as the 
expression of the SCVMEP-la gene can be regulated by a variety of agents, 
rather than being determined solely by the action of one opposing factor.
In the marrow stromal layer, heparin-binding SCVMIP-la might be 
associated with the extracellular matrix which could allow the localisation of 
expression of the molecule to discrete areas of the marrow. If this were the 
case, however, it is unlikely that mRNA for SCVMIP-la mRNA could be 
detected in normal marrow; levels of molecule necessary to fulfil such a 
function are more likely to be expressed at the "subliminal" level 
demonstrated by Kittler et al (1992) for IL-3 and GM-CSF in long-term bone 
marrow culture stroma.
Lord and Wright (1984) reported some evidence to support the idea of spatial 
distribution of the Manchester Inhibitor and Stimulator across the murine 
femur, so it remains possible that the level of SCVMIP-la mRNA detected in 
normal bone marrow is due to very high, continuous expression by 
geographically distinct subset of macrophages. In situ hybridisation studies 
with SCVMIP-la mRNA may be informative in this respect, although it is
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possible that SCI/MIP-la is produced by most macrophages in the marrow 
and the specific deposition of the protein is responsible for its localisation.
The experiments described in chapter 5 also indicated that it is possible that 
the mononuclear phagocyte lineage-specific growth factor CSF-1 also 
upregulates SCI/MIP-la mRNA expression and that, although BMDM 
proliferation is not necessary for increased accumulation of SCI/MIP-la and 
MIP-ip mRNA, the two processes can be induced by the same agent, L929- 
conditioned medium. It is, therefore, possible that proliferating, maturing 
monocytes might secrete SCI/MIP-la during the final stages of their 
differentiation before leaving the marrow for the blood. SCI/MIP-la would 
then act to inhibit the proliferation of the myeloid stem cells in the marrow in 
the manner of a classical feedback loop, as discussed in chapter 1 .
The major problem with such a model is that the myeloid stem cell, by 
definition, gives rise to at least four blood cell lineages. It is unlikely, 
therefore, that the most important control point for the production of these 
cells could be dictated solely by the status of the monocytic compartment. In 
order for such a mechanism to be feasible, complex interactions between 
several lineage-specific feedback factors would have to be invoked. This idea 
might have more weight if expression of the SCVMIP-la and MIP-ip genes 
was dependent on concurrent macrophage proliferation; however, it has been 
clearly demonstrated in this study that the accumulation of SCVMIP-la and 
MIP-lp mRNA can take place in its absence which means that fixed resident 
bone marrow macrophages should not be restricted in their ability to express 
these genes.
Wdzieczak-Bakala et al (1990) have reported constitutive production of the 
tetrapeptide AcSDKP in normal murine bone marrow. The ability of a specific 
anti-serum against this molecule to greatly increase CFU-S cycling in vivo
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(Lauret et al 1988, Frindel and Monpezat 1989) suggests that this molecule 
may be necessary, though not necessarily sufficient, for the maintenance of 
CFU-S quiescence.
A similar approach might be used to ascertain whether SCI/MIP-la displays a 
similar activity. It should be borne in mind, however, that the interpretation of 
such experiments may be difficult when inhibiting the activity of a molecule 
with such pleiotropic effects.
The potential role of other inhibitors of haemopoietic stem cell proliferation 
should also be borne in mind when considering the biology of SCI/MIP-la. 
The redundancy of the action of haemopoietic growth factors in many aspects 
of their biology is now well-established. This also seems to be the case for the 
positive control of haemopoietic stem cell proliferation as discussed in chapter
1. It seems unlikely, given the primacy of the stem cell proliferation in the 
regulation of haemopoiesis, that negative regulation of these cells is controlled 
by only one switch, although the results of Lauret et al 1988 and Frindel and 
Monpezat 1989 would seem to indicate this. It is possible also that the roles 
played by the different negative regulators are overlapping but not identical, 
which would introduce a high degree of flexibility into the system. For 
example, studies on the mechanism of action of the tetrapeptide AcSDKP 
indicate that while it is effective at opposing proliferation of CFU-S, it is 
incapable of recruiting proliferating CFU-S into quiescence (Monpezat and 
Frindel 1989). On the other hand, SCI/MIP-la has been shown to render 
proliferating CFU-S quiescent (Graham et al 1990, Dunlop et al 1992). It is 
possible, therefore, that AcSDKP may be primarily responsible for the 
maintenance of CFU-S quiescence while the main role of SCI/MIP-la might 
be to recruit inappropriately cycling CFU-S back to minimal proliferation.
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The exact cellular populations within the stem cell compartment affected by 
the different negative regulators also appear to be overlapping but not 
identical. For example, TGFp appears capable of inhibiting the proliferation 
of a wide range of primitive haemopoietic progenitors (Keller et al 1992), 
while the action of SCVMIP-la and AcSDKP appears to be centred largely 
around the CFU-S compartment (Monpezat and Frindel 1989, Graham et al
1990). It may be possible, therefore, to define the subset of the stem cell 
compartment which is capable of responding to a positive growth regulator 
within a very narrow range by differential regulation of the expression of 
these molecules within the marrow. In terms of gene expression studies it may 
be of interest to determine whether, and under what circumstances the 
expression of the genes for SCVMIP-la, MIP-ip and TGFp might be 
regulated differentially in the bone marrow. Studies of the regulation of 
production of AcSDKP and the hemoregulatory peptide await identification of 
the producing cells.
Emergency Haemopoiesis and Marrow Regeneration.
One of the features of the acute phase response is the need for the rapid 
delivery of a large number of functional, mature haemopoietic cells. This is 
achieved in part by migration, however, it is possible that marrow- 
independent haemopoiesis also plays a role. Activated macrophages and 
infected tissue cells such as fibroblasts and endothelial cells secrete a number 
of haemopoietically active cytokines including IL-3 and GM-CSF (Morstyn 
and Burgess 1988). The elevation of the levels of these cytokines in the blood 
might be capable of mobilising haemopoietic progenitors from storage sites, 
including possibly the marrow, and induce extensive proliferation and 
differentiation so as to provide a sufficient number of activated cells to
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counter the emergency state. The increased number of activated mature 
haemopoietic cells are, in turn, a source of CSFs. This would lead to a 
considerable concentration of haemopoietic growth factors in the bloodstream. 
It is a possibility that the primary function of negative regulatory cytokines 
produced by activated macrophages, such as SCI/MIP-la may be to feedback 
and prevent the extinction of stem cells through proliferation and 
differentiation induced by the elevated levels of growth factors with the ability 
to act on primitive cells. Such a role for negative regulators has been 
postulated by Zipori (1991). However, the blood-bone marrow barrier formed 
by the basal lamina of the marrow venous sinus may be sufficient to prevent 
the exposure of stem cells to abnormal concentrations of growth factors in 
most cases; it is likely, therefore, that the protection of stem cells by SCI/MIP- 
l a  secreted by blood-borne monocytes is only relevant during abnormally 
advanced infections such as, for example, severe bacteraemia. However, the 
localisation of SCI/MIP-la by binding to the extracellular matrix may in fact 
limit the ability of SCI/MIP-la produced in the blood to affect the marrow.
It is possible, however, that the abilty of SCI/MIP-la to augment the 
proliferation of haemopoietic progenitors (Broxmeyer et al 1990) and mature 
macrophages (Fahey et al 1992) could make a contribution to the 
enhancement of the number of immune effector cells at inflammatory sites 
infiltrated by macrophages.
G.Graham and K.Parkinson (personal communication) have recently 
demonstrated the ability of SCI/MIP-la to inhibit the proliferation of 
primitive epidermal cells in vitro. In addition to the potential role of SCI/MIP- 
l a  (produced by epidermal Langerhan's cells) in regulating the production of 
keratinocytes, it is possible that SCI/MIP-la, produced by activated 
macrophages may protect primitive epidermal stem cells from extinction by
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differentiation induced by positive regulatory factors in situations such as skin 
wounding.
As discussed in chapter 1 it is likely that there are specific regulatory signals 
which control the rapid, marked increase in proliferation and the subsequent 
return to quiescence of stem cells in regenerating marrow. The dramatic 
increase in SCI/MIP-la mRNA seen in murine bone marrow in the later 
stages of the recovery period following treatment with 5-FU suggests a role 
for SCI/MIP-la in this process.
The rise in SCI/MIP-la mRNA levels corresponds roughly, although not 
exactly, with the return of marrow cellularity to normal levels and of CFU-A 
to the quiescent state. The presumed increased level of SCI/MIP-la protein 
accompanying the mRNA increase could be responsible for either causing the 
reduction in myeloid stem cell proliferation or for maintaining the cells in that 
state or both.
It could be that the main role of SCI/MIP-la in haemopoietic regulation 
concerns the maintenance of myeloid stem cells in a quiescent state in the face 
of powerful proliferative stimuli. This would be directly analogous to its 
activity in vitro in inhibiting the growth of colonies derived from CFU-A 
cells. The demonstration by Dunlop et al (1992) and Lord et al (1992) of the 
efficacy of recombinant human M IP-la in inducing quiescence in rapidly 
cycling CFU-S and CFU-A in vivo lends weight to this hypothesis. This 
possibility could also be tested with the use of antisera specific for SCI/MIP- 
la ; failure of CFU-S/ CFU-A to return to quiescence in the presence of a 
specific blocking agent would indicate the necessity of SCI/MIP-la for the 
return to quiescence. If, as discussed above, the role of SCI/MIP-la is to 
maintain minimal proliferation in the myeloid stem cell compartment in 
unperturbed marrow, the burst of expression seen in the regeneration period
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may be part of a process in which components of the microenvironment, 
disrupted during marrow ablation, are replaced. For instance, the deposition of 
secreted SC1/MIP-la protein on extracellular matrix components. Therefore, 
the observed increase in SCI/MIP-la mRNA seen in regeneration may relate 
to tissue "refurbishment" rather than correlate directly with the control of stem 
cell proliferation per se. Further studies correlating SCI/MIP-la mRNA and 
protein expression in murine bone marrow and stem cell cycling will allow 
this issue to be addressed.
8.5 Concluding Remarks.
This thesis represents the first study of the expression of the murine SCI/MIP- 
l a  and MIP-ip genes in primary, untransformed cells. The characteristics of 
expression of these genes in bone marrow-derived macrophages establish 
these as belonging to the "immediate early" group of genes whose expression 
is induced as part of the early phase of the response of macrophages to 
stimulation. This must be taken into account in all future models concerning 
the involvement of SCI/MIP-la and MIP-lp and the expression of their genes 
in both the regulation of haemopoiesis and in the inflammatory response.
Bone marrow-derived macrophages also appear to be a suitable model system 
for identifying candidate regulators of SCI/MIP-la and MIP-ip gene 
expression, although further refinement of the culture conditions used may be 
helpful given the demonstration in this study of the ability of sera and certain 
culture media to affect accumulation of mRNA for these genes.
In this study, the expression of the SCI/MIP-la gene in normal, unperturbed 
bone marrow was demonstrated. The level of SCI/MIP-la mRNA expressed 
in normal bone marrow was seen to be altered by the treatment of animals 
with the drug 5-fluorouracil. While this data is not inconsistent with a role for
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the modulation of SCVMIP-la gene expression in the control of myeloid stem 
cell proliferation, further studies will be required to clarify this issue.
Taken together, the studies presented in this thesis represent a strong basis for 
future work on the expression of the genes for SCI/MIP-la and MIP-lp in 
both macrophages and bone marrow.
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